uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q34.1866 | Q34 | What are the names of the genes that are targeted by the drug Thalidomide in the treatment of immune system disease? | In the context of immune system disease, the drug Thalidomide targets the gene cereblon, damage specific DNA binding protein 1, cullin 4A and ring-box 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%immune system disease%" OR LOWER(efo_term) LIKE "%immune system disease%") AND (LOWER(drugName) LIKE "%thalidomide%" OR LOWER(tradeNames_list) LIKE "%thalidomide%" OR LOWER(syns_list) LIKE "%thalidomide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1105129', 'drugName': 'Thalidomide', 'tradeNames_list': "['Talidex', 'Thalomid']", 'syns_list': "['.alpha.-phthalimidoglutarimide', 'Celgene', 'Contergan', 'Distaval', 'K-17Myrin', 'N-phthalylglutamic acid imide', 'NSC-527179', 'NSC-66847Neurosedyn', 'Pantosediv', 'Pharmion', 'Softenon', 'Thaled', 'ThalidomideThalidomide ']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DDB1', 'approvedName': 'damage specific DNA binding protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1105390', 'drugName': 'Thalidomide', 'tradeNames_list': "['Talidex', 'Thalomid']", 'syns_list': "['.alpha.-phthalimidoglutarimide', 'Celgene', 'Contergan', 'Distaval', 'K-17Myrin', 'N-phthalylglutamic acid imide', 'NSC-527179', 'NSC-66847Neurosedyn', 'Pantosediv', 'Pharmion', 'Softenon', 'Thaled', 'ThalidomideThalidomide ']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CUL4A', 'approvedName': 'cullin 4A'}, {'UUID': 'DrugTargetsIndication121923_text_1105477', 'drugName': 'Thalidomide', 'tradeNames_list': "['Talidex', 'Thalomid']", 'syns_list': "['.alpha.-phthalimidoglutarimide', 'Celgene', 'Contergan', 'Distaval', 'K-17Myrin', 'N-phthalylglutamic acid imide', 'NSC-527179', 'NSC-66847Neurosedyn', 'Pantosediv', 'Pharmion', 'Softenon', 'Thaled', 'ThalidomideThalidomide ']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'RBX1', 'approvedName': 'ring-box 1'}, {'UUID': 'DrugTargetsIndication121923_text_1105564', 'drugName': 'Thalidomide', 'tradeNames_list': "['Talidex', 'Thalomid']", 'syns_list': "['.alpha.-phthalimidoglutarimide', 'Celgene', 'Contergan', 'Distaval', 'K-17Myrin', 'N-phthalylglutamic acid imide', 'NSC-527179', 'NSC-66847Neurosedyn', 'Pantosediv', 'Pharmion', 'Softenon', 'Thaled', 'ThalidomideThalidomide ']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'RBX1', 'approvedName': 'ring-box 1'}, {'UUID': 'DrugTargetsIndication121923_text_1105303', 'drugName': 'Thalidomide', 'tradeNames_list': "['Talidex', 'Thalomid']", 'syns_list': "['.alpha.-phthalimidoglutarimide', 'Celgene', 'Contergan', 'Distaval', 'K-17Myrin', 'N-phthalylglutamic acid imide', 'NSC-527179', 'NSC-66847Neurosedyn', 'Pantosediv', 'Pharmion', 'Softenon', 'Thaled', 'ThalidomideThalidomide ']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CUL4A', 'approvedName': 'cullin 4A'}, {'UUID': 'DrugTargetsIndication121923_text_1104955', 'drugName': 'Thalidomide', 'tradeNames_list': "['Talidex', 'Thalomid']", 'syns_list': "['.alpha.-phthalimidoglutarimide', 'Celgene', 'Contergan', 'Distaval', 'K-17Myrin', 'N-phthalylglutamic acid imide', 'NSC-527179', 'NSC-66847Neurosedyn', 'Pantosediv', 'Pharmion', 'Softenon', 'Thaled', 'ThalidomideThalidomide ']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DDB1', 'approvedName': 'damage specific DNA binding protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1104781', 'drugName': 'Thalidomide', 'tradeNames_list': "['Talidex', 'Thalomid']", 'syns_list': "['.alpha.-phthalimidoglutarimide', 'Celgene', 'Contergan', 'Distaval', 'K-17Myrin', 'N-phthalylglutamic acid imide', 'NSC-527179', 'NSC-66847Neurosedyn', 'Pantosediv', 'Pharmion', 'Softenon', 'Thaled', 'ThalidomideThalidomide ']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1104694', 'drugName': 'Thalidomide', 'tradeNames_list': "['Talidex', 'Thalomid']", 'syns_list': "['.alpha.-phthalimidoglutarimide', 'Celgene', 'Contergan', 'Distaval', 'K-17Myrin', 'N-phthalylglutamic acid imide', 'NSC-527179', 'NSC-66847Neurosedyn', 'Pantosediv', 'Pharmion', 'Softenon', 'Thaled', 'ThalidomideThalidomide ']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1105651', 'drugName': 'Thalidomide', 'tradeNames_list': "['Talidex', 'Thalomid']", 'syns_list': "['.alpha.-phthalimidoglutarimide', 'Celgene', 'Contergan', 'Distaval', 'K-17Myrin', 'N-phthalylglutamic acid imide', 'NSC-527179', 'NSC-66847Neurosedyn', 'Pantosediv', 'Pharmion', 'Softenon', 'Thaled', 'ThalidomideThalidomide ']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'RBX1', 'approvedName': 'ring-box 1'}, {'UUID': 'DrugTargetsIndication121923_text_1105216', 'drugName': 'Thalidomide', 'tradeNames_list': "['Talidex', 'Thalomid']", 'syns_list': "['.alpha.-phthalimidoglutarimide', 'Celgene', 'Contergan', 'Distaval', 'K-17Myrin', 'N-phthalylglutamic acid imide', 'NSC-527179', 'NSC-66847Neurosedyn', 'Pantosediv', 'Pharmion', 'Softenon', 'Thaled', 'ThalidomideThalidomide ']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CUL4A', 'approvedName': 'cullin 4A'}, {'UUID': 'DrugTargetsIndication121923_text_1105042', 'drugName': 'Thalidomide', 'tradeNames_list': "['Talidex', 'Thalomid']", 'syns_list': "['.alpha.-phthalimidoglutarimide', 'Celgene', 'Contergan', 'Distaval', 'K-17Myrin', 'N-phthalylglutamic acid imide', 'NSC-527179', 'NSC-66847Neurosedyn', 'Pantosediv', 'Pharmion', 'Softenon', 'Thaled', 'ThalidomideThalidomide ']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'DDB1', 'approvedName': 'damage specific DNA binding protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1104868', 'drugName': 'Thalidomide', 'tradeNames_list': "['Talidex', 'Thalomid']", 'syns_list': "['.alpha.-phthalimidoglutarimide', 'Celgene', 'Contergan', 'Distaval', 'K-17Myrin', 'N-phthalylglutamic acid imide', 'NSC-527179', 'NSC-66847Neurosedyn', 'Pantosediv', 'Pharmion', 'Softenon', 'Thaled', 'ThalidomideThalidomide ']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.33 | Q34 | What are the names of the genes that are targeted by the drug Aripiprazole Lauroxil in the treatment of Tourette syndrome? | In the context of Tourette syndrome, the drug Aripiprazole Lauroxil targets the gene dopamine receptor D2, 5-hydroxytryptamine receptor 2A and 5-hydroxytryptamine receptor 1A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%tourette syndrome%" OR LOWER(efo_term) LIKE "%tourette syndrome%") AND (LOWER(drugName) LIKE "%aripiprazole lauroxil%" OR LOWER(tradeNames_list) LIKE "%aripiprazole lauroxil%" OR LOWER(syns_list) LIKE "%aripiprazole lauroxil%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_158028', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158046', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158052', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158058', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158070', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158076', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158082', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158094', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158100', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158106', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158112', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158124', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158130', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158136', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158142', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158148', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158154', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158160', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158166', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158172', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158178', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158190', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158196', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158202', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158208', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158214', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158226', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158232', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158238', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158244', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158250', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158256', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158262', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158268', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158274', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158280', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158286', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158292', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158298', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158304', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158310', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158316', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158322', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158328', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158334', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158340', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158346', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158352', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158358', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158364', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158370', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158382', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158388', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158394', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158400', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158406', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158412', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158424', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158430', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158436', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158442', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158448', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158454', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158460', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158466', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158472', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158478', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158484', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158490', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158496', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158502', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158508', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158514', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158520', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158526', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158532', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158538', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158544', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158550', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158556', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158562', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158568', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158574', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158580', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158586', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158592', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158376', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158184', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158088', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158040', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158016', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158004', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_157998', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158418', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158220', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158118', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158064', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158034', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158022', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158010', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.937 | Q34 | What are the names of the genes that are targeted by the drug Ibuprofen in the treatment of arthritis? | In the context of arthritis, the drug Ibuprofen targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%arthritis%" OR LOWER(efo_term) LIKE "%arthritis%") AND (LOWER(drugName) LIKE "%ibuprofen%" OR LOWER(tradeNames_list) LIKE "%ibuprofen%" OR LOWER(syns_list) LIKE "%ibuprofen%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_840479', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839852', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840964', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840405', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839768', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840163', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839846', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840247', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840005', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840010', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841426', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841111', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839779', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841584', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839925', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839926', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840162', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841590', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840168', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840648', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839937', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839847', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840795', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840004', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840873', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840320', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840326', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841432', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840016', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841037', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839858', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841438', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840083', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840084', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840478', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841585', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840484', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840490', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840095', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840557', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840558', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840563', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840569', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841663', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840636', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840637', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840642', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841596', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840174', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840715', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840716', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840727', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840242', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840794', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841280', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840800', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840806', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841353', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840874', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840879', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840885', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841348', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840952', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840953', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840958', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841506', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840332', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841031', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841032', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841427', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841043', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840400', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841110', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841505', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841116', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841122', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840411', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841189', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841190', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841195', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841201', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841664', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841268', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841269', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841274', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841675', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841669', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841511', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841359', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841347', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840721', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840241', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839773', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840253', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840321', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840399', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841517', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839931', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839767', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840089', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1152 | Q34 | What are the names of the genes that are targeted by the drug Trametinib in the treatment of non-small cell lung carcinoma? | Trametinib has not been approved by the FDA as a treatment for non-small cell lung carcinoma, but it is currently undergoing evaluation in clinical trials for this purpose. However, the proposed gene target names are mitogen-activated protein kinase kinase 2 and mitogen-activated protein kinase kinase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%non-small cell lung carcinoma%" OR LOWER(efo_term) LIKE "%non-small cell lung carcinoma%") AND (LOWER(drugName) LIKE "%trametinib%" OR LOWER(tradeNames_list) LIKE "%trametinib%" OR LOWER(syns_list) LIKE "%trametinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_928700', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928820', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928860', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928900', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928980', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929020', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929060', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929140', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929180', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929220', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929260', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929340', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929380', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929420', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929460', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929500', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929540', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929580', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929620', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929660', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929700', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929780', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929820', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929860', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929900', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929940', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930020', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930060', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930100', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930140', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930180', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930220', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930260', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930300', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930340', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930380', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930420', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930460', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930500', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930540', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930580', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930620', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930660', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930700', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930740', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930780', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930820', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930860', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930900', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930940', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930980', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931060', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931100', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931140', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931180', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931220', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931260', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931340', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931380', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931420', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931460', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931500', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931540', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931580', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931620', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931660', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931700', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931740', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931780', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931820', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931860', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931900', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931940', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931980', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932020', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932060', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932100', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932140', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932180', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932220', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932260', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932300', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932340', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932380', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932420', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932460', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931020', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_929740', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929100', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928780', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928620', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928540', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928500', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_931300', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_929980', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929300', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928940', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928740', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928660', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928580', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1418 | Q34 | What are the names of the genes that are targeted by the drug Lutetium Dotatate Lu-177 in the treatment of pancreatic neuroendocrine tumor? | In the context of pancreatic neuroendocrine tumor, the drug Lutetium Dotatate Lu-177 targets the gene somatostatin receptor 5, somatostatin receptor 2, somatostatin receptor 3, somatostatin receptor 1 and somatostatin receptor 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pancreatic neuroendocrine tumor%" OR LOWER(efo_term) LIKE "%pancreatic neuroendocrine tumor%") AND (LOWER(drugName) LIKE "%lutetium dotatate lu-177%" OR LOWER(tradeNames_list) LIKE "%lutetium dotatate lu-177%" OR LOWER(syns_list) LIKE "%lutetium dotatate lu-177%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1041962', 'drugName': 'Lutetium Dotatate Lu-177', 'tradeNames_list': "['Lutathera']", 'syns_list': "['(177)lu-dotatate', '177lu-dota-tyr3-octreotate', '177lu-dotatateDota-octreotate lutetium lu-177', 'Dotatate lutenium lu-177Dotatate lutetium lu-177', 'Lutetium (177lu) dotatateLutetium (177lu) oxodotreotide', 'Lutetium dotatate lu-177Lutetium dotatate, lu-177', 'Lutetium lu 177 dotatateLutetium lu-177 dotatate', 'Lutetium oxodotreotide lu-177Oxodotreotide lutetium lu-177', 'Oxodotreotide lutetium, lu-177']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1041989', 'drugName': 'Lutetium Dotatate Lu-177', 'tradeNames_list': "['Lutathera']", 'syns_list': "['(177)lu-dotatate', '177lu-dota-tyr3-octreotate', '177lu-dotatateDota-octreotate lutetium lu-177', 'Dotatate lutenium lu-177Dotatate lutetium lu-177', 'Lutetium (177lu) dotatateLutetium (177lu) oxodotreotide', 'Lutetium dotatate lu-177Lutetium dotatate, lu-177', 'Lutetium lu 177 dotatateLutetium lu-177 dotatate', 'Lutetium oxodotreotide lu-177Oxodotreotide lutetium lu-177', 'Oxodotreotide lutetium, lu-177']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'SSTR4', 'approvedName': 'somatostatin receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_1041998', 'drugName': 'Lutetium Dotatate Lu-177', 'tradeNames_list': "['Lutathera']", 'syns_list': "['(177)lu-dotatate', '177lu-dota-tyr3-octreotate', '177lu-dotatateDota-octreotate lutetium lu-177', 'Dotatate lutenium lu-177Dotatate lutetium lu-177', 'Lutetium (177lu) dotatateLutetium (177lu) oxodotreotide', 'Lutetium dotatate lu-177Lutetium dotatate, lu-177', 'Lutetium lu 177 dotatateLutetium lu-177 dotatate', 'Lutetium oxodotreotide lu-177Oxodotreotide lutetium lu-177', 'Oxodotreotide lutetium, lu-177']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'SSTR4', 'approvedName': 'somatostatin receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_1041980', 'drugName': 'Lutetium Dotatate Lu-177', 'tradeNames_list': "['Lutathera']", 'syns_list': "['(177)lu-dotatate', '177lu-dota-tyr3-octreotate', '177lu-dotatateDota-octreotate lutetium lu-177', 'Dotatate lutenium lu-177Dotatate lutetium lu-177', 'Lutetium (177lu) dotatateLutetium (177lu) oxodotreotide', 'Lutetium dotatate lu-177Lutetium dotatate, lu-177', 'Lutetium lu 177 dotatateLutetium lu-177 dotatate', 'Lutetium oxodotreotide lu-177Oxodotreotide lutetium lu-177', 'Oxodotreotide lutetium, lu-177']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1041926', 'drugName': 'Lutetium Dotatate Lu-177', 'tradeNames_list': "['Lutathera']", 'syns_list': "['(177)lu-dotatate', '177lu-dota-tyr3-octreotate', '177lu-dotatateDota-octreotate lutetium lu-177', 'Dotatate lutenium lu-177Dotatate lutetium lu-177', 'Lutetium (177lu) dotatateLutetium (177lu) oxodotreotide', 'Lutetium dotatate lu-177Lutetium dotatate, lu-177', 'Lutetium lu 177 dotatateLutetium lu-177 dotatate', 'Lutetium oxodotreotide lu-177Oxodotreotide lutetium lu-177', 'Oxodotreotide lutetium, lu-177']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_1041917', 'drugName': 'Lutetium Dotatate Lu-177', 'tradeNames_list': "['Lutathera']", 'syns_list': "['(177)lu-dotatate', '177lu-dota-tyr3-octreotate', '177lu-dotatateDota-octreotate lutetium lu-177', 'Dotatate lutenium lu-177Dotatate lutetium lu-177', 'Lutetium (177lu) dotatateLutetium (177lu) oxodotreotide', 'Lutetium dotatate lu-177Lutetium dotatate, lu-177', 'Lutetium lu 177 dotatateLutetium lu-177 dotatate', 'Lutetium oxodotreotide lu-177Oxodotreotide lutetium lu-177', 'Oxodotreotide lutetium, lu-177']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'SSTR5', 'approvedName': 'somatostatin receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_1041944', 'drugName': 'Lutetium Dotatate Lu-177', 'tradeNames_list': "['Lutathera']", 'syns_list': "['(177)lu-dotatate', '177lu-dota-tyr3-octreotate', '177lu-dotatateDota-octreotate lutetium lu-177', 'Dotatate lutenium lu-177Dotatate lutetium lu-177', 'Lutetium (177lu) dotatateLutetium (177lu) oxodotreotide', 'Lutetium dotatate lu-177Lutetium dotatate, lu-177', 'Lutetium lu 177 dotatateLutetium lu-177 dotatate', 'Lutetium oxodotreotide lu-177Oxodotreotide lutetium lu-177', 'Oxodotreotide lutetium, lu-177']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1041971', 'drugName': 'Lutetium Dotatate Lu-177', 'tradeNames_list': "['Lutathera']", 'syns_list': "['(177)lu-dotatate', '177lu-dota-tyr3-octreotate', '177lu-dotatateDota-octreotate lutetium lu-177', 'Dotatate lutenium lu-177Dotatate lutetium lu-177', 'Lutetium (177lu) dotatateLutetium (177lu) oxodotreotide', 'Lutetium dotatate lu-177Lutetium dotatate, lu-177', 'Lutetium lu 177 dotatateLutetium lu-177 dotatate', 'Lutetium oxodotreotide lu-177Oxodotreotide lutetium lu-177', 'Oxodotreotide lutetium, lu-177']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'SSTR1', 'approvedName': 'somatostatin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1041953', 'drugName': 'Lutetium Dotatate Lu-177', 'tradeNames_list': "['Lutathera']", 'syns_list': "['(177)lu-dotatate', '177lu-dota-tyr3-octreotate', '177lu-dotatateDota-octreotate lutetium lu-177', 'Dotatate lutenium lu-177Dotatate lutetium lu-177', 'Lutetium (177lu) dotatateLutetium (177lu) oxodotreotide', 'Lutetium dotatate lu-177Lutetium dotatate, lu-177', 'Lutetium lu 177 dotatateLutetium lu-177 dotatate', 'Lutetium oxodotreotide lu-177Oxodotreotide lutetium lu-177', 'Oxodotreotide lutetium, lu-177']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'SSTR3', 'approvedName': 'somatostatin receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1041935', 'drugName': 'Lutetium Dotatate Lu-177', 'tradeNames_list': "['Lutathera']", 'syns_list': "['(177)lu-dotatate', '177lu-dota-tyr3-octreotate', '177lu-dotatateDota-octreotate lutetium lu-177', 'Dotatate lutenium lu-177Dotatate lutetium lu-177', 'Lutetium (177lu) dotatateLutetium (177lu) oxodotreotide', 'Lutetium dotatate lu-177Lutetium dotatate, lu-177', 'Lutetium lu 177 dotatateLutetium lu-177 dotatate', 'Lutetium oxodotreotide lu-177Oxodotreotide lutetium lu-177', 'Oxodotreotide lutetium, lu-177']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'SSTR2', 'approvedName': 'somatostatin receptor 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1970 | Q34 | What are the names of the genes that are targeted by the drug Topotecan Hydrochloride in the treatment of small cell lung carcinoma? | In the context of small cell lung carcinoma, the drug Topotecan Hydrochloride targets the gene DNA topoisomerase I mitochondrial. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%small cell lung carcinoma%" OR LOWER(efo_term) LIKE "%small cell lung carcinoma%") AND (LOWER(drugName) LIKE "%topotecan hydrochloride%" OR LOWER(tradeNames_list) LIKE "%topotecan hydrochloride%" OR LOWER(syns_list) LIKE "%topotecan hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1193645', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193573', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193563', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193635', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.126 | Q34 | What are the names of the genes that are targeted by the drug Levomilnacipran Hydrochloride in the treatment of unipolar depression? | In the context of unipolar depression, the drug Levomilnacipran Hydrochloride targets the gene solute carrier family 6 member 4 and solute carrier family 6 member 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%unipolar depression%" OR LOWER(efo_term) LIKE "%unipolar depression%") AND (LOWER(drugName) LIKE "%levomilnacipran hydrochloride%" OR LOWER(tradeNames_list) LIKE "%levomilnacipran hydrochloride%" OR LOWER(syns_list) LIKE "%levomilnacipran hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_206892', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206904', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206908', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206912', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206920', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206924', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206928', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206936', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206940', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206944', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206948', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206956', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206960', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206964', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206932', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206900', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206884', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206876', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206872', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206952', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206916', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206896', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206888', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206880', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1379 | Q34 | What are the names of the genes that are targeted by the drug Guanfacine in the treatment of hypertension? | In the context of hypertension, the drug Guanfacine targets the gene adrenoceptor alpha 2A, adrenoceptor alpha 2C and adrenoceptor alpha 2B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hypertension%" OR LOWER(efo_term) LIKE "%hypertension%") AND (LOWER(drugName) LIKE "%guanfacine%" OR LOWER(tradeNames_list) LIKE "%guanfacine%" OR LOWER(syns_list) LIKE "%guanfacine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1025306', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': "['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']", 'syns_list': "['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1025312', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': "['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']", 'syns_list': "['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1025314', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': "['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']", 'syns_list': "['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1025316', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': "['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']", 'syns_list': "['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1025320', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': "['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']", 'syns_list': "['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1025322', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': "['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']", 'syns_list': "['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1025324', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': "['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']", 'syns_list': "['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1025328', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': "['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']", 'syns_list': "['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1025330', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': "['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']", 'syns_list': "['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1025332', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': "['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']", 'syns_list': "['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1025334', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': "['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']", 'syns_list': "['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1025338', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': "['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']", 'syns_list': "['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1025340', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': "['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']", 'syns_list': "['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1025342', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': "['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']", 'syns_list': "['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1025359', 'drugName': 'Guanfacine', 'tradeNames_list': "['Intuniv']", 'syns_list': "['Guanfacine', 'NSC-759121', 'Tenex']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1025375', 'drugName': 'Guanfacine', 'tradeNames_list': "['Intuniv']", 'syns_list': "['Guanfacine', 'NSC-759121', 'Tenex']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1025391', 'drugName': 'Guanfacine', 'tradeNames_list': "['Intuniv']", 'syns_list': "['Guanfacine', 'NSC-759121', 'Tenex']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1025407', 'drugName': 'Guanfacine', 'tradeNames_list': "['Intuniv']", 'syns_list': "['Guanfacine', 'NSC-759121', 'Tenex']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1025423', 'drugName': 'Guanfacine', 'tradeNames_list': "['Intuniv']", 'syns_list': "['Guanfacine', 'NSC-759121', 'Tenex']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1025439', 'drugName': 'Guanfacine', 'tradeNames_list': "['Intuniv']", 'syns_list': "['Guanfacine', 'NSC-759121', 'Tenex']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1025455', 'drugName': 'Guanfacine', 'tradeNames_list': "['Intuniv']", 'syns_list': "['Guanfacine', 'NSC-759121', 'Tenex']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1025487', 'drugName': 'Guanfacine', 'tradeNames_list': "['Intuniv']", 'syns_list': "['Guanfacine', 'NSC-759121', 'Tenex']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1025503', 'drugName': 'Guanfacine', 'tradeNames_list': "['Intuniv']", 'syns_list': "['Guanfacine', 'NSC-759121', 'Tenex']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1025519', 'drugName': 'Guanfacine', 'tradeNames_list': "['Intuniv']", 'syns_list': "['Guanfacine', 'NSC-759121', 'Tenex']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1025535', 'drugName': 'Guanfacine', 'tradeNames_list': "['Intuniv']", 'syns_list': "['Guanfacine', 'NSC-759121', 'Tenex']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1025551', 'drugName': 'Guanfacine', 'tradeNames_list': "['Intuniv']", 'syns_list': "['Guanfacine', 'NSC-759121', 'Tenex']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1025583', 'drugName': 'Guanfacine', 'tradeNames_list': "['Intuniv']", 'syns_list': "['Guanfacine', 'NSC-759121', 'Tenex']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1025599', 'drugName': 'Guanfacine', 'tradeNames_list': "['Intuniv']", 'syns_list': "['Guanfacine', 'NSC-759121', 'Tenex']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1025615', 'drugName': 'Guanfacine', 'tradeNames_list': "['Intuniv']", 'syns_list': "['Guanfacine', 'NSC-759121', 'Tenex']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1025631', 'drugName': 'Guanfacine', 'tradeNames_list': "['Intuniv']", 'syns_list': "['Guanfacine', 'NSC-759121', 'Tenex']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1025647', 'drugName': 'Guanfacine', 'tradeNames_list': "['Intuniv']", 'syns_list': "['Guanfacine', 'NSC-759121', 'Tenex']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1025663', 'drugName': 'Guanfacine', 'tradeNames_list': "['Intuniv']", 'syns_list': "['Guanfacine', 'NSC-759121', 'Tenex']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1025679', 'drugName': 'Guanfacine', 'tradeNames_list': "['Intuniv']", 'syns_list': "['Guanfacine', 'NSC-759121', 'Tenex']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1025695', 'drugName': 'Guanfacine', 'tradeNames_list': "['Intuniv']", 'syns_list': "['Guanfacine', 'NSC-759121', 'Tenex']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1025711', 'drugName': 'Guanfacine', 'tradeNames_list': "['Intuniv']", 'syns_list': "['Guanfacine', 'NSC-759121', 'Tenex']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1025727', 'drugName': 'Guanfacine', 'tradeNames_list': "['Intuniv']", 'syns_list': "['Guanfacine', 'NSC-759121', 'Tenex']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1025471', 'drugName': 'Guanfacine', 'tradeNames_list': "['Intuniv']", 'syns_list': "['Guanfacine', 'NSC-759121', 'Tenex']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1025326', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': "['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']", 'syns_list': "['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1025310', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': "['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']", 'syns_list': "['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1025302', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': "['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']", 'syns_list': "['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1025298', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': "['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']", 'syns_list': "['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1025296', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': "['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']", 'syns_list': "['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1025567', 'drugName': 'Guanfacine', 'tradeNames_list': "['Intuniv']", 'syns_list': "['Guanfacine', 'NSC-759121', 'Tenex']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1025336', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': "['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']", 'syns_list': "['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1025318', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': "['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']", 'syns_list': "['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1025308', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': "['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']", 'syns_list': "['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1025304', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': "['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']", 'syns_list': "['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1025300', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': "['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']", 'syns_list': "['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.352 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of primary adrenal insufficiency? | In the context of primary adrenal insufficiency, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%primary adrenal insufficiency%" OR LOWER(efo_term) LIKE "%primary adrenal insufficiency%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_227808', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228663', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228948', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229233', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229803', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230088', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230373', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230943', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231228', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231513', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231798', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232368', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230658', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228378', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227238', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226668', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226383', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232083', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229518', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228093', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227523', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226953', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Addison Disease', 'efo_term': 'primary adrenal insufficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.165 | Q34 | What are the names of the genes that are targeted by the drug Prednisone in the treatment of leukemia? | In the context of leukemia, the drug Prednisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%leukemia%" OR LOWER(efo_term) LIKE "%leukemia%") AND (LOWER(drugName) LIKE "%prednisone%" OR LOWER(tradeNames_list) LIKE "%prednisone%" OR LOWER(syns_list) LIKE "%prednisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_220543', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia', 'efo_term': 'leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218463', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia', 'efo_term': 'leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220127', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia', 'efo_term': 'leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220335', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia', 'efo_term': 'leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217631', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia', 'efo_term': 'leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219919', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia', 'efo_term': 'leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217839', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia', 'efo_term': 'leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219295', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia', 'efo_term': 'leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218255', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia', 'efo_term': 'leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219711', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia', 'efo_term': 'leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219087', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia', 'efo_term': 'leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218671', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia', 'efo_term': 'leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220751', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia', 'efo_term': 'leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218047', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia', 'efo_term': 'leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218879', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia', 'efo_term': 'leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219503', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia', 'efo_term': 'leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219221', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Biphenotypic, Acute', 'efo_term': 'B-cell acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219284', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor T-Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'T-lymphoblastic lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219430', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217981', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218451', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia-Lymphoma, Adult T-Cell', 'efo_term': 'adult T-cell leukemia/lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219222', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218182', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219478', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218597', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Biphenotypic, Acute', 'efo_term': 'B-cell acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217557', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Biphenotypic, Acute', 'efo_term': 'B-cell acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219479', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218397', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218396', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217980', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217978', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Biphenotypic, Acute', 'efo_term': 'T-cell acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218438', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219429', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Biphenotypic, Acute', 'efo_term': 'B-cell acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217973', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Biphenotypic, Acute', 'efo_term': 'B-cell acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218186', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Biphenotypic, Acute', 'efo_term': 'T-cell acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219021', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219436', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219076', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor T-Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'T-lymphoblastic lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218389', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Biphenotypic, Acute', 'efo_term': 'B-cell acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219434', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Biphenotypic, Acute', 'efo_term': 'T-cell acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218394', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Biphenotypic, Acute', 'efo_term': 'T-cell acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218605', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218023', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219492', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor T-Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'T-lymphoblastic lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218439', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218244', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor T-Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'T-lymphoblastic lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218452', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor T-Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'T-lymphoblastic lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219270', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218854', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219013', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Biphenotypic, Acute', 'efo_term': 'B-cell acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218243', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia-Lymphoma, Adult T-Cell', 'efo_term': 'adult T-cell leukemia/lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218390', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217564', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217814', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219437', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218181', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Biphenotypic, Acute', 'efo_term': 'B-cell acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217773', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217558', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218231', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218868', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor T-Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'T-lymphoblastic lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218230', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218855', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218813', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217619', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia-Lymphoma, Adult T-Cell', 'efo_term': 'adult T-cell leukemia/lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217815', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219271', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218812', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218867', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia-Lymphoma, Adult T-Cell', 'efo_term': 'adult T-cell leukemia/lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218810', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Biphenotypic, Acute', 'efo_term': 'T-cell acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217562', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Biphenotypic, Acute', 'efo_term': 'T-cell acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218660', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor T-Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'T-lymphoblastic lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218188', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218189', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219014', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219018', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Biphenotypic, Acute', 'efo_term': 'T-cell acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219020', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218806', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218805', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Biphenotypic, Acute', 'efo_term': 'B-cell acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217620', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor T-Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'T-lymphoblastic lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219062', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219063', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219075', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia-Lymphoma, Adult T-Cell', 'efo_term': 'adult T-cell leukemia/lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218659', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia-Lymphoma, Adult T-Cell', 'efo_term': 'adult T-cell leukemia/lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218036', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor T-Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'T-lymphoblastic lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218647', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219491', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia-Lymphoma, Adult T-Cell', 'efo_term': 'adult T-cell leukemia/lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218646', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218035', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia-Lymphoma, Adult T-Cell', 'efo_term': 'adult T-cell leukemia/lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217770', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Biphenotypic, Acute', 'efo_term': 'T-cell acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218604', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217607', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219226', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Biphenotypic, Acute', 'efo_term': 'T-cell acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218602', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Biphenotypic, Acute', 'efo_term': 'T-cell acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219228', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217772', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217827', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia-Lymphoma, Adult T-Cell', 'efo_term': 'adult T-cell leukemia/lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217828', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor T-Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'T-lymphoblastic lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217565', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217974', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217765', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Biphenotypic, Acute', 'efo_term': 'B-cell acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.205 | Q34 | What are the names of the genes that are targeted by the drug Prednisone in the treatment of posterior uveitis? | In the context of posterior uveitis, the drug Prednisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%posterior uveitis%" OR LOWER(efo_term) LIKE "%posterior uveitis%") AND (LOWER(drugName) LIKE "%prednisone%" OR LOWER(tradeNames_list) LIKE "%prednisone%" OR LOWER(syns_list) LIKE "%prednisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_218711', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219335', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219543', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219751', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220167', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220375', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220583', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220791', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219127', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218295', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217879', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217671', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219959', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218919', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218503', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218087', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.861 | Q34 | What are the names of the genes that are targeted by the drug Aspirin in the treatment of myocardial infarction? | In the context of myocardial infarction, the drug Aspirin targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%myocardial infarction%" OR LOWER(efo_term) LIKE "%myocardial infarction%") AND (LOWER(drugName) LIKE "%aspirin%" OR LOWER(tradeNames_list) LIKE "%aspirin%" OR LOWER(syns_list) LIKE "%aspirin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_834594', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834908', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835850', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835222', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_834431', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_835373', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835530', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835059', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_833809', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834588', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834745', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_835065', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836007', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836001', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_834117', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_835216', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_833652', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834902', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_833646', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_835844', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_834123', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834437', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834280', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833966', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833803', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833960', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_835693', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835536', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_834274', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834751', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_835687', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835379', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_833921', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'ST Elevation Myocardial Infarction', 'efo_term': 'ST Elevation Myocardial Infarction', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834235', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'ST Elevation Myocardial Infarction', 'efo_term': 'ST Elevation Myocardial Infarction', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834863', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'ST Elevation Myocardial Infarction', 'efo_term': 'ST Elevation Myocardial Infarction', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_834236', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Non-ST Elevated Myocardial Infarction', 'efo_term': 'Non-ST Elevation Myocardial Infarction', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_835020', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'ST Elevation Myocardial Infarction', 'efo_term': 'ST Elevation Myocardial Infarction', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835021', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Non-ST Elevated Myocardial Infarction', 'efo_term': 'Non-ST Elevation Myocardial Infarction', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_833922', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Non-ST Elevated Myocardial Infarction', 'efo_term': 'Non-ST Elevation Myocardial Infarction', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_835177', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'ST Elevation Myocardial Infarction', 'efo_term': 'ST Elevation Myocardial Infarction', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_834392', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'ST Elevation Myocardial Infarction', 'efo_term': 'ST Elevation Myocardial Infarction', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_835178', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Non-ST Elevated Myocardial Infarction', 'efo_term': 'Non-ST Elevation Myocardial Infarction', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_834393', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Non-ST Elevated Myocardial Infarction', 'efo_term': 'Non-ST Elevation Myocardial Infarction', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_835334', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'ST Elevation Myocardial Infarction', 'efo_term': 'ST Elevation Myocardial Infarction', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835335', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Non-ST Elevated Myocardial Infarction', 'efo_term': 'Non-ST Elevation Myocardial Infarction', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_833765', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Non-ST Elevated Myocardial Infarction', 'efo_term': 'Non-ST Elevation Myocardial Infarction', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834078', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'ST Elevation Myocardial Infarction', 'efo_term': 'ST Elevation Myocardial Infarction', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834549', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'ST Elevation Myocardial Infarction', 'efo_term': 'ST Elevation Myocardial Infarction', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_835491', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'ST Elevation Myocardial Infarction', 'efo_term': 'ST Elevation Myocardial Infarction', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_833764', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'ST Elevation Myocardial Infarction', 'efo_term': 'ST Elevation Myocardial Infarction', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_835492', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Non-ST Elevated Myocardial Infarction', 'efo_term': 'Non-ST Elevation Myocardial Infarction', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_834550', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Non-ST Elevated Myocardial Infarction', 'efo_term': 'Non-ST Elevation Myocardial Infarction', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_835648', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'ST Elevation Myocardial Infarction', 'efo_term': 'ST Elevation Myocardial Infarction', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835649', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Non-ST Elevated Myocardial Infarction', 'efo_term': 'Non-ST Elevation Myocardial Infarction', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_834864', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Non-ST Elevated Myocardial Infarction', 'efo_term': 'Non-ST Elevation Myocardial Infarction', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_834079', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Non-ST Elevated Myocardial Infarction', 'efo_term': 'Non-ST Elevation Myocardial Infarction', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834706', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'ST Elevation Myocardial Infarction', 'efo_term': 'ST Elevation Myocardial Infarction', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833608', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Non-ST Elevated Myocardial Infarction', 'efo_term': 'Non-ST Elevation Myocardial Infarction', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_835805', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'ST Elevation Myocardial Infarction', 'efo_term': 'ST Elevation Myocardial Infarction', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835806', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Non-ST Elevated Myocardial Infarction', 'efo_term': 'Non-ST Elevation Myocardial Infarction', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_833607', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'ST Elevation Myocardial Infarction', 'efo_term': 'ST Elevation Myocardial Infarction', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834707', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Non-ST Elevated Myocardial Infarction', 'efo_term': 'Non-ST Elevation Myocardial Infarction', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_835962', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'ST Elevation Myocardial Infarction', 'efo_term': 'ST Elevation Myocardial Infarction', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835963', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Non-ST Elevated Myocardial Infarction', 'efo_term': 'Non-ST Elevation Myocardial Infarction', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1924 | Q34 | What are the names of the genes that are targeted by the drug Avacopan in the treatment of anti-neutrophil antibody associated vasculitis? | In the context of anti-neutrophil antibody associated vasculitis, the drug Avacopan targets the gene complement C5a receptor 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%anti-neutrophil antibody associated vasculitis%" OR LOWER(efo_term) LIKE "%anti-neutrophil antibody associated vasculitis%") AND (LOWER(drugName) LIKE "%avacopan%" OR LOWER(tradeNames_list) LIKE "%avacopan%" OR LOWER(syns_list) LIKE "%avacopan%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1191848', 'drugName': 'Avacopan', 'tradeNames_list': "['Tavneos']", 'syns_list': "['Avacopan', 'CCX-168', 'CCX168', 'Ccx168']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis', 'efo_term': 'anti-neutrophil antibody associated vasculitis', 'approvedSymbol': 'C5AR1', 'approvedName': 'complement C5a receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1191856', 'drugName': 'Avacopan', 'tradeNames_list': "['Tavneos']", 'syns_list': "['Avacopan', 'CCX-168', 'CCX168', 'Ccx168']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis', 'efo_term': 'anti-neutrophil antibody associated vasculitis', 'approvedSymbol': 'C5AR1', 'approvedName': 'complement C5a receptor 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1921 | Q34 | What are the names of the genes that are targeted by the drug Bempedoic Acid in the treatment of coronary artery disease? | In the context of coronary artery disease, the drug Bempedoic Acid targets the gene ATP citrate lyase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%coronary artery disease%" OR LOWER(efo_term) LIKE "%coronary artery disease%") AND (LOWER(drugName) LIKE "%bempedoic acid%" OR LOWER(tradeNames_list) LIKE "%bempedoic acid%" OR LOWER(syns_list) LIKE "%bempedoic acid%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1191841', 'drugName': 'Bempedoic Acid', 'tradeNames_list': "['Nexletol']", 'syns_list': "['Bempedoic acid', 'ESP-55016', 'ETC-1002', 'ETC1002']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'ACLY', 'approvedName': 'ATP citrate lyase'}, {'UUID': 'DrugTargetsIndication121923_text_1191809', 'drugName': 'Bempedoic Acid', 'tradeNames_list': "['Nexletol']", 'syns_list': "['Bempedoic acid', 'ESP-55016', 'ETC-1002', 'ETC1002']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'ACLY', 'approvedName': 'ATP citrate lyase'}, {'UUID': 'DrugTargetsIndication121923_text_1191801', 'drugName': 'Bempedoic Acid', 'tradeNames_list': "['Nexletol']", 'syns_list': "['Bempedoic acid', 'ESP-55016', 'ETC-1002', 'ETC1002']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'ACLY', 'approvedName': 'ATP citrate lyase'}, {'UUID': 'DrugTargetsIndication121923_text_1191825', 'drugName': 'Bempedoic Acid', 'tradeNames_list': "['Nexletol']", 'syns_list': "['Bempedoic acid', 'ESP-55016', 'ETC-1002', 'ETC1002']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'ACLY', 'approvedName': 'ATP citrate lyase'}, {'UUID': 'DrugTargetsIndication121923_text_1191833', 'drugName': 'Bempedoic Acid', 'tradeNames_list': "['Nexletol']", 'syns_list': "['Bempedoic acid', 'ESP-55016', 'ETC-1002', 'ETC1002']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'ACLY', 'approvedName': 'ATP citrate lyase'}, {'UUID': 'DrugTargetsIndication121923_text_1191817', 'drugName': 'Bempedoic Acid', 'tradeNames_list': "['Nexletol']", 'syns_list': "['Bempedoic acid', 'ESP-55016', 'ETC-1002', 'ETC1002']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'ACLY', 'approvedName': 'ATP citrate lyase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.522 | Q34 | What are the names of the genes that are targeted by the drug Bepotastine Besylate in the treatment of allergic conjunctivitis? | In the context of allergic conjunctivitis, the drug Bepotastine Besylate targets the gene histamine receptor H1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%allergic conjunctivitis%" OR LOWER(efo_term) LIKE "%allergic conjunctivitis%") AND (LOWER(drugName) LIKE "%bepotastine besylate%" OR LOWER(tradeNames_list) LIKE "%bepotastine besylate%" OR LOWER(syns_list) LIKE "%bepotastine besylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_455769', 'drugName': 'Bepotastine Besylate', 'tradeNames_list': "['Bepreve']", 'syns_list': "['BB', 'Bepotastine Besilate', 'Bepotastine benzenesulfonate saltBepotastine besilate', 'Bepotastine besylate', 'TAU-284', 'Talion']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455772', 'drugName': 'Bepotastine Besylate', 'tradeNames_list': "['Bepreve']", 'syns_list': "['BB', 'Bepotastine Besilate', 'Bepotastine benzenesulfonate saltBepotastine besilate', 'Bepotastine besylate', 'TAU-284', 'Talion']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.50 | Q34 | What are the names of the genes that are targeted by the drug Asenapine Maleate in the treatment of bipolar disorder? | In the context of bipolar disorder, the drug Asenapine Maleate targets the gene dopamine receptor D2 and 5-hydroxytryptamine receptor 2A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%bipolar disorder%" OR LOWER(efo_term) LIKE "%bipolar disorder%") AND (LOWER(drugName) LIKE "%asenapine maleate%" OR LOWER(tradeNames_list) LIKE "%asenapine maleate%" OR LOWER(syns_list) LIKE "%asenapine maleate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_197572', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197583', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197584', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197589', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197595', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197596', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197601', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197607', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197608', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197613', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197614', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197620', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197625', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197626', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197631', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197632', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197637', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197638', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197643', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197644', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197649', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197655', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197656', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197661', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197662', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197667', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197673', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197674', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197679', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197680', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197685', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197686', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197691', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197692', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197697', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197698', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197703', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197704', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197709', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197710', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197715', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197716', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197721', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197722', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197727', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197728', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197733', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197734', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197739', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197740', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197745', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197751', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197752', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197757', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197758', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197763', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197764', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197770', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197775', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197776', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197781', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197782', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197787', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197788', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197793', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197794', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197799', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197800', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197805', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197806', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197746', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197650', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197602', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197578', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197566', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197560', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197559', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197769', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197668', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197619', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197590', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197577', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197571', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197565', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.679 | Q34 | What are the names of the genes that are targeted by the drug Erdafitinib in the treatment of cancer? | In the context of cancer, the drug Erdafitinib targets the gene fibroblast growth factor receptor 1, fibroblast growth factor receptor 3, fibroblast growth factor receptor 2 and fibroblast growth factor receptor 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cancer%" OR LOWER(efo_term) LIKE "%cancer%") AND (LOWER(drugName) LIKE "%erdafitinib%" OR LOWER(tradeNames_list) LIKE "%erdafitinib%" OR LOWER(syns_list) LIKE "%erdafitinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_707573', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707369', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707525', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707433', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707289', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707589', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707321', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707353', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707513', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707385', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707673', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707541', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707449', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707797', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707781', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707577', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707189', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707833', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707109', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707593', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707205', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707145', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707493', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707221', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707637', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707097', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707237', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707705', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707161', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707685', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707253', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707721', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707125', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707545', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707269', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707817', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707177', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707785', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707285', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707813', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707093', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707801', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707301', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707861', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_707193', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707829', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707317', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707849', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707141', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707845', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707333', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707209', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707129', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707349', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707609', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707113', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707561', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707657', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707225', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707625', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707381', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707653', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707157', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707641', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707397', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707753', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707241', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707557', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707413', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707701', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707529', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707689', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707429', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707749', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707257', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707717', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707445', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707737', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707173', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707733', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707461', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707865', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_707273', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707605', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707477', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707881', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_707877', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_707765', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707669', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707621', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707497', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707481', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707337', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707365', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707509', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707417', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707769', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_707305', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707401', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_707465', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'syns_list': "['Erdafitinib', 'JNJ-42756493', 'Jnj-42756493']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.385 | Q34 | What are the names of the genes that are targeted by the drug Mometasone Furoate in the treatment of skin disease? | In the context of skin disease, the drug Mometasone Furoate targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%skin disease%" OR LOWER(efo_term) LIKE "%skin disease%") AND (LOWER(drugName) LIKE "%mometasone furoate%" OR LOWER(tradeNames_list) LIKE "%mometasone furoate%" OR LOWER(syns_list) LIKE "%mometasone furoate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_242039', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242117', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242143', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242169', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242221', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242091', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241987', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241935', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241909', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242195', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242065', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242013', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241961', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1514 | Q34 | What are the names of the genes that are targeted by the drug Angiotensin Ii Acetate in the treatment of septic shock? | In the context of septic shock, the drug Angiotensin Ii Acetate targets the gene angiotensin II receptor type 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%septic shock%" OR LOWER(efo_term) LIKE "%septic shock%") AND (LOWER(drugName) LIKE "%angiotensin ii acetate%" OR LOWER(tradeNames_list) LIKE "%angiotensin ii acetate%" OR LOWER(syns_list) LIKE "%angiotensin ii acetate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1072628', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'syns_list': "['Angiotensin ii acetate', 'Angiotensin ii acetate humanAngiotensin ii triacetate', 'Human angiotensin ii acetate salt']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072631', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'syns_list': "['Angiotensin ii acetate', 'Angiotensin ii acetate humanAngiotensin ii triacetate', 'Human angiotensin ii acetate salt']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072632', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'syns_list': "['Angiotensin ii acetate', 'Angiotensin ii acetate humanAngiotensin ii triacetate', 'Human angiotensin ii acetate salt']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072633', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'syns_list': "['Angiotensin ii acetate', 'Angiotensin ii acetate humanAngiotensin ii triacetate', 'Human angiotensin ii acetate salt']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072635', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'syns_list': "['Angiotensin ii acetate', 'Angiotensin ii acetate humanAngiotensin ii triacetate', 'Human angiotensin ii acetate salt']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072636', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'syns_list': "['Angiotensin ii acetate', 'Angiotensin ii acetate humanAngiotensin ii triacetate', 'Human angiotensin ii acetate salt']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072637', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'syns_list': "['Angiotensin ii acetate', 'Angiotensin ii acetate humanAngiotensin ii triacetate', 'Human angiotensin ii acetate salt']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072639', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'syns_list': "['Angiotensin ii acetate', 'Angiotensin ii acetate humanAngiotensin ii triacetate', 'Human angiotensin ii acetate salt']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072640', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'syns_list': "['Angiotensin ii acetate', 'Angiotensin ii acetate humanAngiotensin ii triacetate', 'Human angiotensin ii acetate salt']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072641', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'syns_list': "['Angiotensin ii acetate', 'Angiotensin ii acetate humanAngiotensin ii triacetate', 'Human angiotensin ii acetate salt']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072642', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'syns_list': "['Angiotensin ii acetate', 'Angiotensin ii acetate humanAngiotensin ii triacetate', 'Human angiotensin ii acetate salt']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072644', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'syns_list': "['Angiotensin ii acetate', 'Angiotensin ii acetate humanAngiotensin ii triacetate', 'Human angiotensin ii acetate salt']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072645', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'syns_list': "['Angiotensin ii acetate', 'Angiotensin ii acetate humanAngiotensin ii triacetate', 'Human angiotensin ii acetate salt']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072646', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'syns_list': "['Angiotensin ii acetate', 'Angiotensin ii acetate humanAngiotensin ii triacetate', 'Human angiotensin ii acetate salt']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072647', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'syns_list': "['Angiotensin ii acetate', 'Angiotensin ii acetate humanAngiotensin ii triacetate', 'Human angiotensin ii acetate salt']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072648', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'syns_list': "['Angiotensin ii acetate', 'Angiotensin ii acetate humanAngiotensin ii triacetate', 'Human angiotensin ii acetate salt']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072649', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'syns_list': "['Angiotensin ii acetate', 'Angiotensin ii acetate humanAngiotensin ii triacetate', 'Human angiotensin ii acetate salt']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072650', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'syns_list': "['Angiotensin ii acetate', 'Angiotensin ii acetate humanAngiotensin ii triacetate', 'Human angiotensin ii acetate salt']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072651', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'syns_list': "['Angiotensin ii acetate', 'Angiotensin ii acetate humanAngiotensin ii triacetate', 'Human angiotensin ii acetate salt']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072652', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'syns_list': "['Angiotensin ii acetate', 'Angiotensin ii acetate humanAngiotensin ii triacetate', 'Human angiotensin ii acetate salt']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072653', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'syns_list': "['Angiotensin ii acetate', 'Angiotensin ii acetate humanAngiotensin ii triacetate', 'Human angiotensin ii acetate salt']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072655', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'syns_list': "['Angiotensin ii acetate', 'Angiotensin ii acetate humanAngiotensin ii triacetate', 'Human angiotensin ii acetate salt']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072656', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'syns_list': "['Angiotensin ii acetate', 'Angiotensin ii acetate humanAngiotensin ii triacetate', 'Human angiotensin ii acetate salt']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072657', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'syns_list': "['Angiotensin ii acetate', 'Angiotensin ii acetate humanAngiotensin ii triacetate', 'Human angiotensin ii acetate salt']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072658', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'syns_list': "['Angiotensin ii acetate', 'Angiotensin ii acetate humanAngiotensin ii triacetate', 'Human angiotensin ii acetate salt']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072659', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'syns_list': "['Angiotensin ii acetate', 'Angiotensin ii acetate humanAngiotensin ii triacetate', 'Human angiotensin ii acetate salt']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072661', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'syns_list': "['Angiotensin ii acetate', 'Angiotensin ii acetate humanAngiotensin ii triacetate', 'Human angiotensin ii acetate salt']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072662', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'syns_list': "['Angiotensin ii acetate', 'Angiotensin ii acetate humanAngiotensin ii triacetate', 'Human angiotensin ii acetate salt']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072663', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'syns_list': "['Angiotensin ii acetate', 'Angiotensin ii acetate humanAngiotensin ii triacetate', 'Human angiotensin ii acetate salt']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072664', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'syns_list': "['Angiotensin ii acetate', 'Angiotensin ii acetate humanAngiotensin ii triacetate', 'Human angiotensin ii acetate salt']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072654', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'syns_list': "['Angiotensin ii acetate', 'Angiotensin ii acetate humanAngiotensin ii triacetate', 'Human angiotensin ii acetate salt']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072638', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'syns_list': "['Angiotensin ii acetate', 'Angiotensin ii acetate humanAngiotensin ii triacetate', 'Human angiotensin ii acetate salt']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072630', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'syns_list': "['Angiotensin ii acetate', 'Angiotensin ii acetate humanAngiotensin ii triacetate', 'Human angiotensin ii acetate salt']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072626', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'syns_list': "['Angiotensin ii acetate', 'Angiotensin ii acetate humanAngiotensin ii triacetate', 'Human angiotensin ii acetate salt']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072624', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'syns_list': "['Angiotensin ii acetate', 'Angiotensin ii acetate humanAngiotensin ii triacetate', 'Human angiotensin ii acetate salt']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072623', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'syns_list': "['Angiotensin ii acetate', 'Angiotensin ii acetate humanAngiotensin ii triacetate', 'Human angiotensin ii acetate salt']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072660', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'syns_list': "['Angiotensin ii acetate', 'Angiotensin ii acetate humanAngiotensin ii triacetate', 'Human angiotensin ii acetate salt']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072643', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'syns_list': "['Angiotensin ii acetate', 'Angiotensin ii acetate humanAngiotensin ii triacetate', 'Human angiotensin ii acetate salt']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072634', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'syns_list': "['Angiotensin ii acetate', 'Angiotensin ii acetate humanAngiotensin ii triacetate', 'Human angiotensin ii acetate salt']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072629', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'syns_list': "['Angiotensin ii acetate', 'Angiotensin ii acetate humanAngiotensin ii triacetate', 'Human angiotensin ii acetate salt']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072627', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'syns_list': "['Angiotensin ii acetate', 'Angiotensin ii acetate humanAngiotensin ii triacetate', 'Human angiotensin ii acetate salt']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072625', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_list': "['Giapreza']", 'syns_list': "['Angiotensin ii acetate', 'Angiotensin ii acetate humanAngiotensin ii triacetate', 'Human angiotensin ii acetate salt']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Shock, Septic', 'efo_term': 'septic shock', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1946 | Q34 | What are the names of the genes that are targeted by the drug Sapropterin Dihydrochloride in the treatment of Hyperphenylalaninemia? | In the context of Hyperphenylalaninemia, the drug Sapropterin Dihydrochloride targets the gene phenylalanine hydroxylase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hyperphenylalaninemia%" OR LOWER(efo_term) LIKE "%hyperphenylalaninemia%") AND (LOWER(drugName) LIKE "%sapropterin dihydrochloride%" OR LOWER(tradeNames_list) LIKE "%sapropterin dihydrochloride%" OR LOWER(syns_list) LIKE "%sapropterin dihydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1192317', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192350', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192361', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192372', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192394', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192405', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192416', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192438', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192449', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192460', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192471', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192493', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192504', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192515', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192526', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192537', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192548', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192559', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192570', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192581', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192592', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192614', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192625', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192636', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192647', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192658', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192427', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192339', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192295', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192273', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192262', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192603', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192482', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192383', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192328', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192306', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}, {'UUID': 'DrugTargetsIndication121923_text_1192284', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'syns_list': "['Biopten', 'Dapropterin hydrochloride', 'Phenoptin', 'SUN-0588SUN-0588 (SHIRATORI)', 'Sapropterin dihydrochlorideSapropterin hydrochloride', 'T-1401', 'T1401', 'T1401 (BIOMARIN)']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1666 | Q34 | What are the names of the genes that are targeted by the drug Finerenone in the treatment of cardiovascular disease? | In the context of cardiovascular disease, the drug Finerenone targets the gene nuclear receptor subfamily 3 group C member 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cardiovascular disease%" OR LOWER(efo_term) LIKE "%cardiovascular disease%") AND (LOWER(drugName) LIKE "%finerenone%" OR LOWER(tradeNames_list) LIKE "%finerenone%" OR LOWER(syns_list) LIKE "%finerenone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1094662', 'drugName': 'Finerenone', 'tradeNames_list': "['Kerendia']", 'syns_list': "['BAY 94-8862', 'BAY-94-8862', 'Bay94-8862', 'Finerenone']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094666', 'drugName': 'Finerenone', 'tradeNames_list': "['Kerendia']", 'syns_list': "['BAY 94-8862', 'BAY-94-8862', 'Bay94-8862', 'Finerenone']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1520 | Q34 | What are the names of the genes that are targeted by the drug Telmisartan in the treatment of hypertension? | In the context of hypertension, the drug Telmisartan targets the gene angiotensin II receptor type 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hypertension%" OR LOWER(efo_term) LIKE "%hypertension%") AND (LOWER(drugName) LIKE "%telmisartan%" OR LOWER(tradeNames_list) LIKE "%telmisartan%" OR LOWER(syns_list) LIKE "%telmisartan%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1072710', 'drugName': 'Telmisartan', 'tradeNames_list': "['Micardis', 'Telmisartan', 'Tolura']", 'syns_list': "['BIBR 277 SE', 'BIBR-277', 'BIBR-277 SE', 'BIBR-277-SE', 'BIBR-277SEC09CA07', 'Kinzalmono', 'Pritor', 'Semintra', 'TelmisartanTelmisartan actavis', 'Telmisartan teva']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072704', 'drugName': 'Telmisartan', 'tradeNames_list': "['Micardis', 'Telmisartan', 'Tolura']", 'syns_list': "['BIBR 277 SE', 'BIBR-277', 'BIBR-277 SE', 'BIBR-277-SE', 'BIBR-277SEC09CA07', 'Kinzalmono', 'Pritor', 'Semintra', 'TelmisartanTelmisartan actavis', 'Telmisartan teva']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Essential Hypertension', 'efo_term': 'essential hypertension', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1169 | Q34 | What are the names of the genes that are targeted by the drug Trametinib in the treatment of metastatic melanoma? | Trametinib has not been approved by the FDA as a treatment for metastatic melanoma, but it is currently undergoing evaluation in clinical trials for this purpose. However, the proposed gene target names are mitogen-activated protein kinase kinase 2 and mitogen-activated protein kinase kinase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%metastatic melanoma%" OR LOWER(efo_term) LIKE "%metastatic melanoma%") AND (LOWER(drugName) LIKE "%trametinib%" OR LOWER(tradeNames_list) LIKE "%trametinib%" OR LOWER(syns_list) LIKE "%trametinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_927765', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927786', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927793', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927800', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927814', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927821', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927828', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927842', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927849', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927856', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927863', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927877', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927884', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927891', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927898', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927905', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927912', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927919', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927926', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927933', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927940', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927954', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927961', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927968', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927975', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927982', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927996', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928003', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928010', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928017', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928024', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928031', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928038', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928045', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928052', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928059', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928066', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928073', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928080', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928087', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928094', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928101', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928108', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928115', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928122', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928129', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928136', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928143', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928150', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928157', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928164', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928178', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928185', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928192', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928199', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928206', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928213', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928227', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928234', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928241', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928248', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928255', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928262', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928269', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928276', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928283', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928290', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928297', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928304', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928311', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928318', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928325', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928332', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928339', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928346', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928353', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928360', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928367', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928374', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928381', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928388', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928395', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928402', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928409', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928416', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928423', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928171', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927947', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927835', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927779', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927751', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927737', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927730', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928220', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927989', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927870', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927807', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927772', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927758', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927744', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.356 | Q34 | What are the names of the genes that are targeted by the drug Fluticasone Propionate in the treatment of Airway obstruction? | In the context of Airway obstruction, the drug Fluticasone Propionate targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%airway obstruction%" OR LOWER(efo_term) LIKE "%airway obstruction%") AND (LOWER(drugName) LIKE "%fluticasone propionate%" OR LOWER(tradeNames_list) LIKE "%fluticasone propionate%" OR LOWER(syns_list) LIKE "%fluticasone propionate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_232526', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232607', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232634', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232661', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232715', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232742', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232769', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232823', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232850', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232877', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232904', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232958', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232985', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233012', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233039', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233066', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233093', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233120', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233147', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233174', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233201', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233255', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233282', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233309', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233336', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233363', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233417', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233444', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233471', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233498', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233525', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233552', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233579', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233606', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233633', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233660', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233687', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233714', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233741', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233768', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233795', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233822', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233849', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233876', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233903', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233930', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233957', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233984', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234011', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234038', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234065', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234119', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234146', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234173', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234200', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234227', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234254', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234308', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234335', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234362', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234389', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234416', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234443', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234470', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234497', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234524', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234551', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234578', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234605', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234632', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234659', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234686', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234713', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234740', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234767', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234794', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234821', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234848', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234875', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234902', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234929', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234956', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234983', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_235010', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_235037', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_235064', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234092', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233228', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232796', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232580', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232472', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232418', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232391', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234281', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233390', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232931', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232688', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232553', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232499', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232445', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1500 | Q34 | What are the names of the genes that are targeted by the drug Methotrexate in the treatment of breast cancer? | In the context of breast cancer, the drug Methotrexate targets the gene dihydrofolate reductase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%breast cancer%" OR LOWER(efo_term) LIKE "%breast cancer%") AND (LOWER(drugName) LIKE "%methotrexate%" OR LOWER(tradeNames_list) LIKE "%methotrexate%" OR LOWER(syns_list) LIKE "%methotrexate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1057601', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058084', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058245', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058406', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058728', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058889', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059050', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059372', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059533', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059694', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059855', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060177', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060338', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060499', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060660', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060821', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060982', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061143', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061304', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061465', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061626', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061948', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062109', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062270', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062431', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062592', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062914', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063075', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063236', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063397', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063558', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063719', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063880', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064041', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064202', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064363', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064524', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064685', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064846', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065007', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065168', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065329', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065490', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065651', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065812', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065973', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066134', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066295', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066456', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066617', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066778', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067100', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067261', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067422', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067583', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067744', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067905', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068227', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068388', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068549', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068710', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068871', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069032', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069193', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069354', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069515', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069676', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069837', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069998', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070159', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070320', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070481', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070642', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070803', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070964', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071125', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071286', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071447', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071608', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071769', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071930', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072091', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072252', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072413', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066939', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061787', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059211', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057923', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057279', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1056957', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1056796', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068066', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062753', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060016', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058567', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057762', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057440', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057118', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1349 | Q34 | What are the names of the genes that are targeted by the drug Defibrotide Sodium in the treatment of hepatic veno-occlusive disease? | In the context of hepatic veno-occlusive disease, the drug Defibrotide Sodium targets the gene plasminogen. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hepatic veno-occlusive disease%" OR LOWER(efo_term) LIKE "%hepatic veno-occlusive disease%") AND (LOWER(drugName) LIKE "%defibrotide sodium%" OR LOWER(tradeNames_list) LIKE "%defibrotide sodium%" OR LOWER(syns_list) LIKE "%defibrotide sodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_993273', 'drugName': 'Defibrotide Sodium', 'tradeNames_list': "['Defitelio']", 'syns_list': "['Defibrotide sodium', 'JZP-381']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatic Veno-Occlusive Disease', 'efo_term': 'hepatic veno-occlusive disease', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993274', 'drugName': 'Defibrotide Sodium', 'tradeNames_list': "['Defitelio']", 'syns_list': "['Defibrotide sodium', 'JZP-381']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hepatic Veno-Occlusive Disease', 'efo_term': 'hepatic veno-occlusive disease', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.433 | Q34 | What are the names of the genes that are targeted by the drug Carvedilol in the treatment of congestive heart failure? | In the context of congestive heart failure, the drug Carvedilol targets the gene adrenoceptor alpha 1A, adrenoceptor beta 2, adrenoceptor beta 1, adrenoceptor beta 3, adrenoceptor alpha 1D and adrenoceptor alpha 1B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%congestive heart failure%" OR LOWER(efo_term) LIKE "%congestive heart failure%") AND (LOWER(drugName) LIKE "%carvedilol%" OR LOWER(tradeNames_list) LIKE "%carvedilol%" OR LOWER(syns_list) LIKE "%carvedilol%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_357136', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357232', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357264', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357296', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357360', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357392', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357424', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357488', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357520', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357552', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357584', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357648', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357680', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357712', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357744', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357776', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357808', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357840', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357872', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357904', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357936', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_358000', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_358032', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_358064', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_358096', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_358128', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_358192', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_358224', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_358256', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358288', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358320', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358352', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358384', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358416', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358448', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358480', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358512', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358544', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358576', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358608', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358640', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358672', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358704', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358736', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358768', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358800', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358832', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358864', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358896', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_358928', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_358960', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359024', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359056', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359088', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359120', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359152', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359184', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359248', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359280', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359312', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359344', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359376', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359408', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359440', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359472', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359504', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359536', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359568', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359600', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359632', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359664', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359696', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359728', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359760', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359792', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359824', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359856', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359888', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359920', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359952', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359984', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_360016', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_360048', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_360080', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_360112', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_360144', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_358992', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_357968', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357456', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357200', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357072', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357008', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_356976', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_359216', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_358160', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357616', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357328', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357168', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357104', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357040', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1358 | Q34 | What are the names of the genes that are targeted by the drug Acalabrutinib in the treatment of cancer? | In the context of cancer, the drug Acalabrutinib targets the gene Bruton tyrosine kinase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cancer%" OR LOWER(efo_term) LIKE "%cancer%") AND (LOWER(drugName) LIKE "%acalabrutinib%" OR LOWER(tradeNames_list) LIKE "%acalabrutinib%" OR LOWER(syns_list) LIKE "%acalabrutinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_994368', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994598', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994253', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994437', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994552', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994667', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994161', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994414', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994644', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994828', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994299', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994000', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994943', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994322', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994920', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994966', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994690', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994782', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994092', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994230', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994759', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994713', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994069', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994184', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994736', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994345', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994851', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994989', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994897', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994460', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994046', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994207', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_993977', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994529', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994483', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994138', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994621', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994391', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994276', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994023', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994805', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994506', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994575', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994874', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994115', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994500', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994684', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_993994', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994247', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994523', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994546', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994270', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994569', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994109', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994592', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994040', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994293', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994615', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994638', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994132', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994983', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_993971', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994017', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994063', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994339', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994707', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994730', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994362', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994753', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994776', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994178', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994799', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994385', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994822', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994408', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994845', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994868', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994086', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994201', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994155', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994431', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994891', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994914', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994454', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994937', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994960', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994224', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994477', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994661', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_994316', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'syns_list': "['ACP-196', 'Acalabrutinib', 'Acp-196']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.220 | Q34 | What are the names of the genes that are targeted by the drug Desoximetasone in the treatment of psoriasis? | In the context of psoriasis, the drug Desoximetasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%psoriasis%" OR LOWER(efo_term) LIKE "%psoriasis%") AND (LOWER(drugName) LIKE "%desoximetasone%" OR LOWER(tradeNames_list) LIKE "%desoximetasone%" OR LOWER(syns_list) LIKE "%desoximetasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_220822', 'drugName': 'Desoximetasone', 'tradeNames_list': "['Desoximetasone', 'Stiedex', 'Stiedex lp', 'Stiedex lpn', 'TopicortTopicort lp']", 'syns_list': "['A-41-304', 'A-41304', 'Desoximetasone', 'Desoxymethasone', 'HOE 304HOE-304', 'J83.644C', 'NSC-759189', 'R 2113', 'R-2113']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220820', 'drugName': 'Desoximetasone', 'tradeNames_list': "['Desoximetasone', 'Stiedex', 'Stiedex lp', 'Stiedex lpn', 'TopicortTopicort lp']", 'syns_list': "['A-41-304', 'A-41304', 'Desoximetasone', 'Desoxymethasone', 'HOE 304HOE-304', 'J83.644C', 'NSC-759189', 'R 2113', 'R-2113']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220825', 'drugName': 'Desoximetasone', 'tradeNames_list': "['Desoximetasone', 'Stiedex', 'Stiedex lp', 'Stiedex lpn', 'TopicortTopicort lp']", 'syns_list': "['A-41-304', 'A-41304', 'Desoximetasone', 'Desoxymethasone', 'HOE 304HOE-304', 'J83.644C', 'NSC-759189', 'R 2113', 'R-2113']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220823', 'drugName': 'Desoximetasone', 'tradeNames_list': "['Desoximetasone', 'Stiedex', 'Stiedex lp', 'Stiedex lpn', 'TopicortTopicort lp']", 'syns_list': "['A-41-304', 'A-41304', 'Desoximetasone', 'Desoxymethasone', 'HOE 304HOE-304', 'J83.644C', 'NSC-759189', 'R 2113', 'R-2113']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1911 | Q34 | What are the names of the genes that are targeted by the drug Tafluprost in the treatment of glaucoma? | In the context of glaucoma, the drug Tafluprost targets the gene prostaglandin F receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%glaucoma%" OR LOWER(efo_term) LIKE "%glaucoma%") AND (LOWER(drugName) LIKE "%tafluprost%" OR LOWER(tradeNames_list) LIKE "%tafluprost%" OR LOWER(syns_list) LIKE "%tafluprost%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1149440', 'drugName': 'Tafluprost', 'tradeNames_list': "['Saflutan', 'Zioptan']", 'syns_list': "['AFP-168', 'MK-2452', 'Tafluprost']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149434', 'drugName': 'Tafluprost', 'tradeNames_list': "['Saflutan', 'Zioptan']", 'syns_list': "['AFP-168', 'MK-2452', 'Tafluprost']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149433', 'drugName': 'Tafluprost', 'tradeNames_list': "['Saflutan', 'Zioptan']", 'syns_list': "['AFP-168', 'MK-2452', 'Tafluprost']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149437', 'drugName': 'Tafluprost', 'tradeNames_list': "['Saflutan', 'Zioptan']", 'syns_list': "['AFP-168', 'MK-2452', 'Tafluprost']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149439', 'drugName': 'Tafluprost', 'tradeNames_list': "['Saflutan', 'Zioptan']", 'syns_list': "['AFP-168', 'MK-2452', 'Tafluprost']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149436', 'drugName': 'Tafluprost', 'tradeNames_list': "['Saflutan', 'Zioptan']", 'syns_list': "['AFP-168', 'MK-2452', 'Tafluprost']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1618 | Q34 | What are the names of the genes that are targeted by the drug Dabigatran Etexilate Mesylate in the treatment of atrial fibrillation? | In the context of atrial fibrillation, the drug Dabigatran Etexilate Mesylate targets the gene coagulation factor II, thrombin. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%atrial fibrillation%" OR LOWER(efo_term) LIKE "%atrial fibrillation%") AND (LOWER(drugName) LIKE "%dabigatran etexilate mesylate%" OR LOWER(tradeNames_list) LIKE "%dabigatran etexilate mesylate%" OR LOWER(syns_list) LIKE "%dabigatran etexilate mesylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1092393', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092408', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092413', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092418', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092428', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092433', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092438', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092448', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092453', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092458', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092463', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092473', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092478', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092483', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092488', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092493', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092498', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092503', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092508', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092513', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092518', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092528', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092533', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092538', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092543', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092548', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092558', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092563', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092568', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092573', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092578', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092583', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092588', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092593', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092598', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092603', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092608', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092613', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092618', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092623', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092628', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092633', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092638', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092643', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092648', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092523', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092443', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092403', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092383', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092373', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092368', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092553', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092468', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092423', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092398', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092388', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092378', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 1048 MS', 'BIBR-1048-MS', 'Dabigatran etexilate mesilateDabigatran etexilate mesylate']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrial Fibrillation', 'efo_term': 'atrial fibrillation', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1020 | Q34 | What are the names of the genes that are targeted by the drug Tiotropium Bromide in the treatment of Airway obstruction? | In the context of Airway obstruction, the drug Tiotropium Bromide targets the gene cholinergic receptor muscarinic 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%airway obstruction%" OR LOWER(efo_term) LIKE "%airway obstruction%") AND (LOWER(drugName) LIKE "%tiotropium bromide%" OR LOWER(tradeNames_list) LIKE "%tiotropium bromide%" OR LOWER(syns_list) LIKE "%tiotropium bromide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_857911', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857944', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857955', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857966', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857988', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857999', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_858010', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_858032', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_858043', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_858054', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_858065', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_858087', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_858098', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_858109', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_858120', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_858131', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_858142', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_858153', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_858164', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_858175', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_858186', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_858208', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_858219', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_858230', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_858241', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_858252', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_858197', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_858021', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857933', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857889', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857867', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857856', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_858263', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_858076', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857977', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857922', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857900', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857878', 'drugName': 'Tiotropium Bromide', 'tradeNames_list': "['Spiriva', 'Spiriva respimat']", 'syns_list': "['BA 679 BR', 'BA-679 BR', 'BA-679-BR', 'BA-679BR', 'Tiotropium bromideTiotropium bromide anhydrous', 'Tiotropium bromide hydrateTiotropium bromide monohydrate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.685 | Q34 | What are the names of the genes that are targeted by the drug Rivaroxaban in the treatment of Venous thrombosis? | In the context of Venous thrombosis, the drug Rivaroxaban targets the gene coagulation factor X. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%venous thrombosis%" OR LOWER(efo_term) LIKE "%venous thrombosis%") AND (LOWER(drugName) LIKE "%rivaroxaban%" OR LOWER(tradeNames_list) LIKE "%rivaroxaban%" OR LOWER(syns_list) LIKE "%rivaroxaban%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_708753', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_708820', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_708823', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_708855', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_708890', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_708893', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_708925', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_708960', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_708963', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_708995', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_708998', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709033', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709065', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709068', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709100', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709103', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709135', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709138', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709170', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709173', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709205', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709240', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709243', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709275', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709278', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709310', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709345', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709348', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709380', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709383', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709415', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709418', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709450', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709453', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709485', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709488', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709520', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709523', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709555', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709558', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709590', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709593', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709625', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709628', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709660', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709663', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709695', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709698', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709730', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709733', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709765', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709800', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709803', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709835', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709838', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709870', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709873', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709908', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709940', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709943', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709975', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709978', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710010', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710013', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710045', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710048', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710080', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710083', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710115', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710118', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710150', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710153', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710185', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710188', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710220', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710223', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710255', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710258', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710290', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710293', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709768', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709208', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_708928', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_708788', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_708718', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_708683', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_708680', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709905', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709313', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709030', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_708858', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'deep vein thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_708785', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_708750', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_708715', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Venous Thrombosis', 'efo_term': 'Venous thrombosis', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.60 | Q34 | What are the names of the genes that are targeted by the drug Lurasidone in the treatment of schizoaffective disorder? | In the context of schizoaffective disorder, the drug Lurasidone targets the gene dopamine receptor D2 and 5-hydroxytryptamine receptor 2A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%schizoaffective disorder%" OR LOWER(efo_term) LIKE "%schizoaffective disorder%") AND (LOWER(drugName) LIKE "%lurasidone%" OR LOWER(tradeNames_list) LIKE "%lurasidone%" OR LOWER(syns_list) LIKE "%lurasidone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_198425', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198449', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198457', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198465', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198481', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198489', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198497', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198513', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198521', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198529', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198537', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198553', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198561', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198569', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198577', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198585', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198593', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198601', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198609', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198617', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198625', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198641', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198649', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198657', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198665', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198673', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198689', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198697', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198705', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198713', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198721', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198729', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198737', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198745', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198753', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198761', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198769', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198777', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198785', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198793', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198801', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198809', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198817', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198825', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198833', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198841', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198849', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198857', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198865', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198873', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198881', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198897', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198905', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198913', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198921', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198929', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198937', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198953', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198961', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198969', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198977', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198985', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198993', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199001', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199009', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199017', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199025', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_199033', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_199041', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_199049', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_199057', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_199065', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_199073', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_199081', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_199089', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_199097', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_199105', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_199113', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_199121', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_199129', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_199137', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_199145', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_199153', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_199161', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_199169', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_199177', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_198889', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198633', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198505', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198441', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198409', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198393', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198385', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198945', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198681', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198545', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198473', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198433', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198417', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198401', 'drugName': 'Lurasidone', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1237 | Q34 | What are the names of the genes that are targeted by the drug Mirabegron in the treatment of urgency urinary incontinence? | In the context of urgency urinary incontinence, the drug Mirabegron targets the gene adrenoceptor beta 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%urgency urinary incontinence%" OR LOWER(efo_term) LIKE "%urgency urinary incontinence%") AND (LOWER(drugName) LIKE "%mirabegron%" OR LOWER(tradeNames_list) LIKE "%mirabegron%" OR LOWER(syns_list) LIKE "%mirabegron%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_937774', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937822', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937838', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937854', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937886', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937902', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937918', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937950', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937966', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937982', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937998', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938030', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938046', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938062', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938078', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938094', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938110', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938126', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938142', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938158', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938174', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938206', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938222', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938238', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938254', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938190', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937806', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937742', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937710', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937694', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937934', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938014', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937870', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937790', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937758', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_937726', 'drugName': 'Mirabegron', 'tradeNames_list': "['Betmiga', 'Myrbetriq', 'Myrbetriq granules']", 'syns_list': "['Betanis', 'Mirabegron', 'YM-178', 'YM178']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.482 | Q34 | What are the names of the genes that are targeted by the drug Dextroamphetamine in the treatment of arteriosclerosis disorder? | In the context of arteriosclerosis disorder, the drug Dextroamphetamine targets the gene solute carrier family 6 member 2, solute carrier family 18 member A2 and solute carrier family 6 member 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%arteriosclerosis disorder%" OR LOWER(efo_term) LIKE "%arteriosclerosis disorder%") AND (LOWER(drugName) LIKE "%dextroamphetamine%" OR LOWER(tradeNames_list) LIKE "%dextroamphetamine%" OR LOWER(syns_list) LIKE "%dextroamphetamine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_418426', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418465', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418478', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418491', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418517', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418530', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418543', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418569', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418582', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418595', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418608', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418634', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418647', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418660', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418673', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418686', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418699', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418712', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418725', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418738', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418751', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418777', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418790', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418803', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418816', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418829', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418855', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418868', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418881', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418894', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418907', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418920', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418933', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418946', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418959', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418972', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418985', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418998', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419011', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419024', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419037', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419050', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419063', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419076', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419089', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419102', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419115', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419128', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418764', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418556', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418452', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418400', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418374', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418361', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418842', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418621', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418504', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418439', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418413', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418387', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arteriosclerosis', 'efo_term': 'arteriosclerosis disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.75 | Q34 | What are the names of the genes that are targeted by the drug Rotigotine in the treatment of restless legs syndrome? | In the context of restless legs syndrome, the drug Rotigotine targets the gene dopamine receptor D2, dopamine receptor D3 and dopamine receptor D4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%restless legs syndrome%" OR LOWER(efo_term) LIKE "%restless legs syndrome%") AND (LOWER(drugName) LIKE "%rotigotine%" OR LOWER(tradeNames_list) LIKE "%rotigotine%" OR LOWER(syns_list) LIKE "%rotigotine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_200736', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200751', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200756', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200761', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200771', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200776', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200781', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200791', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200796', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200801', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200806', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200816', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200821', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200826', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200831', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200836', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200841', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200846', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200851', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200856', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200861', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200871', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200876', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200881', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200886', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200891', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200901', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200906', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200911', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200916', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200921', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200926', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200931', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200936', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200941', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200946', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200951', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200956', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200961', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200966', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200971', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200976', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200981', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200986', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200991', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200996', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_201001', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_201006', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_201011', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_201016', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_201021', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_201031', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_201036', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_201041', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_201046', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_201051', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_201056', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_201066', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_201071', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_201076', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_201081', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_201086', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_201091', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_201096', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_201101', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_201106', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_201111', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_201116', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_201121', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_201126', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_201131', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_201136', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_201141', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_201146', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_201151', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_201156', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_201161', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_201166', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_201171', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_201176', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_201181', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_201186', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_201191', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_201196', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_201201', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_201206', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_201026', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200866', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200786', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200746', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200726', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200716', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200711', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201061', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200896', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200811', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200766', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200741', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200731', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200721', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Restless Legs Syndrome', 'efo_term': 'restless legs syndrome', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.164 | Q34 | What are the names of the genes that are targeted by the drug Prednisone in the treatment of juvenile dermatomyositis? | In the context of juvenile dermatomyositis, the drug Prednisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%juvenile dermatomyositis%" OR LOWER(efo_term) LIKE "%juvenile dermatomyositis%") AND (LOWER(drugName) LIKE "%prednisone%" OR LOWER(tradeNames_list) LIKE "%prednisone%" OR LOWER(syns_list) LIKE "%prednisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_218670', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatomyositis', 'efo_term': 'juvenile dermatomyositis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219294', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatomyositis', 'efo_term': 'juvenile dermatomyositis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219502', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatomyositis', 'efo_term': 'juvenile dermatomyositis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219710', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatomyositis', 'efo_term': 'juvenile dermatomyositis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220126', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatomyositis', 'efo_term': 'juvenile dermatomyositis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220334', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatomyositis', 'efo_term': 'juvenile dermatomyositis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220542', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatomyositis', 'efo_term': 'juvenile dermatomyositis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220750', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatomyositis', 'efo_term': 'juvenile dermatomyositis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219086', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatomyositis', 'efo_term': 'juvenile dermatomyositis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218254', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatomyositis', 'efo_term': 'juvenile dermatomyositis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217838', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatomyositis', 'efo_term': 'juvenile dermatomyositis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217630', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatomyositis', 'efo_term': 'juvenile dermatomyositis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219918', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatomyositis', 'efo_term': 'juvenile dermatomyositis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218878', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatomyositis', 'efo_term': 'juvenile dermatomyositis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218462', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatomyositis', 'efo_term': 'juvenile dermatomyositis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218046', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatomyositis', 'efo_term': 'juvenile dermatomyositis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1696 | Q34 | What are the names of the genes that are targeted by the drug Relugolix in the treatment of neoplasm? | In the context of neoplasm, the drug Relugolix targets the gene gonadotropin releasing hormone receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%relugolix%" OR LOWER(tradeNames_list) LIKE "%relugolix%" OR LOWER(syns_list) LIKE "%relugolix%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1096971', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096954', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096946', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096970', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096945', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096962', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096963', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096986', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096960', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096978', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096947', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096976', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096977', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096961', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096979', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096985', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096987', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096953', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096969', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096968', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096955', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096984', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096952', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096944', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096943', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096959', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096967', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096975', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096951', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1096983', 'drugName': 'Relugolix', 'tradeNames_list': "['Orgovyx']", 'syns_list': "['Relugolix', 'TAK-385', 'Tak-385']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.489 | Q34 | What are the names of the genes that are targeted by the drug Bupropion Hydrochloride in the treatment of unipolar depression? | In the context of unipolar depression, the drug Bupropion Hydrochloride targets the gene solute carrier family 6 member 2 and solute carrier family 6 member 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%unipolar depression%" OR LOWER(efo_term) LIKE "%unipolar depression%") AND (LOWER(drugName) LIKE "%bupropion hydrochloride%" OR LOWER(tradeNames_list) LIKE "%bupropion hydrochloride%" OR LOWER(syns_list) LIKE "%bupropion hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_434139', 'drugName': 'Bupropion Hydrochloride', 'tradeNames_list': "['Bupropion hydrochloride', 'Forfivo xl', 'Wellbutrin', 'Wellbutrin 100Wellbutrin 75', 'Wellbutrin sr', 'Wellbutrin xl', 'Zyban']", 'syns_list': "['Amfebutamone hydrochloride', 'BW 323', 'BW-323', 'BW323', 'Bupropion HClBupropion hcl', 'Bupropion hydrochloride', 'Mysimba', 'NSC-315851']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434122', 'drugName': 'Bupropion Hydrochloride', 'tradeNames_list': "['Bupropion hydrochloride', 'Forfivo xl', 'Wellbutrin', 'Wellbutrin 100Wellbutrin 75', 'Wellbutrin sr', 'Wellbutrin xl', 'Zyban']", 'syns_list': "['Amfebutamone hydrochloride', 'BW 323', 'BW-323', 'BW323', 'Bupropion HClBupropion hcl', 'Bupropion hydrochloride', 'Mysimba', 'NSC-315851']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seasonal Affective Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434121', 'drugName': 'Bupropion Hydrochloride', 'tradeNames_list': "['Bupropion hydrochloride', 'Forfivo xl', 'Wellbutrin', 'Wellbutrin 100Wellbutrin 75', 'Wellbutrin sr', 'Wellbutrin xl', 'Zyban']", 'syns_list': "['Amfebutamone hydrochloride', 'BW 323', 'BW-323', 'BW323', 'Bupropion HClBupropion hcl', 'Bupropion hydrochloride', 'Mysimba', 'NSC-315851']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434137', 'drugName': 'Bupropion Hydrochloride', 'tradeNames_list': "['Bupropion hydrochloride', 'Forfivo xl', 'Wellbutrin', 'Wellbutrin 100Wellbutrin 75', 'Wellbutrin sr', 'Wellbutrin xl', 'Zyban']", 'syns_list': "['Amfebutamone hydrochloride', 'BW 323', 'BW-323', 'BW323', 'Bupropion HClBupropion hcl', 'Bupropion hydrochloride', 'Mysimba', 'NSC-315851']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434138', 'drugName': 'Bupropion Hydrochloride', 'tradeNames_list': "['Bupropion hydrochloride', 'Forfivo xl', 'Wellbutrin', 'Wellbutrin 100Wellbutrin 75', 'Wellbutrin sr', 'Wellbutrin xl', 'Zyban']", 'syns_list': "['Amfebutamone hydrochloride', 'BW 323', 'BW-323', 'BW323', 'Bupropion HClBupropion hcl', 'Bupropion hydrochloride', 'Mysimba', 'NSC-315851']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seasonal Affective Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_434123', 'drugName': 'Bupropion Hydrochloride', 'tradeNames_list': "['Bupropion hydrochloride', 'Forfivo xl', 'Wellbutrin', 'Wellbutrin 100Wellbutrin 75', 'Wellbutrin sr', 'Wellbutrin xl', 'Zyban']", 'syns_list': "['Amfebutamone hydrochloride', 'BW 323', 'BW-323', 'BW323', 'Bupropion HClBupropion hcl', 'Bupropion hydrochloride', 'Mysimba', 'NSC-315851']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.530 | Q34 | What are the names of the genes that are targeted by the drug Carbinoxamine Maleate in the treatment of seasonal allergic rhinitis? | In the context of seasonal allergic rhinitis, the drug Carbinoxamine Maleate targets the gene histamine receptor H1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%seasonal allergic rhinitis%" OR LOWER(efo_term) LIKE "%seasonal allergic rhinitis%") AND (LOWER(drugName) LIKE "%carbinoxamine maleate%" OR LOWER(tradeNames_list) LIKE "%carbinoxamine maleate%" OR LOWER(syns_list) LIKE "%carbinoxamine maleate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_455848', 'drugName': 'Carbinoxamine Maleate', 'tradeNames_list': "['Carbinoxamine maleate', 'Clistin', 'Davenol', 'Karbinal er']", 'syns_list': "['Carbinoxamine maleate', 'NSC-62362']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455854', 'drugName': 'Carbinoxamine Maleate', 'tradeNames_list': "['Carbinoxamine maleate', 'Clistin', 'Davenol', 'Karbinal er']", 'syns_list': "['Carbinoxamine maleate', 'NSC-62362']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1034 | Q34 | What are the names of the genes that are targeted by the drug Duvelisib in the treatment of neoplasm of mature B-cells? | In the context of neoplasm of mature B-cells, the drug Duvelisib targets the gene phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm of mature b-cells%" OR LOWER(efo_term) LIKE "%neoplasm of mature b-cells%") AND (LOWER(drugName) LIKE "%duvelisib%" OR LOWER(tradeNames_list) LIKE "%duvelisib%" OR LOWER(syns_list) LIKE "%duvelisib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_858836', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858896', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858916', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858936', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858976', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858996', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859016', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859056', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859076', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859096', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859116', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859156', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859176', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859196', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859216', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859236', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859256', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859276', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859036', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858876', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858796', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858756', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858736', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859136', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858956', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858856', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858816', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858776', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.571 | Q34 | What are the names of the genes that are targeted by the drug Lidocaine in the treatment of cardiac arrhythmia? | In the context of cardiac arrhythmia, the drug Lidocaine targets the gene sodium voltage-gated channel alpha subunit 1, sodium voltage-gated channel alpha subunit 5, sodium voltage-gated channel alpha subunit 4, sodium voltage-gated channel alpha subunit 7, sodium voltage-gated channel alpha subunit 2, sodium voltage-gated channel alpha subunit 9, sodium voltage-gated channel alpha subunit 3, sodium voltage-gated channel alpha subunit 11, sodium voltage-gated channel alpha subunit 8 and sodium voltage-gated channel alpha subunit 10. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cardiac arrhythmia%" OR LOWER(efo_term) LIKE "%cardiac arrhythmia%") AND (LOWER(drugName) LIKE "%lidocaine%" OR LOWER(tradeNames_list) LIKE "%lidocaine%" OR LOWER(syns_list) LIKE "%lidocaine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_638360', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_638705', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638820', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638935', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_639165', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639280', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639395', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639625', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639740', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639855', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_639970', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640200', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640315', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640430', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640545', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640660', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640775', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640890', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_641005', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_641120', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_641235', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641465', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641580', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641695', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641810', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641925', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642155', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642270', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642385', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642500', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642615', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_642730', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_642845', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_642960', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_643075', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_643190', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_643305', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643420', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643535', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643650', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643765', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643880', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643995', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_644110', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_644225', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_644340', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_644455', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_644570', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_641350', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_639510', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_638590', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638130', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_637900', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_637785', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_642040', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_640085', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_639050', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638475', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638245', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_638015', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'cardiac arrhythmia', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1312 | Q34 | What are the names of the genes that are targeted by the drug Vericiguat in the treatment of cardiovascular disease? | In the context of cardiovascular disease, the drug Vericiguat targets the gene guanylate cyclase 1 soluble subunit beta 1, guanylate cyclase 1 soluble subunit beta 2 (pseudogene), guanylate cyclase 1 soluble subunit alpha 2 and guanylate cyclase 1 soluble subunit alpha 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cardiovascular disease%" OR LOWER(efo_term) LIKE "%cardiovascular disease%") AND (LOWER(drugName) LIKE "%vericiguat%" OR LOWER(tradeNames_list) LIKE "%vericiguat%" OR LOWER(syns_list) LIKE "%vericiguat%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_972740', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972749', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972752', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972755', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972761', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972764', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972767', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972773', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_972776', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_972779', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_972782', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_972788', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_972791', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_972794', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_972797', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_972800', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_972803', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_972806', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_972809', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_972812', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_972815', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1A2', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_972821', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1A2', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_972824', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1A2', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_972827', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1A2', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_972830', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1A2', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_972833', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1A2', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_972839', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1A2', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_972842', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1A2', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_972845', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1A2', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_972848', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1A2', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_972851', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1A2', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_972854', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1A2', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_972857', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1A2', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_972860', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1A1', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_972863', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1A1', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_972866', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1A1', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_972869', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1A1', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_972872', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1A1', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_972875', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1A1', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_972878', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1A1', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_972881', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1A1', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_972884', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1A1', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_972887', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1A1', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_972890', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1A1', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_972893', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1A1', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_972896', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1A1', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_972899', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1A1', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_972902', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1A1', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_972818', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1A2', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_972770', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_972746', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972734', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972728', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972725', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972836', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1A2', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_972785', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_972758', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972743', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972737', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972731', 'drugName': 'Vericiguat', 'tradeNames_list': "['Verquvo']", 'syns_list': "['BAY 1021189', 'BAY-1021189', 'MK-1242', 'Vericiguat']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.46 | Q34 | What are the names of the genes that are targeted by the drug Aripiprazole in the treatment of depressive disorder? | In the context of depressive disorder, the drug Aripiprazole targets the gene dopamine receptor D2, 5-hydroxytryptamine receptor 2A and 5-hydroxytryptamine receptor 1A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%depressive disorder%" OR LOWER(efo_term) LIKE "%depressive disorder%") AND (LOWER(drugName) LIKE "%aripiprazole%" OR LOWER(tradeNames_list) LIKE "%aripiprazole%" OR LOWER(syns_list) LIKE "%aripiprazole%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_158030', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158048', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158054', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158060', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158072', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158078', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158084', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158096', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158102', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158108', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158114', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158126', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158132', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158138', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158144', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158150', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158156', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158162', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158168', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158174', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158180', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158192', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158198', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158204', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158210', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158216', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158228', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158234', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158240', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158246', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158252', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158258', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158264', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158270', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158276', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158282', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158288', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158294', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158300', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158306', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158312', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158318', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158324', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158330', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158336', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158342', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158348', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158354', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158360', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158366', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158372', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158384', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158390', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158396', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158402', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158408', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158414', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158426', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158432', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158438', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158444', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158450', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158456', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158462', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158468', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158474', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158480', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158486', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158492', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158498', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158504', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158510', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158516', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158522', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158528', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158534', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158540', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158546', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158552', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158558', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158564', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158570', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158576', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158582', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158588', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158594', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158378', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158186', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158090', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158042', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158018', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158006', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158000', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158420', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158222', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158120', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158066', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158036', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158024', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158012', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.923 | Q34 | What are the names of the genes that are targeted by the drug Naproxen in the treatment of osteoarthritis? | In the context of osteoarthritis, the drug Naproxen targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%osteoarthritis%" OR LOWER(efo_term) LIKE "%osteoarthritis%") AND (LOWER(drugName) LIKE "%naproxen%" OR LOWER(tradeNames_list) LIKE "%naproxen%" OR LOWER(syns_list) LIKE "%naproxen%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_839045', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839373', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838069', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838471', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838256', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838239', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838273', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839701', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839660', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839578', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838389', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839086', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839004', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839250', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838676', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838103', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838137', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838222', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839168', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838799', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838717', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838171', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839209', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838348', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838881', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839619', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838963', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838553', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838430', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838086', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838205', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839496', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839127', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838922', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839455', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839414', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838840', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839537', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839291', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838154', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838188', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838052', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838635', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838120', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838290', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839332', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838594', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838307', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838512', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838758', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839223', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838567', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839345', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838607', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838608', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839386', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839387', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838566', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838648', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838649', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839428', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838812', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838813', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838361', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838689', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838690', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838854', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839222', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838362', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838402', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838895', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838935', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839100', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838403', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838976', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839264', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839304', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839058', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838977', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838936', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839018', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838443', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839017', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838444', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838894', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838484', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839059', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839099', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838485', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838853', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839140', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839141', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838321', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838525', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839181', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839182', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839346', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839427', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838526', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838730', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1633 | Q34 | What are the names of the genes that are targeted by the drug Dabigatran in the treatment of injury? | Dabigatran has not been approved by the FDA as a treatment for injury, but it is currently undergoing evaluation in clinical trials for this purpose. However, the proposed gene target name is coagulation factor II, thrombin. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%injury%" OR LOWER(efo_term) LIKE "%injury%") AND (LOWER(drugName) LIKE "%dabigatran%" OR LOWER(tradeNames_list) LIKE "%dabigatran%" OR LOWER(syns_list) LIKE "%dabigatran%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1093466', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093499', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093510', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093521', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093543', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093554', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093565', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093587', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093598', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093609', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093620', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093642', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093653', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093664', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093675', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093686', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093697', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093708', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093719', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093730', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093741', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093763', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093774', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093785', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093796', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093807', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093829', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093840', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093851', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093862', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093873', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093884', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093895', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093906', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093917', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093928', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093939', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093950', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093961', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093972', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093983', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093994', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1094005', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1094016', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1094027', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093752', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093576', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093488', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093444', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093422', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093411', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093818', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093631', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093532', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093477', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093455', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093433', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.533 | Q34 | What are the names of the genes that are targeted by the drug Carbinoxamine Maleate in the treatment of allergic conjunctivitis? | In the context of allergic conjunctivitis, the drug Carbinoxamine Maleate targets the gene histamine receptor H1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%allergic conjunctivitis%" OR LOWER(efo_term) LIKE "%allergic conjunctivitis%") AND (LOWER(drugName) LIKE "%carbinoxamine maleate%" OR LOWER(tradeNames_list) LIKE "%carbinoxamine maleate%" OR LOWER(syns_list) LIKE "%carbinoxamine maleate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_455851', 'drugName': 'Carbinoxamine Maleate', 'tradeNames_list': "['Carbinoxamine maleate', 'Clistin', 'Davenol', 'Karbinal er']", 'syns_list': "['Carbinoxamine maleate', 'NSC-62362']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455857', 'drugName': 'Carbinoxamine Maleate', 'tradeNames_list': "['Carbinoxamine maleate', 'Clistin', 'Davenol', 'Karbinal er']", 'syns_list': "['Carbinoxamine maleate', 'NSC-62362']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.78 | Q34 | What are the names of the genes that are targeted by the drug Bromocriptine Mesylate in the treatment of infertility? | In the context of infertility, the drug Bromocriptine Mesylate targets the gene dopamine receptor D2, dopamine receptor D3 and dopamine receptor D4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%infertility%" OR LOWER(efo_term) LIKE "%infertility%") AND (LOWER(drugName) LIKE "%bromocriptine mesylate%" OR LOWER(tradeNames_list) LIKE "%bromocriptine mesylate%" OR LOWER(syns_list) LIKE "%bromocriptine mesylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_201374', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201395', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201402', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201409', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201423', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201430', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201437', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201451', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201458', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201465', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201472', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201486', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201493', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201500', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201507', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201514', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201521', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201528', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201535', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201542', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201549', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201563', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201570', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201577', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201584', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201591', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201605', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201612', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201619', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201626', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201633', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201640', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201647', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201654', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201661', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201668', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201675', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201682', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201689', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201696', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201703', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201710', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201717', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201724', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201731', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201738', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201745', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201752', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201759', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201766', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201773', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201787', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201794', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201801', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201808', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201815', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201822', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201836', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201843', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201850', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201857', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201864', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201871', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201878', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201885', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201892', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201899', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201906', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201913', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201920', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201927', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201934', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201941', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201948', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201955', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201962', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201969', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201976', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201983', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201990', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201997', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_202004', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_202011', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_202018', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_202025', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_202032', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201780', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201556', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201444', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201388', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201360', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201346', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201339', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201829', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201598', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201479', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201416', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201381', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201367', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201353', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infertility', 'efo_term': 'infertility', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1897 | Q34 | What are the names of the genes that are targeted by the drug Latanoprostene Bunod in the treatment of open-angle glaucoma? | In the context of open-angle glaucoma, the drug Latanoprostene Bunod targets the gene prostaglandin F receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%open-angle glaucoma%" OR LOWER(efo_term) LIKE "%open-angle glaucoma%") AND (LOWER(drugName) LIKE "%latanoprostene bunod%" OR LOWER(tradeNames_list) LIKE "%latanoprostene bunod%" OR LOWER(syns_list) LIKE "%latanoprostene bunod%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1149106', 'drugName': 'Latanoprostene Bunod', 'tradeNames_list': "['Vesneo', 'Vyzulta']", 'syns_list': "['BOL-303259-X', 'Bol-303259-x', 'Latanoprostene bunod', 'NCX 116', 'NCX-116PF-3187207']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149103', 'drugName': 'Latanoprostene Bunod', 'tradeNames_list': "['Vesneo', 'Vyzulta']", 'syns_list': "['BOL-303259-X', 'Bol-303259-x', 'Latanoprostene bunod', 'NCX 116', 'NCX-116PF-3187207']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149112', 'drugName': 'Latanoprostene Bunod', 'tradeNames_list': "['Vesneo', 'Vyzulta']", 'syns_list': "['BOL-303259-X', 'Bol-303259-x', 'Latanoprostene bunod', 'NCX 116', 'NCX-116PF-3187207']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149109', 'drugName': 'Latanoprostene Bunod', 'tradeNames_list': "['Vesneo', 'Vyzulta']", 'syns_list': "['BOL-303259-X', 'Bol-303259-x', 'Latanoprostene bunod', 'NCX 116', 'NCX-116PF-3187207']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1594 | Q34 | What are the names of the genes that are targeted by the drug Rasagiline Mesylate in the treatment of Parkinson disease? | In the context of Parkinson disease, the drug Rasagiline Mesylate targets the gene monoamine oxidase B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%parkinson disease%" OR LOWER(efo_term) LIKE "%parkinson disease%") AND (LOWER(drugName) LIKE "%rasagiline mesylate%" OR LOWER(tradeNames_list) LIKE "%rasagiline mesylate%" OR LOWER(syns_list) LIKE "%rasagiline mesylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1091637', 'drugName': 'Rasagiline Mesylate', 'tradeNames_list': "['Azilect', 'Rasagiline mesylate']", 'syns_list': "['Agilect', 'Azilect', 'Rasagiline (as mesilate)', 'Rasagiline mesilateRasagiline mesylate', 'Rasagline ratiopharm', 'TVP-1012']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'MAOB', 'approvedName': 'monoamine oxidase B'}, {'UUID': 'DrugTargetsIndication121923_text_1091635', 'drugName': 'Rasagiline Mesylate', 'tradeNames_list': "['Azilect', 'Rasagiline mesylate']", 'syns_list': "['Agilect', 'Azilect', 'Rasagiline (as mesilate)', 'Rasagiline mesilateRasagiline mesylate', 'Rasagline ratiopharm', 'TVP-1012']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'MAOB', 'approvedName': 'monoamine oxidase B'}, {'UUID': 'DrugTargetsIndication121923_text_1091641', 'drugName': 'Rasagiline Mesylate', 'tradeNames_list': "['Azilect', 'Rasagiline mesylate']", 'syns_list': "['Agilect', 'Azilect', 'Rasagiline (as mesilate)', 'Rasagiline mesilateRasagiline mesylate', 'Rasagline ratiopharm', 'TVP-1012']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'MAOB', 'approvedName': 'monoamine oxidase B'}, {'UUID': 'DrugTargetsIndication121923_text_1091639', 'drugName': 'Rasagiline Mesylate', 'tradeNames_list': "['Azilect', 'Rasagiline mesylate']", 'syns_list': "['Agilect', 'Azilect', 'Rasagiline (as mesilate)', 'Rasagiline mesilateRasagiline mesylate', 'Rasagline ratiopharm', 'TVP-1012']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'MAOB', 'approvedName': 'monoamine oxidase B'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.490 | Q34 | What are the names of the genes that are targeted by the drug Bupropion Hydrochloride in the treatment of mood disorder? | In the context of mood disorder, the drug Bupropion Hydrochloride targets the gene solute carrier family 6 member 2 and solute carrier family 6 member 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%mood disorder%" OR LOWER(efo_term) LIKE "%mood disorder%") AND (LOWER(drugName) LIKE "%bupropion hydrochloride%" OR LOWER(tradeNames_list) LIKE "%bupropion hydrochloride%" OR LOWER(syns_list) LIKE "%bupropion hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_434124', 'drugName': 'Bupropion Hydrochloride', 'tradeNames_list': "['Bupropion hydrochloride', 'Forfivo xl', 'Wellbutrin', 'Wellbutrin 100Wellbutrin 75', 'Wellbutrin sr', 'Wellbutrin xl', 'Zyban']", 'syns_list': "['Amfebutamone hydrochloride', 'BW 323', 'BW-323', 'BW323', 'Bupropion HClBupropion hcl', 'Bupropion hydrochloride', 'Mysimba', 'NSC-315851']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mood Disorders', 'efo_term': 'mood disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_434140', 'drugName': 'Bupropion Hydrochloride', 'tradeNames_list': "['Bupropion hydrochloride', 'Forfivo xl', 'Wellbutrin', 'Wellbutrin 100Wellbutrin 75', 'Wellbutrin sr', 'Wellbutrin xl', 'Zyban']", 'syns_list': "['Amfebutamone hydrochloride', 'BW 323', 'BW-323', 'BW323', 'Bupropion HClBupropion hcl', 'Bupropion hydrochloride', 'Mysimba', 'NSC-315851']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mood Disorders', 'efo_term': 'mood disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1005 | Q34 | What are the names of the genes that are targeted by the drug Aclidinium Bromide in the treatment of asthma? | In the context of asthma, the drug Aclidinium Bromide targets the gene cholinergic receptor muscarinic 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%asthma%" OR LOWER(efo_term) LIKE "%asthma%") AND (LOWER(drugName) LIKE "%aclidinium bromide%" OR LOWER(tradeNames_list) LIKE "%aclidinium bromide%" OR LOWER(syns_list) LIKE "%aclidinium bromide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_857461', 'drugName': 'Aclidinium Bromide', 'tradeNames_list': "['Eklira', 'Tudorza pressair']", 'syns_list': "['14115700', 'Aclidinium bromide', 'Genuair', 'LAS 34273LAS 34273 MICRONIZED', 'LAS W-330', 'LAS-34273', 'LAS-34273 MICRONIZEDLAS-W-330']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857443', 'drugName': 'Aclidinium Bromide', 'tradeNames_list': "['Eklira', 'Tudorza pressair']", 'syns_list': "['14115700', 'Aclidinium bromide', 'Genuair', 'LAS 34273LAS 34273 MICRONIZED', 'LAS W-330', 'LAS-34273', 'LAS-34273 MICRONIZEDLAS-W-330']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857449', 'drugName': 'Aclidinium Bromide', 'tradeNames_list': "['Eklira', 'Tudorza pressair']", 'syns_list': "['14115700', 'Aclidinium bromide', 'Genuair', 'LAS 34273LAS 34273 MICRONIZED', 'LAS W-330', 'LAS-34273', 'LAS-34273 MICRONIZEDLAS-W-330']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857467', 'drugName': 'Aclidinium Bromide', 'tradeNames_list': "['Eklira', 'Tudorza pressair']", 'syns_list': "['14115700', 'Aclidinium bromide', 'Genuair', 'LAS 34273LAS 34273 MICRONIZED', 'LAS W-330', 'LAS-34273', 'LAS-34273 MICRONIZEDLAS-W-330']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857455', 'drugName': 'Aclidinium Bromide', 'tradeNames_list': "['Eklira', 'Tudorza pressair']", 'syns_list': "['14115700', 'Aclidinium bromide', 'Genuair', 'LAS 34273LAS 34273 MICRONIZED', 'LAS W-330', 'LAS-34273', 'LAS-34273 MICRONIZEDLAS-W-330']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'asthma', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.417 | Q34 | What are the names of the genes that are targeted by the drug Choline Fenofibrate in the treatment of cardiovascular disease? | In the context of cardiovascular disease, the drug Choline Fenofibrate targets the gene peroxisome proliferator activated receptor alpha. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cardiovascular disease%" OR LOWER(efo_term) LIKE "%cardiovascular disease%") AND (LOWER(drugName) LIKE "%choline fenofibrate%" OR LOWER(tradeNames_list) LIKE "%choline fenofibrate%" OR LOWER(syns_list) LIKE "%choline fenofibrate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_243908', 'drugName': 'Choline Fenofibrate', 'tradeNames_list': "['Trilipix']", 'syns_list': "['ABT-335', 'Choline fenofibrate', 'Fenofibric acid choline salt']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243913', 'drugName': 'Choline Fenofibrate', 'tradeNames_list': "['Trilipix']", 'syns_list': "['ABT-335', 'Choline fenofibrate', 'Fenofibric acid choline salt']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.353 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of congenital adrenal hyperplasia? | In the context of congenital adrenal hyperplasia, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%congenital adrenal hyperplasia%" OR LOWER(efo_term) LIKE "%congenital adrenal hyperplasia%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_226954', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'congenital adrenal hyperplasia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227522', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227524', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'congenital adrenal hyperplasia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227807', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228092', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228094', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'congenital adrenal hyperplasia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228377', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228662', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228664', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'congenital adrenal hyperplasia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228947', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228949', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'congenital adrenal hyperplasia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229234', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'congenital adrenal hyperplasia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229517', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229519', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'congenital adrenal hyperplasia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229802', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229804', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'congenital adrenal hyperplasia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230087', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230089', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'congenital adrenal hyperplasia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230372', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230374', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'congenital adrenal hyperplasia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230657', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230942', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230944', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'congenital adrenal hyperplasia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231227', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231229', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'congenital adrenal hyperplasia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231512', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231797', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231799', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'congenital adrenal hyperplasia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232082', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232084', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'congenital adrenal hyperplasia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232367', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232369', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'congenital adrenal hyperplasia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230659', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'congenital adrenal hyperplasia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228379', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'congenital adrenal hyperplasia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227239', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'congenital adrenal hyperplasia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226669', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'congenital adrenal hyperplasia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226384', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'congenital adrenal hyperplasia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226382', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231514', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'congenital adrenal hyperplasia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229232', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227809', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'congenital adrenal hyperplasia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227237', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226952', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226667', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.793 | Q34 | What are the names of the genes that are targeted by the drug Niraparib Tosylate in the treatment of peritoneal neoplasm? | In the context of peritoneal neoplasm, the drug Niraparib Tosylate targets the gene poly(ADP-ribose) polymerase 2 and poly(ADP-ribose) polymerase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%peritoneal neoplasm%" OR LOWER(efo_term) LIKE "%peritoneal neoplasm%") AND (LOWER(drugName) LIKE "%niraparib tosylate%" OR LOWER(tradeNames_list) LIKE "%niraparib tosylate%" OR LOWER(syns_list) LIKE "%niraparib tosylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_823356', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneal neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_823368', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneal neoplasm', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_823372', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneal neoplasm', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_823376', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneal neoplasm', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_823364', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneal neoplasm', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_823348', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneal neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_823340', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneal neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_823336', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneal neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_823380', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneal neoplasm', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_823360', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneal neoplasm', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_823352', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneal neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_823344', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneal neoplasm', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.31 | Q34 | What are the names of the genes that are targeted by the drug Clozapine in the treatment of schizophrenia? | In the context of schizophrenia, the drug Clozapine targets the gene dopamine receptor D2 and 5-hydroxytryptamine receptor 2A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%schizophrenia%" OR LOWER(efo_term) LIKE "%schizophrenia%") AND (LOWER(drugName) LIKE "%clozapine%" OR LOWER(tradeNames_list) LIKE "%clozapine%" OR LOWER(syns_list) LIKE "%clozapine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_157986', 'drugName': 'Clozapine', 'tradeNames_list': "['Clozapine', 'Clozaril', 'Fazaclo', 'Fazaclo odt', 'Versacloz', 'Zaponex']", 'syns_list': "['Clozapine', 'Clozapine (caraco)', 'Clozapine (clozaril)Clozapine (fazaclo)', 'Clozapine (ivax)', 'Clozapine (mylan)Clozapine (teva)', 'Clozapine (udl)', 'Clozapine (versacloz)Clozapine resolution mixture', 'HF 1854', 'HF-1854', 'Leponex', 'NSC-757429']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_157995', 'drugName': 'Clozapine', 'tradeNames_list': "['Clozapine', 'Clozaril', 'Fazaclo', 'Fazaclo odt', 'Versacloz', 'Zaponex']", 'syns_list': "['Clozapine', 'Clozapine (caraco)', 'Clozapine (clozaril)Clozapine (fazaclo)', 'Clozapine (ivax)', 'Clozapine (mylan)Clozapine (teva)', 'Clozapine (udl)', 'Clozapine (versacloz)Clozapine resolution mixture', 'HF 1854', 'HF-1854', 'Leponex', 'NSC-757429']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1575 | Q34 | What are the names of the genes that are targeted by the drug Everolimus in the treatment of neoplasm? | In the context of neoplasm, the drug Everolimus targets the gene FKBP prolyl isomerase 1A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%everolimus%" OR LOWER(tradeNames_list) LIKE "%everolimus%" OR LOWER(syns_list) LIKE "%everolimus%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1085633', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1084955', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085495', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085224', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085765', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086859', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085903', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085359', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085371', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1084961', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086439', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085498', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085239', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086845', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086721', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085779', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085768', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086986', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086979', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085914', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085911', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086035', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086169', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1084954', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086304', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1084958', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1084966', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086575', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086311', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086443', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086446', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086578', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085225', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085506', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085509', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086851', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085636', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086844', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086724', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086848', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085764', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085776', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085771', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087114', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086856', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086983', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086980', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086994', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085900', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086991', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085906', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085374', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086041', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086038', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086176', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086049', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086173', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086305', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085363', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086184', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085089', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085366', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085093', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085096', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085101', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086710', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1084969', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086319', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086316', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086574', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086440', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086454', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086451', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086709', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085236', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085231', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085228', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086589', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085501', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086586', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086581', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087115', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085630', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085644', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085641', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087121', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087118', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086713', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086308', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086181', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086046', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086034', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085360', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086170', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085090', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085494', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086716', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085899', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085104', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085629', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.300 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of juvenile idiopathic arthritis? | In the context of juvenile idiopathic arthritis, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%juvenile idiopathic arthritis%" OR LOWER(efo_term) LIKE "%juvenile idiopathic arthritis%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_227755', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228610', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228895', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229180', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229750', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230035', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230320', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230890', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231175', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231460', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231745', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232315', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230605', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228325', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227185', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226615', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226330', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232030', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229465', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228040', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227470', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226900', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.607 | Q34 | What are the names of the genes that are targeted by the drug Ranolazine in the treatment of angina pectoris? | In the context of angina pectoris, the drug Ranolazine targets the gene sodium voltage-gated channel alpha subunit 5 and sodium voltage-gated channel alpha subunit 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%angina pectoris%" OR LOWER(efo_term) LIKE "%angina pectoris%") AND (LOWER(drugName) LIKE "%ranolazine%" OR LOWER(tradeNames_list) LIKE "%ranolazine%" OR LOWER(syns_list) LIKE "%ranolazine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_662708', 'drugName': 'Ranolazine', 'tradeNames_list': "['Aspruzyo sprinkle', 'Ranexa', 'Ranolazine']", 'syns_list': "['Aspruzyo', 'CVT-303', 'NSC-759100', 'RS-43285-003', 'Ran d', 'Ranolazine']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_662725', 'drugName': 'Ranolazine', 'tradeNames_list': "['Aspruzyo sprinkle', 'Ranexa', 'Ranolazine']", 'syns_list': "['Aspruzyo', 'CVT-303', 'NSC-759100', 'RS-43285-003', 'Ran d', 'Ranolazine']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.777 | Q34 | What are the names of the genes that are targeted by the drug Oliceridine in the treatment of pain? | In the context of pain, the drug Oliceridine targets the gene opioid receptor mu 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pain%" OR LOWER(efo_term) LIKE "%pain%") AND (LOWER(drugName) LIKE "%oliceridine%" OR LOWER(tradeNames_list) LIKE "%oliceridine%" OR LOWER(syns_list) LIKE "%oliceridine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_792092', 'drugName': 'Oliceridine', 'tradeNames_list': "['Olinvyk', 'Olynvik']", 'syns_list': "['Oliceridine', 'TRV-130', 'TRV130']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792095', 'drugName': 'Oliceridine', 'tradeNames_list': "['Olinvyk', 'Olynvik']", 'syns_list': "['Oliceridine', 'TRV-130', 'TRV130']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792096', 'drugName': 'Oliceridine', 'tradeNames_list': "['Olinvyk', 'Olynvik']", 'syns_list': "['Oliceridine', 'TRV-130', 'TRV130']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792097', 'drugName': 'Oliceridine', 'tradeNames_list': "['Olinvyk', 'Olynvik']", 'syns_list': "['Oliceridine', 'TRV-130', 'TRV130']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792099', 'drugName': 'Oliceridine', 'tradeNames_list': "['Olinvyk', 'Olynvik']", 'syns_list': "['Oliceridine', 'TRV-130', 'TRV130']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792100', 'drugName': 'Oliceridine', 'tradeNames_list': "['Olinvyk', 'Olynvik']", 'syns_list': "['Oliceridine', 'TRV-130', 'TRV130']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792101', 'drugName': 'Oliceridine', 'tradeNames_list': "['Olinvyk', 'Olynvik']", 'syns_list': "['Oliceridine', 'TRV-130', 'TRV130']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792103', 'drugName': 'Oliceridine', 'tradeNames_list': "['Olinvyk', 'Olynvik']", 'syns_list': "['Oliceridine', 'TRV-130', 'TRV130']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792104', 'drugName': 'Oliceridine', 'tradeNames_list': "['Olinvyk', 'Olynvik']", 'syns_list': "['Oliceridine', 'TRV-130', 'TRV130']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792105', 'drugName': 'Oliceridine', 'tradeNames_list': "['Olinvyk', 'Olynvik']", 'syns_list': "['Oliceridine', 'TRV-130', 'TRV130']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792106', 'drugName': 'Oliceridine', 'tradeNames_list': "['Olinvyk', 'Olynvik']", 'syns_list': "['Oliceridine', 'TRV-130', 'TRV130']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792108', 'drugName': 'Oliceridine', 'tradeNames_list': "['Olinvyk', 'Olynvik']", 'syns_list': "['Oliceridine', 'TRV-130', 'TRV130']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792109', 'drugName': 'Oliceridine', 'tradeNames_list': "['Olinvyk', 'Olynvik']", 'syns_list': "['Oliceridine', 'TRV-130', 'TRV130']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792110', 'drugName': 'Oliceridine', 'tradeNames_list': "['Olinvyk', 'Olynvik']", 'syns_list': "['Oliceridine', 'TRV-130', 'TRV130']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792102', 'drugName': 'Oliceridine', 'tradeNames_list': "['Olinvyk', 'Olynvik']", 'syns_list': "['Oliceridine', 'TRV-130', 'TRV130']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792094', 'drugName': 'Oliceridine', 'tradeNames_list': "['Olinvyk', 'Olynvik']", 'syns_list': "['Oliceridine', 'TRV-130', 'TRV130']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792090', 'drugName': 'Oliceridine', 'tradeNames_list': "['Olinvyk', 'Olynvik']", 'syns_list': "['Oliceridine', 'TRV-130', 'TRV130']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792088', 'drugName': 'Oliceridine', 'tradeNames_list': "['Olinvyk', 'Olynvik']", 'syns_list': "['Oliceridine', 'TRV-130', 'TRV130']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792087', 'drugName': 'Oliceridine', 'tradeNames_list': "['Olinvyk', 'Olynvik']", 'syns_list': "['Oliceridine', 'TRV-130', 'TRV130']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792107', 'drugName': 'Oliceridine', 'tradeNames_list': "['Olinvyk', 'Olynvik']", 'syns_list': "['Oliceridine', 'TRV-130', 'TRV130']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792098', 'drugName': 'Oliceridine', 'tradeNames_list': "['Olinvyk', 'Olynvik']", 'syns_list': "['Oliceridine', 'TRV-130', 'TRV130']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792093', 'drugName': 'Oliceridine', 'tradeNames_list': "['Olinvyk', 'Olynvik']", 'syns_list': "['Oliceridine', 'TRV-130', 'TRV130']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792091', 'drugName': 'Oliceridine', 'tradeNames_list': "['Olinvyk', 'Olynvik']", 'syns_list': "['Oliceridine', 'TRV-130', 'TRV130']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792089', 'drugName': 'Oliceridine', 'tradeNames_list': "['Olinvyk', 'Olynvik']", 'syns_list': "['Oliceridine', 'TRV-130', 'TRV130']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.498 | Q34 | What are the names of the genes that are targeted by the drug Amphetamine in the treatment of attention deficit hyperactivity disorder? | In the context of attention deficit hyperactivity disorder, the drug Amphetamine targets the gene solute carrier family 6 member 2 and solute carrier family 6 member 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%attention deficit hyperactivity disorder%" OR LOWER(efo_term) LIKE "%attention deficit hyperactivity disorder%") AND (LOWER(drugName) LIKE "%amphetamine%" OR LOWER(tradeNames_list) LIKE "%amphetamine%" OR LOWER(syns_list) LIKE "%amphetamine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_418424', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418463', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418476', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418489', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418515', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418528', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418541', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418567', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418580', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418593', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418606', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418632', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418645', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418658', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418671', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418684', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418697', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418710', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418723', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418736', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418749', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418775', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418788', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418801', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418814', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418827', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418853', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418866', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418879', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418892', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418905', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418918', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418931', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418944', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418957', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418970', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418983', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_418996', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419009', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419022', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419035', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419048', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419061', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419074', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419087', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419100', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419113', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419126', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_419137', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419148', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419159', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419181', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419192', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419203', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419214', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419225', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419236', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419258', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419269', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419280', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419291', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419302', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419313', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419324', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419335', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419346', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419357', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419368', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419379', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419390', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419401', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419412', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419423', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419434', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419445', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419456', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419467', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419478', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419489', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419500', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419511', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419522', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419533', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419544', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419555', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419566', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419170', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418762', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418554', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418450', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418398', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418372', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418359', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_419247', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_list': "['Elvanse', 'Elvanse adult', 'Vyvanse']", 'syns_list': "['Lisdexamfetamine dimesilate', 'Lisdexamfetamine dimesylateLisdexamfetamine dimethanesulfonate', 'Lisdexamfetamine mesilateLisdexamphetamine dimesilate', 'NRP-104', 'NRP104', 'SPD-489', 'SPD489Tyvense']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418840', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418619', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_418502', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418437', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418411', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_418385', 'drugName': 'Dextroamphetamine', 'tradeNames_list': "['Dexedrine', 'Dextrostat', 'Xelstrym']", 'syns_list': "['Amfetamine, (s)-', 'Amphetamine, d-', 'D-amphetamine', 'DexamfetamineDexampex', 'Dexamphetamine', 'Dexedrine', 'Dexidrine', 'DextroamphetamineDextroamphetamine resin complex', 'Dextrostat', 'Ferndex', 'NSC-73713Xelstrym']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1060 | Q34 | What are the names of the genes that are targeted by the drug Imiquimod in the treatment of viral disease? | In the context of viral disease, the drug Imiquimod targets the gene toll like receptor 7. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%viral disease%" OR LOWER(efo_term) LIKE "%viral disease%") AND (LOWER(drugName) LIKE "%imiquimod%" OR LOWER(tradeNames_list) LIKE "%imiquimod%" OR LOWER(syns_list) LIKE "%imiquimod%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_919778', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_919937', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_919990', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_920043', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_920149', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_920202', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_920255', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_920308', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_919884', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_919672', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_919566', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_919513', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_920096', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_919831', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_919725', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_919619', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Virus Diseases', 'efo_term': 'viral disease', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1536 | Q34 | What are the names of the genes that are targeted by the drug Dronabinol in the treatment of Nausea and vomiting? | In the context of Nausea and vomiting, the drug Dronabinol targets the gene cannabinoid receptor 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%nausea and vomiting%" OR LOWER(efo_term) LIKE "%nausea and vomiting%") AND (LOWER(drugName) LIKE "%dronabinol%" OR LOWER(tradeNames_list) LIKE "%dronabinol%" OR LOWER(syns_list) LIKE "%dronabinol%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1073292', 'drugName': 'Dronabinol', 'tradeNames_list': "['Dronabinol', 'Marinol', 'Syndros']", 'syns_list': "['.delta.-9-tetrahydrocannabinol', '.delta.1-thc.delta.9-tetrahydrocannabinol', '.delta.9-thc', 'ABBOTT 40566ABBOTT-40566', 'Delta-9-tetrahydrocannabinol', 'Delta-9-thc', 'DronabinolJ882F', 'NSC-134454', 'QCD 84924', 'QCD-84924', 'SP 104', 'SP-104Tetrahydrocannabinol', 'Tetrahydrocannabinols (-)-trans-.delta.9-form']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073328', 'drugName': 'Dronabinol', 'tradeNames_list': "['Dronabinol', 'Marinol', 'Syndros']", 'syns_list': "['.delta.-9-tetrahydrocannabinol', '.delta.1-thc.delta.9-tetrahydrocannabinol', '.delta.9-thc', 'ABBOTT 40566ABBOTT-40566', 'Delta-9-tetrahydrocannabinol', 'Delta-9-thc', 'DronabinolJ882F', 'NSC-134454', 'QCD 84924', 'QCD-84924', 'SP 104', 'SP-104Tetrahydrocannabinol', 'Tetrahydrocannabinols (-)-trans-.delta.9-form']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073256', 'drugName': 'Dronabinol', 'tradeNames_list': "['Dronabinol', 'Marinol', 'Syndros']", 'syns_list': "['.delta.-9-tetrahydrocannabinol', '.delta.1-thc.delta.9-tetrahydrocannabinol', '.delta.9-thc', 'ABBOTT 40566ABBOTT-40566', 'Delta-9-tetrahydrocannabinol', 'Delta-9-thc', 'DronabinolJ882F', 'NSC-134454', 'QCD 84924', 'QCD-84924', 'SP 104', 'SP-104Tetrahydrocannabinol', 'Tetrahydrocannabinols (-)-trans-.delta.9-form']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073220', 'drugName': 'Dronabinol', 'tradeNames_list': "['Dronabinol', 'Marinol', 'Syndros']", 'syns_list': "['.delta.-9-tetrahydrocannabinol', '.delta.1-thc.delta.9-tetrahydrocannabinol', '.delta.9-thc', 'ABBOTT 40566ABBOTT-40566', 'Delta-9-tetrahydrocannabinol', 'Delta-9-thc', 'DronabinolJ882F', 'NSC-134454', 'QCD 84924', 'QCD-84924', 'SP 104', 'SP-104Tetrahydrocannabinol', 'Tetrahydrocannabinols (-)-trans-.delta.9-form']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073216', 'drugName': 'Dronabinol', 'tradeNames_list': "['Dronabinol', 'Marinol', 'Syndros']", 'syns_list': "['.delta.-9-tetrahydrocannabinol', '.delta.1-thc.delta.9-tetrahydrocannabinol', '.delta.9-thc', 'ABBOTT 40566ABBOTT-40566', 'Delta-9-tetrahydrocannabinol', 'Delta-9-thc', 'DronabinolJ882F', 'NSC-134454', 'QCD 84924', 'QCD-84924', 'SP 104', 'SP-104Tetrahydrocannabinol', 'Tetrahydrocannabinols (-)-trans-.delta.9-form']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073324', 'drugName': 'Dronabinol', 'tradeNames_list': "['Dronabinol', 'Marinol', 'Syndros']", 'syns_list': "['.delta.-9-tetrahydrocannabinol', '.delta.1-thc.delta.9-tetrahydrocannabinol', '.delta.9-thc', 'ABBOTT 40566ABBOTT-40566', 'Delta-9-tetrahydrocannabinol', 'Delta-9-thc', 'DronabinolJ882F', 'NSC-134454', 'QCD 84924', 'QCD-84924', 'SP 104', 'SP-104Tetrahydrocannabinol', 'Tetrahydrocannabinols (-)-trans-.delta.9-form']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073288', 'drugName': 'Dronabinol', 'tradeNames_list': "['Dronabinol', 'Marinol', 'Syndros']", 'syns_list': "['.delta.-9-tetrahydrocannabinol', '.delta.1-thc.delta.9-tetrahydrocannabinol', '.delta.9-thc', 'ABBOTT 40566ABBOTT-40566', 'Delta-9-tetrahydrocannabinol', 'Delta-9-thc', 'DronabinolJ882F', 'NSC-134454', 'QCD 84924', 'QCD-84924', 'SP 104', 'SP-104Tetrahydrocannabinol', 'Tetrahydrocannabinols (-)-trans-.delta.9-form']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073252', 'drugName': 'Dronabinol', 'tradeNames_list': "['Dronabinol', 'Marinol', 'Syndros']", 'syns_list': "['.delta.-9-tetrahydrocannabinol', '.delta.1-thc.delta.9-tetrahydrocannabinol', '.delta.9-thc', 'ABBOTT 40566ABBOTT-40566', 'Delta-9-tetrahydrocannabinol', 'Delta-9-thc', 'DronabinolJ882F', 'NSC-134454', 'QCD 84924', 'QCD-84924', 'SP 104', 'SP-104Tetrahydrocannabinol', 'Tetrahydrocannabinols (-)-trans-.delta.9-form']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1553 | Q34 | What are the names of the genes that are targeted by the drug Vorinostat in the treatment of neoplasm? | In the context of neoplasm, the drug Vorinostat targets the gene histone deacetylase 1, histone deacetylase 3, histone deacetylase 6 and histone deacetylase 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%vorinostat%" OR LOWER(tradeNames_list) LIKE "%vorinostat%" OR LOWER(syns_list) LIKE "%vorinostat%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1077226', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1077841', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1078282', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1078633', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1077930', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1076873', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076786', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1079161', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1077665', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1077666', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1078985', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1078458', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1076962', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1078722', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1077753', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1079690', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1079073', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1078017', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1078986', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1079337', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1079338', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1077137', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1077402', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1077314', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1079777', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1077577', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1077754', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1078457', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1078018', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1077049', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1079250', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1078369', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1076874', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1078898', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1078370', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1076961', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1078810', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1078546', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1079074', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1078897', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1077489', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1078193', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1078106', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1078194', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1079249', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1079778', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1076785', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1078809', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1076698', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1079426', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1079425', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1077050', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1077929', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1077138', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1079602', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1077313', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1079601', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1079513', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1077490', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1078545', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1078721', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1079689', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1079514', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1077225', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076697', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1078281', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1077578', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1079162', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1077401', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1077842', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1078105', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1078634', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1079600', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1077576', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1077664', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1077928', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1077752', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1076960', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1078104', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1078016', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1078280', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1076872', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1078368', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1078192', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1078456', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1078544', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1078632', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1077048', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1077840', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3'}, {'UUID': 'DrugTargetsIndication121923_text_1078896', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1078808', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1079248', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1078984', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6'}, {'UUID': 'DrugTargetsIndication121923_text_1079072', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1079160', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1076696', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1079336', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1079512', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}, {'UUID': 'DrugTargetsIndication121923_text_1076784', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1079424', 'drugName': 'Vorinostat', 'tradeNames_list': "['Zolinza']", 'syns_list': "['MK-0683', 'MK0683', 'NSC-701852', 'NSC-748799', 'NSC-759852Suberoylanilide hydroxamic acid', 'Vorinostat']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1522 | Q34 | What are the names of the genes that are targeted by the drug Telmisartan in the treatment of stroke? | In the context of stroke, the drug Telmisartan targets the gene angiotensin II receptor type 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%stroke%" OR LOWER(efo_term) LIKE "%stroke%") AND (LOWER(drugName) LIKE "%telmisartan%" OR LOWER(tradeNames_list) LIKE "%telmisartan%" OR LOWER(syns_list) LIKE "%telmisartan%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1072712', 'drugName': 'Telmisartan', 'tradeNames_list': "['Micardis', 'Telmisartan', 'Tolura']", 'syns_list': "['BIBR 277 SE', 'BIBR-277', 'BIBR-277 SE', 'BIBR-277-SE', 'BIBR-277SEC09CA07', 'Kinzalmono', 'Pritor', 'Semintra', 'TelmisartanTelmisartan actavis', 'Telmisartan teva']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1559 | Q34 | What are the names of the genes that are targeted by the drug Ambrisentan in the treatment of pulmonary arterial hypertension? | In the context of pulmonary arterial hypertension, the drug Ambrisentan targets the gene endothelin receptor type A and endothelin receptor type B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pulmonary arterial hypertension%" OR LOWER(efo_term) LIKE "%pulmonary arterial hypertension%") AND (LOWER(drugName) LIKE "%ambrisentan%" OR LOWER(tradeNames_list) LIKE "%ambrisentan%" OR LOWER(syns_list) LIKE "%ambrisentan%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1084063', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084075', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084084', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084085', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084096', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084097', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084099', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084109', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084111', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084120', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084121', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084132', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084133', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084135', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084144', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084145', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084147', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084156', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084157', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084159', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084168', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084171', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084180', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084181', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084183', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084169', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084073', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084060', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084049', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084048', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084108', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084123', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084087', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084072', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084061', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084051', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.45 | Q34 | What are the names of the genes that are targeted by the drug Aripiprazole in the treatment of major depressive disorder? | In the context of major depressive disorder, the drug Aripiprazole targets the gene dopamine receptor D2, 5-hydroxytryptamine receptor 2A and 5-hydroxytryptamine receptor 1A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%major depressive disorder%" OR LOWER(efo_term) LIKE "%major depressive disorder%") AND (LOWER(drugName) LIKE "%aripiprazole%" OR LOWER(tradeNames_list) LIKE "%aripiprazole%" OR LOWER(syns_list) LIKE "%aripiprazole%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_158030', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158048', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158054', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158060', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158072', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158078', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158084', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158096', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158102', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158108', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158114', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158126', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158132', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158138', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158144', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158150', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158156', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158162', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158168', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158174', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158180', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158192', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158198', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158204', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158210', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158216', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158228', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158234', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158240', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158246', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158252', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158258', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158264', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158270', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158276', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158282', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158288', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158294', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158300', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158306', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158312', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158318', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158324', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158330', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158336', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158342', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158348', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158354', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158360', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158366', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158372', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158384', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158390', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158396', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158402', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158408', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158414', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158426', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158432', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158438', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158444', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158450', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158456', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158462', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158468', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158474', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158480', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158486', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158492', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158498', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158504', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158510', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158516', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158522', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158528', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158534', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158540', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158546', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158552', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158558', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158564', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158570', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158576', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158582', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158588', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158594', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158378', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158186', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158090', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158042', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158018', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158006', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158000', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158420', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158222', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158120', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158066', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158036', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158024', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158012', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.993 | Q34 | What are the names of the genes that are targeted by the drug Solifenacin Succinate in the treatment of urgency urinary incontinence? | In the context of urgency urinary incontinence, the drug Solifenacin Succinate targets the gene cholinergic receptor muscarinic 3 and cholinergic receptor muscarinic 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%urgency urinary incontinence%" OR LOWER(efo_term) LIKE "%urgency urinary incontinence%") AND (LOWER(drugName) LIKE "%solifenacin succinate%" OR LOWER(tradeNames_list) LIKE "%solifenacin succinate%" OR LOWER(syns_list) LIKE "%solifenacin succinate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_857279', 'drugName': 'Solifenacin Succinate', 'tradeNames_list': "['Solifenacin succinate', 'Vesicare', 'Vesicare ls']", 'syns_list': "['Solifenacin succinate', 'YM-67905', 'YM-905', 'YM67905', 'YM905']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857282', 'drugName': 'Solifenacin Succinate', 'tradeNames_list': "['Solifenacin succinate', 'Vesicare', 'Vesicare ls']", 'syns_list': "['Solifenacin succinate', 'YM-67905', 'YM-905', 'YM67905', 'YM905']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.170 | Q34 | What are the names of the genes that are targeted by the drug Prednisone in the treatment of juvenile idiopathic arthritis? | In the context of juvenile idiopathic arthritis, the drug Prednisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%juvenile idiopathic arthritis%" OR LOWER(efo_term) LIKE "%juvenile idiopathic arthritis%") AND (LOWER(drugName) LIKE "%prednisone%" OR LOWER(tradeNames_list) LIKE "%prednisone%" OR LOWER(syns_list) LIKE "%prednisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_218676', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219300', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219508', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219716', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220132', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220340', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220548', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220756', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219092', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218260', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217844', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217636', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219924', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218884', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218468', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218052', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1065 | Q34 | What are the names of the genes that are targeted by the drug Ticagrelor in the treatment of Recurrent thrombophlebitis? | In the context of Recurrent thrombophlebitis, the drug Ticagrelor targets the gene purinergic receptor P2Y12. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%recurrent thrombophlebitis%" OR LOWER(efo_term) LIKE "%recurrent thrombophlebitis%") AND (LOWER(drugName) LIKE "%ticagrelor%" OR LOWER(tradeNames_list) LIKE "%ticagrelor%" OR LOWER(syns_list) LIKE "%ticagrelor%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_920464', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920542', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920568', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920594', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920646', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920672', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920698', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920750', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920776', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920802', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920828', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920880', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920906', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920932', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920958', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920984', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920724', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920516', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920412', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920360', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920334', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920854', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920620', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920490', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920438', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920386', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.715 | Q34 | What are the names of the genes that are targeted by the drug Tirbanibulin in the treatment of actinic keratosis? | In the context of actinic keratosis, the drug Tirbanibulin targets the gene SRC proto-oncogene, non-receptor tyrosine kinase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%actinic keratosis%" OR LOWER(efo_term) LIKE "%actinic keratosis%") AND (LOWER(drugName) LIKE "%tirbanibulin%" OR LOWER(tradeNames_list) LIKE "%tirbanibulin%" OR LOWER(syns_list) LIKE "%tirbanibulin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_752074', 'drugName': 'Tirbanibulin', 'tradeNames_list': "['Klisyri']", 'syns_list': "['KX-01', 'KX-2-391', 'KX-2391', 'KX2-391', 'KX2391', 'Kx2-391', 'Tirbanibulin']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752066', 'drugName': 'Tirbanibulin', 'tradeNames_list': "['Klisyri']", 'syns_list': "['KX-01', 'KX-2-391', 'KX-2391', 'KX2-391', 'KX2391', 'Kx2-391', 'Tirbanibulin']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752058', 'drugName': 'Tirbanibulin', 'tradeNames_list': "['Klisyri']", 'syns_list': "['KX-01', 'KX-2-391', 'KX-2391', 'KX2-391', 'KX2391', 'Kx2-391', 'Tirbanibulin']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752054', 'drugName': 'Tirbanibulin', 'tradeNames_list': "['Klisyri']", 'syns_list': "['KX-01', 'KX-2-391', 'KX-2391', 'KX2-391', 'KX2391', 'Kx2-391', 'Tirbanibulin']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752078', 'drugName': 'Tirbanibulin', 'tradeNames_list': "['Klisyri']", 'syns_list': "['KX-01', 'KX-2-391', 'KX-2391', 'KX2-391', 'KX2391', 'Kx2-391', 'Tirbanibulin']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752070', 'drugName': 'Tirbanibulin', 'tradeNames_list': "['Klisyri']", 'syns_list': "['KX-01', 'KX-2-391', 'KX-2391', 'KX2-391', 'KX2391', 'Kx2-391', 'Tirbanibulin']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752062', 'drugName': 'Tirbanibulin', 'tradeNames_list': "['Klisyri']", 'syns_list': "['KX-01', 'KX-2-391', 'KX-2391', 'KX2-391', 'KX2391', 'Kx2-391', 'Tirbanibulin']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1905 | Q34 | What are the names of the genes that are targeted by the drug Bimatoprost in the treatment of ocular hypertension? | In the context of ocular hypertension, the drug Bimatoprost targets the gene prostaglandin F receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%ocular hypertension%" OR LOWER(efo_term) LIKE "%ocular hypertension%") AND (LOWER(drugName) LIKE "%bimatoprost%" OR LOWER(tradeNames_list) LIKE "%bimatoprost%" OR LOWER(syns_list) LIKE "%bimatoprost%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1149176', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149203', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149212', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149221', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149239', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149248', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149257', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149275', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149284', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149293', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149302', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149320', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149329', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149338', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149347', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149356', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149365', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149374', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149383', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149392', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149401', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149266', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149194', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149158', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149140', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149131', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149311', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149230', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149185', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149167', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149149', 'drugName': 'Bimatoprost', 'tradeNames_list': "['Bimatoprost', 'Durysta', 'Latisse', 'Lumigan']", 'syns_list': "['AGN 192024', 'AGN-192024', 'Bimatoprost', 'Prostamide']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.588 | Q34 | What are the names of the genes that are targeted by the drug Carbamazepine in the treatment of partial epilepsy? | In the context of partial epilepsy, the drug Carbamazepine targets the gene sodium voltage-gated channel alpha subunit 1, sodium voltage-gated channel alpha subunit 5, sodium voltage-gated channel alpha subunit 4, sodium voltage-gated channel alpha subunit 7, sodium voltage-gated channel alpha subunit 2, sodium voltage-gated channel alpha subunit 9, sodium voltage-gated channel alpha subunit 3, sodium voltage-gated channel alpha subunit 11, sodium voltage-gated channel alpha subunit 8 and sodium voltage-gated channel alpha subunit 10. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%partial epilepsy%" OR LOWER(efo_term) LIKE "%partial epilepsy%") AND (LOWER(drugName) LIKE "%carbamazepine%" OR LOWER(tradeNames_list) LIKE "%carbamazepine%" OR LOWER(syns_list) LIKE "%carbamazepine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_651945', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_651145', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651433', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651641', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_652089', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_652249', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_652329', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_651017', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_651177', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651257', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651497', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651673', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_651753', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_652073', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_652025', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_652121', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_652137', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_652313', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_652265', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_652361', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_652377', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_650953', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_651049', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_651065', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_651241', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651193', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651305', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651625', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_651449', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651545', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651561', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651737', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_651689', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_651785', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_651801', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_652201', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_651961', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_652057', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_652041', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_652185', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_652105', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_652169', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_652153', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_652441', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_652233', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_652297', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_652281', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_652425', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_652345', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_652409', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_652393', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_650921', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_650985', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_650969', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_651113', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651033', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_651097', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651369', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651161', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651225', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651209', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651353', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651273', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651337', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651321', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651881', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_651417', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651481', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651465', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651609', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_651529', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651593', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651577', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651865', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_651657', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_651721', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_651705', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_651849', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_651769', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_651833', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_651817', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_652457', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_651929', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_651993', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_651977', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_652489', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_652473', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_651897', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_651385', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651129', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651001', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_650937', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_650905', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_651081', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651289', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651513', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_652009', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_652217', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_651401', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651913', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsies, Partial', 'efo_term': 'partial epilepsy', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.642 | Q34 | What are the names of the genes that are targeted by the drug Lenvatinib Mesylate in the treatment of thyroid carcinoma? | In the context of thyroid carcinoma, the drug Lenvatinib Mesylate targets the gene kinase insert domain receptor, fms related receptor tyrosine kinase 1 and fms related receptor tyrosine kinase 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%thyroid carcinoma%" OR LOWER(efo_term) LIKE "%thyroid carcinoma%") AND (LOWER(drugName) LIKE "%lenvatinib mesylate%" OR LOWER(tradeNames_list) LIKE "%lenvatinib mesylate%" OR LOWER(syns_list) LIKE "%lenvatinib mesylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_690183', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690213', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690223', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690233', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690253', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690263', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690273', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690293', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690303', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690313', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690323', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690343', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690353', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690363', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690373', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690383', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690393', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690403', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690413', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690423', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690433', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690453', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690463', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690473', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690483', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690443', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690203', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690163', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690143', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690133', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690283', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690333', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690243', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690193', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690173', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690153', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.355 | Q34 | What are the names of the genes that are targeted by the drug Fluticasone Propionate in the treatment of Nasal congestion? | In the context of Nasal congestion, the drug Fluticasone Propionate targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%nasal congestion%" OR LOWER(efo_term) LIKE "%nasal congestion%") AND (LOWER(drugName) LIKE "%fluticasone propionate%" OR LOWER(tradeNames_list) LIKE "%fluticasone propionate%" OR LOWER(syns_list) LIKE "%fluticasone propionate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_232525', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232606', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232633', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232660', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232714', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232741', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232768', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232822', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232849', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232876', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232903', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232957', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232984', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233011', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233038', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233065', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233092', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233119', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233146', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233173', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233200', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233254', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233281', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233308', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233335', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233362', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233416', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233443', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233470', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233497', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233524', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233551', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233578', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233605', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233632', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233659', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233686', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233713', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233740', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233767', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233794', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233821', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233848', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233875', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233902', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233929', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233956', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233983', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234010', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234037', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234064', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234118', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234145', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234172', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234199', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234226', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234253', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234307', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234334', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234361', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234388', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234415', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234442', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234469', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234496', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234523', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234550', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234577', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234604', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234631', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234658', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234685', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234712', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234739', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234766', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234793', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234820', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234847', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234874', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234901', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234928', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234955', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234982', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_235009', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_235036', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_235063', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234091', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233227', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232795', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232579', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232471', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232417', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232390', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234280', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233389', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232930', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232687', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232552', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232498', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232444', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1471 | Q34 | What are the names of the genes that are targeted by the drug Dimethyl Fumarate in the treatment of immune system disease? | In the context of immune system disease, the drug Dimethyl Fumarate targets the gene kelch like ECH associated protein 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%immune system disease%" OR LOWER(efo_term) LIKE "%immune system disease%") AND (LOWER(drugName) LIKE "%dimethyl fumarate%" OR LOWER(tradeNames_list) LIKE "%dimethyl fumarate%" OR LOWER(syns_list) LIKE "%dimethyl fumarate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1055756', 'drugName': 'Dimethyl Fumarate', 'tradeNames_list': "['Tecfidera']", 'syns_list': "['AZL 0 211089', 'AZL O 211089', 'AZL-0211089', 'AZL-O-211089', 'BG 00012BG 12', 'BG-00012', 'BG-12', 'BG00012', 'Dimethyl fumar', 'Dimethyl fumarateFAG-201', 'FP-187', 'FP187', 'Fumaric acid dimethyl ester', 'LAS-41008LAS41008', 'Las41008', 'NSC-167432', 'NSC-25942', 'Panaclar']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055801', 'drugName': 'Dimethyl Fumarate', 'tradeNames_list': "['Tecfidera']", 'syns_list': "['AZL 0 211089', 'AZL O 211089', 'AZL-0211089', 'AZL-O-211089', 'BG 00012BG 12', 'BG-00012', 'BG-12', 'BG00012', 'Dimethyl fumar', 'Dimethyl fumarateFAG-201', 'FP-187', 'FP187', 'Fumaric acid dimethyl ester', 'LAS-41008LAS41008', 'Las41008', 'NSC-167432', 'NSC-25942', 'Panaclar']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055816', 'drugName': 'Dimethyl Fumarate', 'tradeNames_list': "['Tecfidera']", 'syns_list': "['AZL 0 211089', 'AZL O 211089', 'AZL-0211089', 'AZL-O-211089', 'BG 00012BG 12', 'BG-00012', 'BG-12', 'BG00012', 'Dimethyl fumar', 'Dimethyl fumarateFAG-201', 'FP-187', 'FP187', 'Fumaric acid dimethyl ester', 'LAS-41008LAS41008', 'Las41008', 'NSC-167432', 'NSC-25942', 'Panaclar']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055831', 'drugName': 'Dimethyl Fumarate', 'tradeNames_list': "['Tecfidera']", 'syns_list': "['AZL 0 211089', 'AZL O 211089', 'AZL-0211089', 'AZL-O-211089', 'BG 00012BG 12', 'BG-00012', 'BG-12', 'BG00012', 'Dimethyl fumar', 'Dimethyl fumarateFAG-201', 'FP-187', 'FP187', 'Fumaric acid dimethyl ester', 'LAS-41008LAS41008', 'Las41008', 'NSC-167432', 'NSC-25942', 'Panaclar']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055861', 'drugName': 'Dimethyl Fumarate', 'tradeNames_list': "['Tecfidera']", 'syns_list': "['AZL 0 211089', 'AZL O 211089', 'AZL-0211089', 'AZL-O-211089', 'BG 00012BG 12', 'BG-00012', 'BG-12', 'BG00012', 'Dimethyl fumar', 'Dimethyl fumarateFAG-201', 'FP-187', 'FP187', 'Fumaric acid dimethyl ester', 'LAS-41008LAS41008', 'Las41008', 'NSC-167432', 'NSC-25942', 'Panaclar']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055876', 'drugName': 'Dimethyl Fumarate', 'tradeNames_list': "['Tecfidera']", 'syns_list': "['AZL 0 211089', 'AZL O 211089', 'AZL-0211089', 'AZL-O-211089', 'BG 00012BG 12', 'BG-00012', 'BG-12', 'BG00012', 'Dimethyl fumar', 'Dimethyl fumarateFAG-201', 'FP-187', 'FP187', 'Fumaric acid dimethyl ester', 'LAS-41008LAS41008', 'Las41008', 'NSC-167432', 'NSC-25942', 'Panaclar']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055891', 'drugName': 'Dimethyl Fumarate', 'tradeNames_list': "['Tecfidera']", 'syns_list': "['AZL 0 211089', 'AZL O 211089', 'AZL-0211089', 'AZL-O-211089', 'BG 00012BG 12', 'BG-00012', 'BG-12', 'BG00012', 'Dimethyl fumar', 'Dimethyl fumarateFAG-201', 'FP-187', 'FP187', 'Fumaric acid dimethyl ester', 'LAS-41008LAS41008', 'Las41008', 'NSC-167432', 'NSC-25942', 'Panaclar']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055921', 'drugName': 'Dimethyl Fumarate', 'tradeNames_list': "['Tecfidera']", 'syns_list': "['AZL 0 211089', 'AZL O 211089', 'AZL-0211089', 'AZL-O-211089', 'BG 00012BG 12', 'BG-00012', 'BG-12', 'BG00012', 'Dimethyl fumar', 'Dimethyl fumarateFAG-201', 'FP-187', 'FP187', 'Fumaric acid dimethyl ester', 'LAS-41008LAS41008', 'Las41008', 'NSC-167432', 'NSC-25942', 'Panaclar']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055936', 'drugName': 'Dimethyl Fumarate', 'tradeNames_list': "['Tecfidera']", 'syns_list': "['AZL 0 211089', 'AZL O 211089', 'AZL-0211089', 'AZL-O-211089', 'BG 00012BG 12', 'BG-00012', 'BG-12', 'BG00012', 'Dimethyl fumar', 'Dimethyl fumarateFAG-201', 'FP-187', 'FP187', 'Fumaric acid dimethyl ester', 'LAS-41008LAS41008', 'Las41008', 'NSC-167432', 'NSC-25942', 'Panaclar']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055906', 'drugName': 'Dimethyl Fumarate', 'tradeNames_list': "['Tecfidera']", 'syns_list': "['AZL 0 211089', 'AZL O 211089', 'AZL-0211089', 'AZL-O-211089', 'BG 00012BG 12', 'BG-00012', 'BG-12', 'BG00012', 'Dimethyl fumar', 'Dimethyl fumarateFAG-201', 'FP-187', 'FP187', 'Fumaric acid dimethyl ester', 'LAS-41008LAS41008', 'Las41008', 'NSC-167432', 'NSC-25942', 'Panaclar']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055786', 'drugName': 'Dimethyl Fumarate', 'tradeNames_list': "['Tecfidera']", 'syns_list': "['AZL 0 211089', 'AZL O 211089', 'AZL-0211089', 'AZL-O-211089', 'BG 00012BG 12', 'BG-00012', 'BG-12', 'BG00012', 'Dimethyl fumar', 'Dimethyl fumarateFAG-201', 'FP-187', 'FP187', 'Fumaric acid dimethyl ester', 'LAS-41008LAS41008', 'Las41008', 'NSC-167432', 'NSC-25942', 'Panaclar']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055696', 'drugName': 'Dimethyl Fumarate', 'tradeNames_list': "['Tecfidera']", 'syns_list': "['AZL 0 211089', 'AZL O 211089', 'AZL-0211089', 'AZL-O-211089', 'BG 00012BG 12', 'BG-00012', 'BG-12', 'BG00012', 'Dimethyl fumar', 'Dimethyl fumarateFAG-201', 'FP-187', 'FP187', 'Fumaric acid dimethyl ester', 'LAS-41008LAS41008', 'Las41008', 'NSC-167432', 'NSC-25942', 'Panaclar']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055681', 'drugName': 'Dimethyl Fumarate', 'tradeNames_list': "['Tecfidera']", 'syns_list': "['AZL 0 211089', 'AZL O 211089', 'AZL-0211089', 'AZL-O-211089', 'BG 00012BG 12', 'BG-00012', 'BG-12', 'BG00012', 'Dimethyl fumar', 'Dimethyl fumarateFAG-201', 'FP-187', 'FP187', 'Fumaric acid dimethyl ester', 'LAS-41008LAS41008', 'Las41008', 'NSC-167432', 'NSC-25942', 'Panaclar']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055726', 'drugName': 'Dimethyl Fumarate', 'tradeNames_list': "['Tecfidera']", 'syns_list': "['AZL 0 211089', 'AZL O 211089', 'AZL-0211089', 'AZL-O-211089', 'BG 00012BG 12', 'BG-00012', 'BG-12', 'BG00012', 'Dimethyl fumar', 'Dimethyl fumarateFAG-201', 'FP-187', 'FP187', 'Fumaric acid dimethyl ester', 'LAS-41008LAS41008', 'Las41008', 'NSC-167432', 'NSC-25942', 'Panaclar']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055846', 'drugName': 'Dimethyl Fumarate', 'tradeNames_list': "['Tecfidera']", 'syns_list': "['AZL 0 211089', 'AZL O 211089', 'AZL-0211089', 'AZL-O-211089', 'BG 00012BG 12', 'BG-00012', 'BG-12', 'BG00012', 'Dimethyl fumar', 'Dimethyl fumarateFAG-201', 'FP-187', 'FP187', 'Fumaric acid dimethyl ester', 'LAS-41008LAS41008', 'Las41008', 'NSC-167432', 'NSC-25942', 'Panaclar']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055771', 'drugName': 'Dimethyl Fumarate', 'tradeNames_list': "['Tecfidera']", 'syns_list': "['AZL 0 211089', 'AZL O 211089', 'AZL-0211089', 'AZL-O-211089', 'BG 00012BG 12', 'BG-00012', 'BG-12', 'BG00012', 'Dimethyl fumar', 'Dimethyl fumarateFAG-201', 'FP-187', 'FP187', 'Fumaric acid dimethyl ester', 'LAS-41008LAS41008', 'Las41008', 'NSC-167432', 'NSC-25942', 'Panaclar']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055741', 'drugName': 'Dimethyl Fumarate', 'tradeNames_list': "['Tecfidera']", 'syns_list': "['AZL 0 211089', 'AZL O 211089', 'AZL-0211089', 'AZL-O-211089', 'BG 00012BG 12', 'BG-00012', 'BG-12', 'BG00012', 'Dimethyl fumar', 'Dimethyl fumarateFAG-201', 'FP-187', 'FP187', 'Fumaric acid dimethyl ester', 'LAS-41008LAS41008', 'Las41008', 'NSC-167432', 'NSC-25942', 'Panaclar']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055711', 'drugName': 'Dimethyl Fumarate', 'tradeNames_list': "['Tecfidera']", 'syns_list': "['AZL 0 211089', 'AZL O 211089', 'AZL-0211089', 'AZL-O-211089', 'BG 00012BG 12', 'BG-00012', 'BG-12', 'BG00012', 'Dimethyl fumar', 'Dimethyl fumarateFAG-201', 'FP-187', 'FP187', 'Fumaric acid dimethyl ester', 'LAS-41008LAS41008', 'Las41008', 'NSC-167432', 'NSC-25942', 'Panaclar']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.945 | Q34 | What are the names of the genes that are targeted by the drug Ketorolac Tromethamine in the treatment of Ocular pain? | In the context of Ocular pain, the drug Ketorolac Tromethamine targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%ocular pain%" OR LOWER(efo_term) LIKE "%ocular pain%") AND (LOWER(drugName) LIKE "%ketorolac tromethamine%" OR LOWER(tradeNames_list) LIKE "%ketorolac tromethamine%" OR LOWER(syns_list) LIKE "%ketorolac tromethamine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_841846', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841894', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841910', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841926', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841958', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841974', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841990', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842022', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842038', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842054', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842070', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842102', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842118', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842134', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842150', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842166', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842182', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842198', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842214', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842230', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842246', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842262', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842006', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841878', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841814', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841782', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841766', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842086', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841942', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841862', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841830', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841798', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'syns_list': "['Dolac', 'Ketorolac trometamol', 'Ketorolac tromethamine', 'LixidolNSC-758637', 'Tarasyn']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.612 | Q34 | What are the names of the genes that are targeted by the drug Cabozantinib S-Malate in the treatment of papillary renal cell carcinoma? | In the context of papillary renal cell carcinoma, the drug Cabozantinib S-Malate targets the gene kinase insert domain receptor and MET proto-oncogene, receptor tyrosine kinase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%papillary renal cell carcinoma%" OR LOWER(efo_term) LIKE "%papillary renal cell carcinoma%") AND (LOWER(drugName) LIKE "%cabozantinib s-malate%" OR LOWER(tradeNames_list) LIKE "%cabozantinib s-malate%" OR LOWER(syns_list) LIKE "%cabozantinib s-malate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_669672', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669741', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669764', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669787', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669833', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669856', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669879', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669925', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669948', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669971', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669994', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670040', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670063', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670086', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670109', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670132', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670155', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670178', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670201', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670224', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670247', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670293', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670316', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670339', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670362', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670385', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670431', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670454', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670477', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670500', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670523', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670546', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670569', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670592', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670615', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670638', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670661', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670684', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670707', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670730', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670753', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670776', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670799', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670822', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670845', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670868', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670891', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670914', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670937', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670960', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670983', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671029', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671052', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671075', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671098', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671121', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671144', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671190', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671213', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671236', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671259', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671282', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671305', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671328', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671351', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671374', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671397', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671420', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671443', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671466', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671489', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671512', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671535', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671558', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671581', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671604', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671627', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671650', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671673', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671696', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671719', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671742', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671765', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671788', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671811', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671834', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_671006', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_670270', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669902', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669718', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669626', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669580', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669557', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_671167', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_670408', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_670017', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669810', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669695', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669649', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_669603', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'syns_list': "['BMS-907351', 'Cabozantinib malate', 'Cabozantinib s-malate', 'XL-184XL184']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1722 | Q34 | What are the names of the genes that are targeted by the drug Brivaracetam in the treatment of epilepsy? | In the context of epilepsy, the drug Brivaracetam targets the gene synaptic vesicle glycoprotein 2A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%epilepsy%" OR LOWER(efo_term) LIKE "%epilepsy%") AND (LOWER(drugName) LIKE "%brivaracetam%" OR LOWER(tradeNames_list) LIKE "%brivaracetam%" OR LOWER(syns_list) LIKE "%brivaracetam%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097450', 'drugName': 'Brivaracetam', 'tradeNames_list': "['Briviact']", 'syns_list': "['Brivaracetam', 'UCB 34714', 'UCB-34714']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1097468', 'drugName': 'Brivaracetam', 'tradeNames_list': "['Briviact']", 'syns_list': "['Brivaracetam', 'UCB 34714', 'UCB-34714']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1097474', 'drugName': 'Brivaracetam', 'tradeNames_list': "['Briviact']", 'syns_list': "['Brivaracetam', 'UCB 34714', 'UCB-34714']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1097480', 'drugName': 'Brivaracetam', 'tradeNames_list': "['Briviact']", 'syns_list': "['Brivaracetam', 'UCB 34714', 'UCB-34714']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1097492', 'drugName': 'Brivaracetam', 'tradeNames_list': "['Briviact']", 'syns_list': "['Brivaracetam', 'UCB 34714', 'UCB-34714']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1097462', 'drugName': 'Brivaracetam', 'tradeNames_list': "['Briviact']", 'syns_list': "['Brivaracetam', 'UCB 34714', 'UCB-34714']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1097438', 'drugName': 'Brivaracetam', 'tradeNames_list': "['Briviact']", 'syns_list': "['Brivaracetam', 'UCB 34714', 'UCB-34714']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1097426', 'drugName': 'Brivaracetam', 'tradeNames_list': "['Briviact']", 'syns_list': "['Brivaracetam', 'UCB 34714', 'UCB-34714']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1097420', 'drugName': 'Brivaracetam', 'tradeNames_list': "['Briviact']", 'syns_list': "['Brivaracetam', 'UCB 34714', 'UCB-34714']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1097486', 'drugName': 'Brivaracetam', 'tradeNames_list': "['Briviact']", 'syns_list': "['Brivaracetam', 'UCB 34714', 'UCB-34714']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1097456', 'drugName': 'Brivaracetam', 'tradeNames_list': "['Briviact']", 'syns_list': "['Brivaracetam', 'UCB 34714', 'UCB-34714']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1097444', 'drugName': 'Brivaracetam', 'tradeNames_list': "['Briviact']", 'syns_list': "['Brivaracetam', 'UCB 34714', 'UCB-34714']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1097432', 'drugName': 'Brivaracetam', 'tradeNames_list': "['Briviact']", 'syns_list': "['Brivaracetam', 'UCB 34714', 'UCB-34714']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.437 | Q34 | What are the names of the genes that are targeted by the drug Epinephrine in the treatment of sudden cardiac arrest? | In the context of sudden cardiac arrest, the drug Epinephrine targets the gene adrenoceptor alpha 1A, adrenoceptor beta 2, adrenoceptor beta 1, adrenoceptor beta 3, adrenoceptor alpha 1D, adrenoceptor alpha 1B, adrenoceptor alpha 2A, adrenoceptor alpha 2C and adrenoceptor alpha 2B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%sudden cardiac arrest%" OR LOWER(efo_term) LIKE "%sudden cardiac arrest%") AND (LOWER(drugName) LIKE "%epinephrine%" OR LOWER(tradeNames_list) LIKE "%epinephrine%" OR LOWER(syns_list) LIKE "%epinephrine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_365066', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362681', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364218', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363105', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362151', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365543', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362363', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362575', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363794', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362787', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364324', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364589', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363211', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365278', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362098', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365331', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362204', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365649', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362310', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365702', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362416', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362522', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363582', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362628', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363900', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362734', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362840', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364536', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362946', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364377', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363052', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364695', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363158', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364748', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363264', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365490', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363370', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365225', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361091', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365437', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361462', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365384', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360932', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365914', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361515', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365596', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361144', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365861', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361568', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365808', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365755', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361621', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363476', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361197', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363688', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361674', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363635', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364112', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361727', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363847', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361250', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364059', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361780', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364006', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360879', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364960', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361833', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364271', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361303', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364483', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361886', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364430', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361038', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364907', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361939', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364642', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361356', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364854', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361992', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364801', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360826', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365967', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362045', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365119', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361409', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_366073', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_366020', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365013', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364165', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363741', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363529', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363423', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362469', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360985', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363953', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362999', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365172', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362257', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362893', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363317', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1604 | Q34 | What are the names of the genes that are targeted by the drug Enalapril Maleate in the treatment of congestive heart failure? | In the context of congestive heart failure, the drug Enalapril Maleate targets the gene angiotensin I converting enzyme. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%congestive heart failure%" OR LOWER(efo_term) LIKE "%congestive heart failure%") AND (LOWER(drugName) LIKE "%enalapril maleate%" OR LOWER(tradeNames_list) LIKE "%enalapril maleate%" OR LOWER(syns_list) LIKE "%enalapril maleate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1091899', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091923', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091931', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091939', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091955', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091963', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091971', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091987', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091995', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1092003', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1092011', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1092027', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1092035', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1092043', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1092051', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1092059', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1092067', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1092075', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1092083', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091979', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091915', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091883', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091867', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091859', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1092019', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091947', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091907', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091891', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091875', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.187 | Q34 | What are the names of the genes that are targeted by the drug Prednisone in the treatment of berylliosis? | In the context of berylliosis, the drug Prednisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%berylliosis%" OR LOWER(efo_term) LIKE "%berylliosis%") AND (LOWER(drugName) LIKE "%prednisone%" OR LOWER(tradeNames_list) LIKE "%prednisone%" OR LOWER(syns_list) LIKE "%prednisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_218693', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Berylliosis', 'efo_term': 'berylliosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219317', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Berylliosis', 'efo_term': 'berylliosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219525', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Berylliosis', 'efo_term': 'berylliosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219733', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Berylliosis', 'efo_term': 'berylliosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220149', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Berylliosis', 'efo_term': 'berylliosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220357', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Berylliosis', 'efo_term': 'berylliosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220565', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Berylliosis', 'efo_term': 'berylliosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220773', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Berylliosis', 'efo_term': 'berylliosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219109', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Berylliosis', 'efo_term': 'berylliosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218277', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Berylliosis', 'efo_term': 'berylliosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217861', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Berylliosis', 'efo_term': 'berylliosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217653', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Berylliosis', 'efo_term': 'berylliosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219941', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Berylliosis', 'efo_term': 'berylliosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218901', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Berylliosis', 'efo_term': 'berylliosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218485', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Berylliosis', 'efo_term': 'berylliosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218069', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Berylliosis', 'efo_term': 'berylliosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1300 | Q34 | What are the names of the genes that are targeted by the drug Amiodarone Hydrochloride in the treatment of ventricular tachycardia? | In the context of ventricular tachycardia, the drug Amiodarone Hydrochloride targets the gene potassium voltage-gated channel subfamily H member 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%ventricular tachycardia%" OR LOWER(efo_term) LIKE "%ventricular tachycardia%") AND (LOWER(drugName) LIKE "%amiodarone hydrochloride%" OR LOWER(tradeNames_list) LIKE "%amiodarone hydrochloride%" OR LOWER(syns_list) LIKE "%amiodarone hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_969595', 'drugName': 'Amiodarone Hydrochloride', 'tradeNames_list': "['Amidox', 'Amiodarone hydrochloride', 'Amyben', 'Cordarone', 'Cordarone xCordarone x 100', 'Cordarone x 200', 'Darmil', 'Nexterone', 'Pacerone']", 'syns_list': "['Amiodar', 'Amiodarone', 'Amiodarone hcl', 'Amiodarone hydrochlorideL-3428', 'Miodaron', 'NSC-343341', 'NSC-85442', 'Ortacrone', 'RitmocardylSK&F-33134-A', 'SKF 33134-A', 'SKF-33134-A', 'Trangorex', 'VF-236']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tachycardia, Ventricular', 'efo_term': 'ventricular tachycardia', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2'}, {'UUID': 'DrugTargetsIndication121923_text_969567', 'drugName': 'Amiodarone Hydrochloride', 'tradeNames_list': "['Amidox', 'Amiodarone hydrochloride', 'Amyben', 'Cordarone', 'Cordarone xCordarone x 100', 'Cordarone x 200', 'Darmil', 'Nexterone', 'Pacerone']", 'syns_list': "['Amiodar', 'Amiodarone', 'Amiodarone hcl', 'Amiodarone hydrochlorideL-3428', 'Miodaron', 'NSC-343341', 'NSC-85442', 'Ortacrone', 'RitmocardylSK&F-33134-A', 'SKF 33134-A', 'SKF-33134-A', 'Trangorex', 'VF-236']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tachycardia, Ventricular', 'efo_term': 'ventricular tachycardia', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2'}, {'UUID': 'DrugTargetsIndication121923_text_969560', 'drugName': 'Amiodarone Hydrochloride', 'tradeNames_list': "['Amidox', 'Amiodarone hydrochloride', 'Amyben', 'Cordarone', 'Cordarone xCordarone x 100', 'Cordarone x 200', 'Darmil', 'Nexterone', 'Pacerone']", 'syns_list': "['Amiodar', 'Amiodarone', 'Amiodarone hcl', 'Amiodarone hydrochlorideL-3428', 'Miodaron', 'NSC-343341', 'NSC-85442', 'Ortacrone', 'RitmocardylSK&F-33134-A', 'SKF 33134-A', 'SKF-33134-A', 'Trangorex', 'VF-236']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tachycardia, Ventricular', 'efo_term': 'ventricular tachycardia', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2'}, {'UUID': 'DrugTargetsIndication121923_text_969581', 'drugName': 'Amiodarone Hydrochloride', 'tradeNames_list': "['Amidox', 'Amiodarone hydrochloride', 'Amyben', 'Cordarone', 'Cordarone xCordarone x 100', 'Cordarone x 200', 'Darmil', 'Nexterone', 'Pacerone']", 'syns_list': "['Amiodar', 'Amiodarone', 'Amiodarone hcl', 'Amiodarone hydrochlorideL-3428', 'Miodaron', 'NSC-343341', 'NSC-85442', 'Ortacrone', 'RitmocardylSK&F-33134-A', 'SKF 33134-A', 'SKF-33134-A', 'Trangorex', 'VF-236']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tachycardia, Ventricular', 'efo_term': 'ventricular tachycardia', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2'}, {'UUID': 'DrugTargetsIndication121923_text_969588', 'drugName': 'Amiodarone Hydrochloride', 'tradeNames_list': "['Amidox', 'Amiodarone hydrochloride', 'Amyben', 'Cordarone', 'Cordarone xCordarone x 100', 'Cordarone x 200', 'Darmil', 'Nexterone', 'Pacerone']", 'syns_list': "['Amiodar', 'Amiodarone', 'Amiodarone hcl', 'Amiodarone hydrochlorideL-3428', 'Miodaron', 'NSC-343341', 'NSC-85442', 'Ortacrone', 'RitmocardylSK&F-33134-A', 'SKF 33134-A', 'SKF-33134-A', 'Trangorex', 'VF-236']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tachycardia, Ventricular', 'efo_term': 'ventricular tachycardia', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2'}, {'UUID': 'DrugTargetsIndication121923_text_969574', 'drugName': 'Amiodarone Hydrochloride', 'tradeNames_list': "['Amidox', 'Amiodarone hydrochloride', 'Amyben', 'Cordarone', 'Cordarone xCordarone x 100', 'Cordarone x 200', 'Darmil', 'Nexterone', 'Pacerone']", 'syns_list': "['Amiodar', 'Amiodarone', 'Amiodarone hcl', 'Amiodarone hydrochlorideL-3428', 'Miodaron', 'NSC-343341', 'NSC-85442', 'Ortacrone', 'RitmocardylSK&F-33134-A', 'SKF 33134-A', 'SKF-33134-A', 'Trangorex', 'VF-236']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tachycardia, Ventricular', 'efo_term': 'ventricular tachycardia', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1191 | Q34 | What are the names of the genes that are targeted by the drug Ripretinib in the treatment of gastrointestinal stromal tumor? | In the context of gastrointestinal stromal tumor, the drug Ripretinib targets the gene KIT proto-oncogene, receptor tyrosine kinase and platelet derived growth factor receptor alpha. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%gastrointestinal stromal tumor%" OR LOWER(efo_term) LIKE "%gastrointestinal stromal tumor%") AND (LOWER(drugName) LIKE "%ripretinib%" OR LOWER(tradeNames_list) LIKE "%ripretinib%" OR LOWER(syns_list) LIKE "%ripretinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_933996', 'drugName': 'Ripretinib', 'tradeNames_list': "['Qinlock']", 'syns_list': "['DCC-2618', 'Dcc-2618', 'Ripretinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934002', 'drugName': 'Ripretinib', 'tradeNames_list': "['Qinlock']", 'syns_list': "['DCC-2618', 'Dcc-2618', 'Ripretinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_934004', 'drugName': 'Ripretinib', 'tradeNames_list': "['Qinlock']", 'syns_list': "['DCC-2618', 'Dcc-2618', 'Ripretinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_934006', 'drugName': 'Ripretinib', 'tradeNames_list': "['Qinlock']", 'syns_list': "['DCC-2618', 'Dcc-2618', 'Ripretinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_934010', 'drugName': 'Ripretinib', 'tradeNames_list': "['Qinlock']", 'syns_list': "['DCC-2618', 'Dcc-2618', 'Ripretinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_934012', 'drugName': 'Ripretinib', 'tradeNames_list': "['Qinlock']", 'syns_list': "['DCC-2618', 'Dcc-2618', 'Ripretinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_934014', 'drugName': 'Ripretinib', 'tradeNames_list': "['Qinlock']", 'syns_list': "['DCC-2618', 'Dcc-2618', 'Ripretinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_934016', 'drugName': 'Ripretinib', 'tradeNames_list': "['Qinlock']", 'syns_list': "['DCC-2618', 'Dcc-2618', 'Ripretinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_934000', 'drugName': 'Ripretinib', 'tradeNames_list': "['Qinlock']", 'syns_list': "['DCC-2618', 'Dcc-2618', 'Ripretinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_933992', 'drugName': 'Ripretinib', 'tradeNames_list': "['Qinlock']", 'syns_list': "['DCC-2618', 'Dcc-2618', 'Ripretinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_933988', 'drugName': 'Ripretinib', 'tradeNames_list': "['Qinlock']", 'syns_list': "['DCC-2618', 'Dcc-2618', 'Ripretinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_933986', 'drugName': 'Ripretinib', 'tradeNames_list': "['Qinlock']", 'syns_list': "['DCC-2618', 'Dcc-2618', 'Ripretinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934008', 'drugName': 'Ripretinib', 'tradeNames_list': "['Qinlock']", 'syns_list': "['DCC-2618', 'Dcc-2618', 'Ripretinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_933998', 'drugName': 'Ripretinib', 'tradeNames_list': "['Qinlock']", 'syns_list': "['DCC-2618', 'Dcc-2618', 'Ripretinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_933994', 'drugName': 'Ripretinib', 'tradeNames_list': "['Qinlock']", 'syns_list': "['DCC-2618', 'Dcc-2618', 'Ripretinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_933990', 'drugName': 'Ripretinib', 'tradeNames_list': "['Qinlock']", 'syns_list': "['DCC-2618', 'Dcc-2618', 'Ripretinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1664 | Q34 | What are the names of the genes that are targeted by the drug Spironolactone in the treatment of heart failure? | In the context of heart failure, the drug Spironolactone targets the gene nuclear receptor subfamily 3 group C member 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%heart failure%" OR LOWER(efo_term) LIKE "%heart failure%") AND (LOWER(drugName) LIKE "%spironolactone%" OR LOWER(tradeNames_list) LIKE "%spironolactone%" OR LOWER(syns_list) LIKE "%spironolactone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1094582', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094468', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094544', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094463', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094354', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094501', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094506', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094539', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094577', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094430', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094615', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094425', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094349', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094392', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094658', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094653', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094620', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'heart failure', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094387', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094382', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Heart Failure, Diastolic', 'efo_term': 'diastolic heart failure', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094534', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Heart Failure, Diastolic', 'efo_term': 'diastolic heart failure', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094572', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Heart Failure, Diastolic', 'efo_term': 'diastolic heart failure', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094344', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Heart Failure, Diastolic', 'efo_term': 'diastolic heart failure', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094458', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Heart Failure, Diastolic', 'efo_term': 'diastolic heart failure', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094610', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Heart Failure, Diastolic', 'efo_term': 'diastolic heart failure', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094420', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Heart Failure, Diastolic', 'efo_term': 'diastolic heart failure', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094496', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Heart Failure, Diastolic', 'efo_term': 'diastolic heart failure', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094648', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Heart Failure, Diastolic', 'efo_term': 'diastolic heart failure', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1601 | Q34 | What are the names of the genes that are targeted by the drug Lisinopril in the treatment of myocardial infarction? | In the context of myocardial infarction, the drug Lisinopril targets the gene angiotensin I converting enzyme. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%myocardial infarction%" OR LOWER(efo_term) LIKE "%myocardial infarction%") AND (LOWER(drugName) LIKE "%lisinopril%" OR LOWER(tradeNames_list) LIKE "%lisinopril%" OR LOWER(syns_list) LIKE "%lisinopril%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1091711', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091732', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091739', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091746', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091760', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091767', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091774', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091788', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091795', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091802', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091809', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091823', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091830', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091837', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091844', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091851', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091781', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091725', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091697', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091683', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091676', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091816', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091753', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091718', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091704', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091690', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'syns_list': "['Lisinopril', 'Lisinopril dihydrate', 'Lisinopril hydrate', 'MK-521Ranolip']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1940 | Q34 | What are the names of the genes that are targeted by the drug Belzutifan in the treatment of hemangioblastoma? | In the context of hemangioblastoma, the drug Belzutifan targets the gene endothelial PAS domain protein 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hemangioblastoma%" OR LOWER(efo_term) LIKE "%hemangioblastoma%") AND (LOWER(drugName) LIKE "%belzutifan%" OR LOWER(tradeNames_list) LIKE "%belzutifan%" OR LOWER(syns_list) LIKE "%belzutifan%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1192115', 'drugName': 'Belzutifan', 'tradeNames_list': "['Welireg']", 'syns_list': "['Belzutifan', 'MK-6482', 'MK6482', 'Mk-6482', 'PT-2977', 'PT2977', 'Pt 2977Pt2977']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemangioblastoma', 'efo_term': 'hemangioblastoma', 'approvedSymbol': 'EPAS1', 'approvedName': 'endothelial PAS domain protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192123', 'drugName': 'Belzutifan', 'tradeNames_list': "['Welireg']", 'syns_list': "['Belzutifan', 'MK-6482', 'MK6482', 'Mk-6482', 'PT-2977', 'PT2977', 'Pt 2977Pt2977']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemangioblastoma', 'efo_term': 'hemangioblastoma', 'approvedSymbol': 'EPAS1', 'approvedName': 'endothelial PAS domain protein 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.523 | Q34 | What are the names of the genes that are targeted by the drug Fexofenadine Hydrochloride in the treatment of seasonal allergic rhinitis? | In the context of seasonal allergic rhinitis, the drug Fexofenadine Hydrochloride targets the gene histamine receptor H1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%seasonal allergic rhinitis%" OR LOWER(efo_term) LIKE "%seasonal allergic rhinitis%") AND (LOWER(drugName) LIKE "%fexofenadine hydrochloride%" OR LOWER(tradeNames_list) LIKE "%fexofenadine hydrochloride%" OR LOWER(syns_list) LIKE "%fexofenadine hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_455783', 'drugName': 'Fexofenadine Hydrochloride', 'tradeNames_list': '[\'Allegra\', \'Allegra allergy\', \'Allegra hives\', "Children\'s allegra allergyChildren\'s allegra hivesChildren\'s fexofenadine hydrochloride allergyChildren\'s fexofenadine hydrochloride hivesFexofenadine hydrochloride", \'Fexofenadine hydrochloride allergyFexofenadine hydrochloride hives\', \'Telfast 120\', \'Telfast 180Telfast 30\']', 'syns_list': "['Fexofenadine hcl', 'Fexofenadine hydrochloride', 'MDL 16,455AMDL-16455A']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455789', 'drugName': 'Fexofenadine Hydrochloride', 'tradeNames_list': '[\'Allegra\', \'Allegra allergy\', \'Allegra hives\', "Children\'s allegra allergyChildren\'s allegra hivesChildren\'s fexofenadine hydrochloride allergyChildren\'s fexofenadine hydrochloride hivesFexofenadine hydrochloride", \'Fexofenadine hydrochloride allergyFexofenadine hydrochloride hives\', \'Telfast 120\', \'Telfast 180Telfast 30\']', 'syns_list': "['Fexofenadine hcl', 'Fexofenadine hydrochloride', 'MDL 16,455AMDL-16455A']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1586 | Q34 | What are the names of the genes that are targeted by the drug Everolimus in the treatment of breast cancer? | In the context of breast cancer, the drug Everolimus targets the gene FKBP prolyl isomerase 1A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%breast cancer%" OR LOWER(efo_term) LIKE "%breast cancer%") AND (LOWER(drugName) LIKE "%everolimus%" OR LOWER(tradeNames_list) LIKE "%everolimus%" OR LOWER(syns_list) LIKE "%everolimus%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1087129', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088749', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085644', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087804', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088344', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090234', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089694', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089964', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086589', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089559', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089424', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086859', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085914', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089019', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088209', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085239', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088479', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088074', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086454', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1084969', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086184', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089289', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087264', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085779', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085374', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085104', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086049', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090639', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090369', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090504', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085509', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086319', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087939', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087669', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086994', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087534', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089154', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089829', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087399', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088884', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088614', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090099', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086724', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086330', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087815', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087950', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1084980', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085655', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086465', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088085', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088220', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086600', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088355', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089030', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088490', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085250', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086735', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088625', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090515', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088760', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1084845', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085115', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085385', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087005', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089165', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089300', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085790', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089435', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089570', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086060', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087275', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089705', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089840', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087410', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087140', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085925', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089975', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090110', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085520', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086195', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087545', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090245', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090380', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087680', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088895', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086870', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.955 | Q34 | What are the names of the genes that are targeted by the drug Bromfenac Sodium in the treatment of Ocular pain? | In the context of Ocular pain, the drug Bromfenac Sodium targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%ocular pain%" OR LOWER(efo_term) LIKE "%ocular pain%") AND (LOWER(drugName) LIKE "%bromfenac sodium%" OR LOWER(tradeNames_list) LIKE "%bromfenac sodium%" OR LOWER(syns_list) LIKE "%bromfenac sodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_842557', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842566', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842569', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842572', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842578', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842581', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842584', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842590', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842593', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842596', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842599', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842605', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842608', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842611', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842587', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842563', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842551', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842545', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842542', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842602', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842575', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842560', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842554', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842548', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'syns_list': "['AHR-10282B', 'Bromfenac monosodium saltBromfenac monosodium salt sesquihydrate', 'Bromfenac sodiumBromfenac sodium anhydrous', 'Bromfenac sodium hydrateBromfenac sodium sesquihydrate']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1913 | Q34 | What are the names of the genes that are targeted by the drug Tafluprost in the treatment of ocular hypertension? | In the context of ocular hypertension, the drug Tafluprost targets the gene prostaglandin F receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%ocular hypertension%" OR LOWER(efo_term) LIKE "%ocular hypertension%") AND (LOWER(drugName) LIKE "%tafluprost%" OR LOWER(tradeNames_list) LIKE "%tafluprost%" OR LOWER(syns_list) LIKE "%tafluprost%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1149435', 'drugName': 'Tafluprost', 'tradeNames_list': "['Saflutan', 'Zioptan']", 'syns_list': "['AFP-168', 'MK-2452', 'Tafluprost']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149438', 'drugName': 'Tafluprost', 'tradeNames_list': "['Saflutan', 'Zioptan']", 'syns_list': "['AFP-168', 'MK-2452', 'Tafluprost']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149441', 'drugName': 'Tafluprost', 'tradeNames_list': "['Saflutan', 'Zioptan']", 'syns_list': "['AFP-168', 'MK-2452', 'Tafluprost']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1350 | Q34 | What are the names of the genes that are targeted by the drug Tranexamic Acid in the treatment of Menorrhagia? | In the context of Menorrhagia, the drug Tranexamic Acid targets the gene plasminogen. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%menorrhagia%" OR LOWER(efo_term) LIKE "%menorrhagia%") AND (LOWER(drugName) LIKE "%tranexamic acid%" OR LOWER(tradeNames_list) LIKE "%tranexamic acid%" OR LOWER(syns_list) LIKE "%tranexamic acid%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_993617', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menorrhagia', 'efo_term': 'Menorrhagia', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993733', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menorrhagia', 'efo_term': 'Menorrhagia', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993501', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menorrhagia', 'efo_term': 'Menorrhagia', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993385', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menorrhagia', 'efo_term': 'Menorrhagia', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993327', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menorrhagia', 'efo_term': 'Menorrhagia', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993675', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menorrhagia', 'efo_term': 'Menorrhagia', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993559', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menorrhagia', 'efo_term': 'Menorrhagia', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993443', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menorrhagia', 'efo_term': 'Menorrhagia', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.943 | Q34 | What are the names of the genes that are targeted by the drug Ibuprofen in the treatment of osteoarthritis? | In the context of osteoarthritis, the drug Ibuprofen targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%osteoarthritis%" OR LOWER(efo_term) LIKE "%osteoarthritis%") AND (LOWER(drugName) LIKE "%ibuprofen%" OR LOWER(tradeNames_list) LIKE "%ibuprofen%" OR LOWER(syns_list) LIKE "%ibuprofen%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_840016', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841122', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840964', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840411', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840490', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839779', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841596', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840885', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840569', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841201', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839858', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840095', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841043', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840253', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840727', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840174', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841517', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841675', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841438', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841280', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840332', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840648', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839937', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841754', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841359', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840806', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840732', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839942', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840811', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839705', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840021', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840337', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840969', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840258', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840416', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841127', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841206', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840100', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840495', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841285', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841364', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841048', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840574', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841443', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841522', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839784', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839863', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840179', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840653', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841601', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841680', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840890', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1298 | Q34 | What are the names of the genes that are targeted by the drug Amiodarone Hydrochloride in the treatment of Ventricular arrhythmia? | In the context of Ventricular arrhythmia, the drug Amiodarone Hydrochloride targets the gene potassium voltage-gated channel subfamily H member 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%ventricular arrhythmia%" OR LOWER(efo_term) LIKE "%ventricular arrhythmia%") AND (LOWER(drugName) LIKE "%amiodarone hydrochloride%" OR LOWER(tradeNames_list) LIKE "%amiodarone hydrochloride%" OR LOWER(syns_list) LIKE "%amiodarone hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_969593', 'drugName': 'Amiodarone Hydrochloride', 'tradeNames_list': "['Amidox', 'Amiodarone hydrochloride', 'Amyben', 'Cordarone', 'Cordarone xCordarone x 100', 'Cordarone x 200', 'Darmil', 'Nexterone', 'Pacerone']", 'syns_list': "['Amiodar', 'Amiodarone', 'Amiodarone hcl', 'Amiodarone hydrochlorideL-3428', 'Miodaron', 'NSC-343341', 'NSC-85442', 'Ortacrone', 'RitmocardylSK&F-33134-A', 'SKF 33134-A', 'SKF-33134-A', 'Trangorex', 'VF-236']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2'}, {'UUID': 'DrugTargetsIndication121923_text_969565', 'drugName': 'Amiodarone Hydrochloride', 'tradeNames_list': "['Amidox', 'Amiodarone hydrochloride', 'Amyben', 'Cordarone', 'Cordarone xCordarone x 100', 'Cordarone x 200', 'Darmil', 'Nexterone', 'Pacerone']", 'syns_list': "['Amiodar', 'Amiodarone', 'Amiodarone hcl', 'Amiodarone hydrochlorideL-3428', 'Miodaron', 'NSC-343341', 'NSC-85442', 'Ortacrone', 'RitmocardylSK&F-33134-A', 'SKF 33134-A', 'SKF-33134-A', 'Trangorex', 'VF-236']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2'}, {'UUID': 'DrugTargetsIndication121923_text_969558', 'drugName': 'Amiodarone Hydrochloride', 'tradeNames_list': "['Amidox', 'Amiodarone hydrochloride', 'Amyben', 'Cordarone', 'Cordarone xCordarone x 100', 'Cordarone x 200', 'Darmil', 'Nexterone', 'Pacerone']", 'syns_list': "['Amiodar', 'Amiodarone', 'Amiodarone hcl', 'Amiodarone hydrochlorideL-3428', 'Miodaron', 'NSC-343341', 'NSC-85442', 'Ortacrone', 'RitmocardylSK&F-33134-A', 'SKF 33134-A', 'SKF-33134-A', 'Trangorex', 'VF-236']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2'}, {'UUID': 'DrugTargetsIndication121923_text_969579', 'drugName': 'Amiodarone Hydrochloride', 'tradeNames_list': "['Amidox', 'Amiodarone hydrochloride', 'Amyben', 'Cordarone', 'Cordarone xCordarone x 100', 'Cordarone x 200', 'Darmil', 'Nexterone', 'Pacerone']", 'syns_list': "['Amiodar', 'Amiodarone', 'Amiodarone hcl', 'Amiodarone hydrochlorideL-3428', 'Miodaron', 'NSC-343341', 'NSC-85442', 'Ortacrone', 'RitmocardylSK&F-33134-A', 'SKF 33134-A', 'SKF-33134-A', 'Trangorex', 'VF-236']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2'}, {'UUID': 'DrugTargetsIndication121923_text_969586', 'drugName': 'Amiodarone Hydrochloride', 'tradeNames_list': "['Amidox', 'Amiodarone hydrochloride', 'Amyben', 'Cordarone', 'Cordarone xCordarone x 100', 'Cordarone x 200', 'Darmil', 'Nexterone', 'Pacerone']", 'syns_list': "['Amiodar', 'Amiodarone', 'Amiodarone hcl', 'Amiodarone hydrochlorideL-3428', 'Miodaron', 'NSC-343341', 'NSC-85442', 'Ortacrone', 'RitmocardylSK&F-33134-A', 'SKF 33134-A', 'SKF-33134-A', 'Trangorex', 'VF-236']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2'}, {'UUID': 'DrugTargetsIndication121923_text_969572', 'drugName': 'Amiodarone Hydrochloride', 'tradeNames_list': "['Amidox', 'Amiodarone hydrochloride', 'Amyben', 'Cordarone', 'Cordarone xCordarone x 100', 'Cordarone x 200', 'Darmil', 'Nexterone', 'Pacerone']", 'syns_list': "['Amiodar', 'Amiodarone', 'Amiodarone hcl', 'Amiodarone hydrochlorideL-3428', 'Miodaron', 'NSC-343341', 'NSC-85442', 'Ortacrone', 'RitmocardylSK&F-33134-A', 'SKF 33134-A', 'SKF-33134-A', 'Trangorex', 'VF-236']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.995 | Q34 | What are the names of the genes that are targeted by the drug Fesoterodine Fumarate in the treatment of urgency urinary incontinence? | In the context of urgency urinary incontinence, the drug Fesoterodine Fumarate targets the gene cholinergic receptor muscarinic 3 and cholinergic receptor muscarinic 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%urgency urinary incontinence%" OR LOWER(efo_term) LIKE "%urgency urinary incontinence%") AND (LOWER(drugName) LIKE "%fesoterodine fumarate%" OR LOWER(tradeNames_list) LIKE "%fesoterodine fumarate%" OR LOWER(syns_list) LIKE "%fesoterodine fumarate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_857308', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857317', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857320', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857323', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857329', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857332', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857335', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857341', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2'}, {'UUID': 'DrugTargetsIndication121923_text_857344', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2'}, {'UUID': 'DrugTargetsIndication121923_text_857347', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2'}, {'UUID': 'DrugTargetsIndication121923_text_857350', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2'}, {'UUID': 'DrugTargetsIndication121923_text_857356', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2'}, {'UUID': 'DrugTargetsIndication121923_text_857359', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2'}, {'UUID': 'DrugTargetsIndication121923_text_857362', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2'}, {'UUID': 'DrugTargetsIndication121923_text_857365', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2'}, {'UUID': 'DrugTargetsIndication121923_text_857368', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2'}, {'UUID': 'DrugTargetsIndication121923_text_857371', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2'}, {'UUID': 'DrugTargetsIndication121923_text_857374', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2'}, {'UUID': 'DrugTargetsIndication121923_text_857377', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2'}, {'UUID': 'DrugTargetsIndication121923_text_857380', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2'}, {'UUID': 'DrugTargetsIndication121923_text_857383', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2'}, {'UUID': 'DrugTargetsIndication121923_text_857386', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2'}, {'UUID': 'DrugTargetsIndication121923_text_857338', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857314', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857302', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857296', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857293', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857353', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2'}, {'UUID': 'DrugTargetsIndication121923_text_857326', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857311', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857305', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857299', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_list': "['Fesoterodine fumarate', 'Toviaz']", 'syns_list': "['Fesoterodine fumarate', 'SPM 8272', 'SPM 907', 'SPM-8272', 'SPM-907']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1596 | Q34 | What are the names of the genes that are targeted by the drug Safinamide in the treatment of Parkinson disease? | In the context of Parkinson disease, the drug Safinamide targets the gene monoamine oxidase B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%parkinson disease%" OR LOWER(efo_term) LIKE "%parkinson disease%") AND (LOWER(drugName) LIKE "%safinamide%" OR LOWER(tradeNames_list) LIKE "%safinamide%" OR LOWER(syns_list) LIKE "%safinamide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1091647', 'drugName': 'Safinamide Mesylate', 'tradeNames_list': "['Xadago']", 'syns_list': "['EMD 1195686', 'NW 1015', 'NW-1015', 'PNU 151774E', 'PNU-151774ESafinamide mesilate', 'Safinamide mesylate', 'Safinamide methanesulfonateSafinamide methansulfonate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'MAOB', 'approvedName': 'monoamine oxidase B'}, {'UUID': 'DrugTargetsIndication121923_text_1091659', 'drugName': 'Safinamide', 'tradeNames_list': "['Xadago']", 'syns_list': "['EMD 1195686', 'EMD-1195686', 'Safinamide']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'MAOB', 'approvedName': 'monoamine oxidase B'}, {'UUID': 'DrugTargetsIndication121923_text_1091663', 'drugName': 'Safinamide', 'tradeNames_list': "['Xadago']", 'syns_list': "['EMD 1195686', 'EMD-1195686', 'Safinamide']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'MAOB', 'approvedName': 'monoamine oxidase B'}, {'UUID': 'DrugTargetsIndication121923_text_1091667', 'drugName': 'Safinamide', 'tradeNames_list': "['Xadago']", 'syns_list': "['EMD 1195686', 'EMD-1195686', 'Safinamide']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'MAOB', 'approvedName': 'monoamine oxidase B'}, {'UUID': 'DrugTargetsIndication121923_text_1091655', 'drugName': 'Safinamide', 'tradeNames_list': "['Xadago']", 'syns_list': "['EMD 1195686', 'EMD-1195686', 'Safinamide']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'MAOB', 'approvedName': 'monoamine oxidase B'}, {'UUID': 'DrugTargetsIndication121923_text_1091645', 'drugName': 'Safinamide Mesylate', 'tradeNames_list': "['Xadago']", 'syns_list': "['EMD 1195686', 'NW 1015', 'NW-1015', 'PNU 151774E', 'PNU-151774ESafinamide mesilate', 'Safinamide mesylate', 'Safinamide methanesulfonateSafinamide methansulfonate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'MAOB', 'approvedName': 'monoamine oxidase B'}, {'UUID': 'DrugTargetsIndication121923_text_1091643', 'drugName': 'Safinamide Mesylate', 'tradeNames_list': "['Xadago']", 'syns_list': "['EMD 1195686', 'NW 1015', 'NW-1015', 'PNU 151774E', 'PNU-151774ESafinamide mesilate', 'Safinamide mesylate', 'Safinamide methanesulfonateSafinamide methansulfonate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'MAOB', 'approvedName': 'monoamine oxidase B'}, {'UUID': 'DrugTargetsIndication121923_text_1091642', 'drugName': 'Safinamide Mesylate', 'tradeNames_list': "['Xadago']", 'syns_list': "['EMD 1195686', 'NW 1015', 'NW-1015', 'PNU 151774E', 'PNU-151774ESafinamide mesilate', 'Safinamide mesylate', 'Safinamide methanesulfonateSafinamide methansulfonate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'MAOB', 'approvedName': 'monoamine oxidase B'}, {'UUID': 'DrugTargetsIndication121923_text_1091671', 'drugName': 'Safinamide', 'tradeNames_list': "['Xadago']", 'syns_list': "['EMD 1195686', 'EMD-1195686', 'Safinamide']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'MAOB', 'approvedName': 'monoamine oxidase B'}, {'UUID': 'DrugTargetsIndication121923_text_1091651', 'drugName': 'Safinamide', 'tradeNames_list': "['Xadago']", 'syns_list': "['EMD 1195686', 'EMD-1195686', 'Safinamide']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'MAOB', 'approvedName': 'monoamine oxidase B'}, {'UUID': 'DrugTargetsIndication121923_text_1091646', 'drugName': 'Safinamide Mesylate', 'tradeNames_list': "['Xadago']", 'syns_list': "['EMD 1195686', 'NW 1015', 'NW-1015', 'PNU 151774E', 'PNU-151774ESafinamide mesilate', 'Safinamide mesylate', 'Safinamide methanesulfonateSafinamide methansulfonate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'MAOB', 'approvedName': 'monoamine oxidase B'}, {'UUID': 'DrugTargetsIndication121923_text_1091644', 'drugName': 'Safinamide Mesylate', 'tradeNames_list': "['Xadago']", 'syns_list': "['EMD 1195686', 'NW 1015', 'NW-1015', 'PNU 151774E', 'PNU-151774ESafinamide mesilate', 'Safinamide mesylate', 'Safinamide methanesulfonateSafinamide methansulfonate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'MAOB', 'approvedName': 'monoamine oxidase B'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.125 | Q34 | What are the names of the genes that are targeted by the drug Milnacipran Hydrochloride in the treatment of fibromyalgia? | In the context of fibromyalgia, the drug Milnacipran Hydrochloride targets the gene solute carrier family 6 member 4 and solute carrier family 6 member 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%fibromyalgia%" OR LOWER(efo_term) LIKE "%fibromyalgia%") AND (LOWER(drugName) LIKE "%milnacipran hydrochloride%" OR LOWER(tradeNames_list) LIKE "%milnacipran hydrochloride%" OR LOWER(syns_list) LIKE "%milnacipran hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_206850', 'drugName': 'Milnacipran Hydrochloride', 'tradeNames_list': "['Dalcipran', 'Ixel', 'Milnacipran hydrochloride', 'Savella', 'Toledomin']", 'syns_list': "['Milnacipran hcl', 'Milnacipran hydrochloride', 'NSC-759806']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206856', 'drugName': 'Milnacipran Hydrochloride', 'tradeNames_list': "['Dalcipran', 'Ixel', 'Milnacipran hydrochloride', 'Savella', 'Toledomin']", 'syns_list': "['Milnacipran hcl', 'Milnacipran hydrochloride', 'NSC-759806']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206858', 'drugName': 'Milnacipran Hydrochloride', 'tradeNames_list': "['Dalcipran', 'Ixel', 'Milnacipran hydrochloride', 'Savella', 'Toledomin']", 'syns_list': "['Milnacipran hcl', 'Milnacipran hydrochloride', 'NSC-759806']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206860', 'drugName': 'Milnacipran Hydrochloride', 'tradeNames_list': "['Dalcipran', 'Ixel', 'Milnacipran hydrochloride', 'Savella', 'Toledomin']", 'syns_list': "['Milnacipran hcl', 'Milnacipran hydrochloride', 'NSC-759806']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206864', 'drugName': 'Milnacipran Hydrochloride', 'tradeNames_list': "['Dalcipran', 'Ixel', 'Milnacipran hydrochloride', 'Savella', 'Toledomin']", 'syns_list': "['Milnacipran hcl', 'Milnacipran hydrochloride', 'NSC-759806']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206866', 'drugName': 'Milnacipran Hydrochloride', 'tradeNames_list': "['Dalcipran', 'Ixel', 'Milnacipran hydrochloride', 'Savella', 'Toledomin']", 'syns_list': "['Milnacipran hcl', 'Milnacipran hydrochloride', 'NSC-759806']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206868', 'drugName': 'Milnacipran Hydrochloride', 'tradeNames_list': "['Dalcipran', 'Ixel', 'Milnacipran hydrochloride', 'Savella', 'Toledomin']", 'syns_list': "['Milnacipran hcl', 'Milnacipran hydrochloride', 'NSC-759806']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206873', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206877', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206881', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206885', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206893', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206897', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206901', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206905', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206909', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206913', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206917', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206921', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206925', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206929', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206937', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206941', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206945', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206949', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206953', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206961', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206965', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206933', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206870', 'drugName': 'Milnacipran Hydrochloride', 'tradeNames_list': "['Dalcipran', 'Ixel', 'Milnacipran hydrochloride', 'Savella', 'Toledomin']", 'syns_list': "['Milnacipran hcl', 'Milnacipran hydrochloride', 'NSC-759806']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206854', 'drugName': 'Milnacipran Hydrochloride', 'tradeNames_list': "['Dalcipran', 'Ixel', 'Milnacipran hydrochloride', 'Savella', 'Toledomin']", 'syns_list': "['Milnacipran hcl', 'Milnacipran hydrochloride', 'NSC-759806']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206846', 'drugName': 'Milnacipran Hydrochloride', 'tradeNames_list': "['Dalcipran', 'Ixel', 'Milnacipran hydrochloride', 'Savella', 'Toledomin']", 'syns_list': "['Milnacipran hcl', 'Milnacipran hydrochloride', 'NSC-759806']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206842', 'drugName': 'Milnacipran Hydrochloride', 'tradeNames_list': "['Dalcipran', 'Ixel', 'Milnacipran hydrochloride', 'Savella', 'Toledomin']", 'syns_list': "['Milnacipran hcl', 'Milnacipran hydrochloride', 'NSC-759806']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206840', 'drugName': 'Milnacipran Hydrochloride', 'tradeNames_list': "['Dalcipran', 'Ixel', 'Milnacipran hydrochloride', 'Savella', 'Toledomin']", 'syns_list': "['Milnacipran hcl', 'Milnacipran hydrochloride', 'NSC-759806']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206957', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206889', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206862', 'drugName': 'Milnacipran Hydrochloride', 'tradeNames_list': "['Dalcipran', 'Ixel', 'Milnacipran hydrochloride', 'Savella', 'Toledomin']", 'syns_list': "['Milnacipran hcl', 'Milnacipran hydrochloride', 'NSC-759806']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206852', 'drugName': 'Milnacipran Hydrochloride', 'tradeNames_list': "['Dalcipran', 'Ixel', 'Milnacipran hydrochloride', 'Savella', 'Toledomin']", 'syns_list': "['Milnacipran hcl', 'Milnacipran hydrochloride', 'NSC-759806']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206848', 'drugName': 'Milnacipran Hydrochloride', 'tradeNames_list': "['Dalcipran', 'Ixel', 'Milnacipran hydrochloride', 'Savella', 'Toledomin']", 'syns_list': "['Milnacipran hcl', 'Milnacipran hydrochloride', 'NSC-759806']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206844', 'drugName': 'Milnacipran Hydrochloride', 'tradeNames_list': "['Dalcipran', 'Ixel', 'Milnacipran hydrochloride', 'Savella', 'Toledomin']", 'syns_list': "['Milnacipran hcl', 'Milnacipran hydrochloride', 'NSC-759806']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1856 | Q34 | What are the names of the genes that are targeted by the drug Rosuvastatin Calcium in the treatment of familial hypercholesterolemia? | In the context of familial hypercholesterolemia, the drug Rosuvastatin Calcium targets the gene 3-hydroxy-3-methylglutaryl-CoA reductase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%familial hypercholesterolemia%" OR LOWER(efo_term) LIKE "%familial hypercholesterolemia%") AND (LOWER(drugName) LIKE "%rosuvastatin calcium%" OR LOWER(tradeNames_list) LIKE "%rosuvastatin calcium%" OR LOWER(syns_list) LIKE "%rosuvastatin calcium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1104218', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104252', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104184', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104150', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104133', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104235', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104201', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104167', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_list': "['Crestor', 'Ezallor', 'Ezallor sprinkle', 'Rosuvastatin calcium']", 'syns_list': "['Fortius', 'NSC-747274', 'NSC-758930', 'Rostar', 'Rosuvastatin (as calcium)Rosuvastatin calcium', 'Rosuvastatin calcium saltRosuvastatin hemicalcium', 'Rozavel', 'S-4522', 'Suvikan', 'ZD-4522ZD-4522 (CALCIUM SALT)', 'ZD-4522 CALCIUM', 'ZD4522 (CALCIUM SALT)ZD4522 CALCIUM']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperlipoproteinemia Type II', 'efo_term': 'familial hypercholesterolemia', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.369 | Q34 | What are the names of the genes that are targeted by the drug Halobetasol Propionate in the treatment of psoriasis vulgaris? | In the context of psoriasis vulgaris, the drug Halobetasol Propionate targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%psoriasis vulgaris%" OR LOWER(efo_term) LIKE "%psoriasis vulgaris%") AND (LOWER(drugName) LIKE "%halobetasol propionate%" OR LOWER(tradeNames_list) LIKE "%halobetasol propionate%" OR LOWER(syns_list) LIKE "%halobetasol propionate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_240741', 'drugName': 'Halobetasol Propionate', 'tradeNames_list': "['Bryhali', 'Halobetasol propionate', 'Lexette', 'Ultravate']", 'syns_list': "['21-chloro diflorasone', 'BMY-30056', 'CGP-14,458', 'CGP-14458Halobetasol', 'Halobetasol propionate', 'IDP-122', 'Jemdel', 'UlobetasolUlobetasol propionate']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_240725', 'drugName': 'Halobetasol Propionate', 'tradeNames_list': "['Bryhali', 'Halobetasol propionate', 'Lexette', 'Ultravate']", 'syns_list': "['21-chloro diflorasone', 'BMY-30056', 'CGP-14,458', 'CGP-14458Halobetasol', 'Halobetasol propionate', 'IDP-122', 'Jemdel', 'UlobetasolUlobetasol propionate']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_240721', 'drugName': 'Halobetasol Propionate', 'tradeNames_list': "['Bryhali', 'Halobetasol propionate', 'Lexette', 'Ultravate']", 'syns_list': "['21-chloro diflorasone', 'BMY-30056', 'CGP-14,458', 'CGP-14458Halobetasol', 'Halobetasol propionate', 'IDP-122', 'Jemdel', 'UlobetasolUlobetasol propionate']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_240733', 'drugName': 'Halobetasol Propionate', 'tradeNames_list': "['Bryhali', 'Halobetasol propionate', 'Lexette', 'Ultravate']", 'syns_list': "['21-chloro diflorasone', 'BMY-30056', 'CGP-14,458', 'CGP-14458Halobetasol', 'Halobetasol propionate', 'IDP-122', 'Jemdel', 'UlobetasolUlobetasol propionate']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_240737', 'drugName': 'Halobetasol Propionate', 'tradeNames_list': "['Bryhali', 'Halobetasol propionate', 'Lexette', 'Ultravate']", 'syns_list': "['21-chloro diflorasone', 'BMY-30056', 'CGP-14,458', 'CGP-14458Halobetasol', 'Halobetasol propionate', 'IDP-122', 'Jemdel', 'UlobetasolUlobetasol propionate']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_240729', 'drugName': 'Halobetasol Propionate', 'tradeNames_list': "['Bryhali', 'Halobetasol propionate', 'Lexette', 'Ultravate']", 'syns_list': "['21-chloro diflorasone', 'BMY-30056', 'CGP-14,458', 'CGP-14458Halobetasol', 'Halobetasol propionate', 'IDP-122', 'Jemdel', 'UlobetasolUlobetasol propionate']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.